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Abstract 
Peanut allergy affects 1-2% of UK schoolchildren. Children with egg allergy are at increased 
risk. The diagnosis of peanut allergy in this group of children is challenging, with current 
diagnostic techniques being inadequate. Clarification of peanut allergy status in egg-allergic, 
peanut-sensitised children is complicated and frequently includes the need for an oral 
provocation challenge. This places considerable pressure on day-case services, poses a 
potential risk to the child and carries health economic implications. Recent research has 
proposed the measurement of specific IgE concentrations to the peanut component Ara h 2 to 
be a better test for the differentiation of allergy and tolerance than existing methods. 
 
The present study attempts to improve the diagnostic process for this group of children. The 
primary aim was to investigate the diagnostic value of measuring Ara h 2-specific IgE 
concentrations in predicting a clinical reaction to peanut. 105 eligible children were 
prospectively recruited via the tertiary allergy clinic at Bristol Royal Hospital for Children. 
Children were subjected to a peanut skin prick test and specific IgE testing to whole peanut 
and Ara h 2 followed by an oral provocation challenge. Children were allocated to either the 
peanut allergic or tolerant group. Outcomes were related to all three tests. 
 
The peanut skin prick test and whole-peanut specific IgE were poor discriminators between 
allergy and tolerance. Ara h 2 was the best predictor of peanut allergy, but had greater clinical 
utility as part of a two-step approach. Receiver-operator curve construction identified optimal 
cut-off values of 6mm for peanut skin prick testing, 0.39kUA/L for Ara h 2-specific IgE 
concentrations and 1.08kUA/L for whole peanut specific IgE. These were included in a 
diagnostic two-step model. When used in isolation, specific IgE concentrations to Ara h 2 were 
unable to replace the need for an oral provocation challenge for the majority of egg-allergic, 
peanut-sensitised children. 
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A group of workers take a break during peanut threshing.  
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1.1 The history of human peanut consumption 
The peanut plant, Arachis hypogaea, is commonly known as the groundnut: hypogaea literally 
means ‘under the earth’. It is a member of the Fabaceae family (also known as Leguminosae) 
and is native to South America. In the 1500s Spanish explorers carried the plant to Spain, from 
where it was subsequently traded with Asia and Africa by slaving ships. In the eighteenth 
century peanuts were transported from Africa back across the Atlantic to North America 
where they were first grown primarily for livestock (Sauer, 1993). Through the late 19th and 
early 20th centuries peanut was primarily used to provide animal feed, although after the 
American Civil War peanuts became a popular high protein food for the army. Popularity 
further increased in the late nineteenth century when travelling circuses and street vendors 
began to sell peanuts to the general public. During this period, peanuts were still being 
harvested by hand. More sophisticated mechanical farm equipment was not developed until 
the 1900s when an epidemic boll weevil infestation devastating the cotton crop led to the 
establishment of peanuts as a commercial crop. To a large extent this was due to numerous 
recommendations by the botanist Dr George Washington Carver for the use of the peanut crop 
as an alternative to cotton for the benefit of poor farmers. Uses for peanut grew rapidly and 
included food products, cosmetics, coffee, glue and plastics (McMurry, 1982). 
 
Peanut is an annual herbaceous plant (that is, it has no persistent woody stem above the 
ground). Botanically, the peanut is not a nut, but a close relative of the legume family, 
Leguminosae, with the mature fruit developing underground in a pod containing up to three 
seeds as shown in Figure 1. The protein content of the peanut is between 24 and 29%, 
comprising primarily of seed storage proteins (Koppelman et al., 2001). Legume seed storage 
proteins comprise the third largest source of dietary protein on Earth (Singh B, 1991). There 
are four main botanical varieties of peanut plant; Valencia, Virginia, Spanish and Peruvian 
Runner, the last of which is the dominant peanut variety. 
 
Peanut remains an important global crop with an annual yield of 29 million metric tonnes per 
year: China, India and the US are the world’s three largest producers (APC, 2014). Peanuts are 
now the twelfth most valuable cash group in the US with a value of over one billion dollars and 
are an important food crop, with 42 million acres being allocated to peanut cultivation 
worldwide. Peanut ingestion can cause severe allergic reactions in some individuals, with 1-2% 
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of UK children having peanut allergy (Sicherer et al., 2010, Venter et al., 2010, Nwaru et al., 
2014). Peanut allergy is an adverse immune response that occurs in susceptible individuals. 
 




Legend. Adapted from Kohler, 1887. The mature fruit develops in pods underground. 
 
 
1.2 Introduction to the human immune system 
The human immune system exists to defend the individual and to eliminate foreign 
substances. It can be considered to have two major branches:  innate and acquired immunity, 
which differ in terms of the specificity and speed of the response, and a memory property. The 
innate response provides immediate host defence by responding in the same way to all foreign 
substances, either new, or previously encountered, and is present in all animals. In 
comparison, the acquired response is highly specific and has a memory property that allows a 
faster and more robust response if the invading pathogen is encountered a second time 
(Moser and Leo, 2010). 
 
1.2.1 Innate immunity   
The innate immune system comprises a number of processes including phagocytic cells, 
neutrophils, eosinophils, interferons, natural killer cells and the complement system. 
Phagocytic cells, which include neutrophils and macrophages, engulf and digest foreign 
organisms at the site of infection; interferons are chemicals released to prevent intra-cellular 





in seed pod 
Main stem 
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cells are able to spontaneously kill target cells without prior sensitisation and finally, the 
complement system comprises at least 20 serum proteins which function to activate a cascade 
pathway to control inflammation. The innate response is able to discriminate foreign cells from 
self but is otherwise a non-specific system, the activation of which can sometimes lead to 
tissue damage (Parkin and Cohen, 2001). 
 
1.2.2 Acquired Immunity 
The acquired immune response is more sophisticated than the innate response, due to its 
ability to recognise and remember minor structural components on the surface of foreign 
organisms. These are known as ‘epitopes’. The highly-specific acquired immune response 
primarily utilises primed T and B lymphocytes to recognise and attack antigenic epitopes. B 
cells can be categorised as antigen presenting cells, a term that also applies to dendritic cells 
and macrophages. All cells of the immune system originate from haematopoietic precursor 
cells in bone marrow; however B cells develop in bone marrow, whereas T cells migrate from 
the bone marrow for development in the thymus. Both types of cell have antigenic-binding 
receptors crucial for successful host defence. Early in cell development, a process of gene 
rearrangement occurs which codes the antigen-binding areas of receptors on the cell surface. 
B cell receptors comprise four gene segments; the variable (V), diversity (D), joining (J) and 
constant (C) regions. There are up to 100 V genes, approximately 25 D genes and 
approximately 50 J genes which assemble at random to form the final VDJ region of the cell 
receptor. This ensures the production of an almost infinite number of variable receptors 
necessary for the individual to survive infection by numerous pathogens throughout life 
(Moser and Leo, 2010). After B cell activation, specific antibody (also known as 
immunoglobulin) is secreted and produced by plasma cells. 
 
T cell receptors (TCRs) are slightly less complex and exist in two forms with both a constant 
and variable domain. T cell receptors bind to linear proteins of up to nine amino acids once the 
antigen has been ingested by antigen presenting cells (usually dendritic cells), processed, and 
then presented to T cells in the lymph nodes (Parkin and Cohen, 2001).  
 
Antigen presenting cells internalise antigens and combine them with major histocompatibility 
molecules (MHC) which are also referred to as Human Leukocyte Antigen (HLA) molecules. 
These molecules are moved to the cell surface ready for presentation to T and B cells. T cells 
are very functionally diverse. There are two subtypes of T cells, T-helper cells which express 
CD4+ surface molecules and T-cytotoxic (killer) cells that express CD8+ surface molecules. 
CD4+ T helper cells typically orchestrate the immune response, by production of cytokines that 
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can assist with antibody production by B cells, whereas CD8+ cells are typically associated with 
direct killing of infected body cells. 
 
CD4+ T cells are divided into two further functional subsets according to their cytokine 
production profile (Swain et al., 1991). T helper 1 (Th1) cells produce interleukin-2 (IL-2) and 
interferon-gamma (IFN-γ) which favours a cell-mediated inflammatory response, whilst T 
helper 2 (Th2) cells promote a humoral response (that is, soluble immunity via antibody 
production; vide infra) by the production of IL-4, IL-5, IL-6, IL-10 and IL-13. The Th2 response is 
associated with allergy as these cytokines favour antibody production. IL-4 induces class-
switching in B cells which promotes IgE production. Stimulation of IgE production is also 
brought about by the local environment in which antigen is encountered (for example, gut-
associated-lymphoid-tissue that produces high levels of transforming growth factor-beta [TGF-
Β]) (Nagler-Anderson, 2001). IL-4 also induces further Th2 responses and suppresses Th1 
activity (Parkin and Cohen, 2001). T-regulatory cells also exist to modulate the immune 
response. 
 
The effector functions of T and B cells are brought about by interaction with MHC molecules, 
which allow the immune system to distinguish between self and non-self. These molecules are 
subdivided into two major classes, MHC class I and class II. T-cytotoxic cells only recognise 
antigens which are bound to the MHC class I molecules expressed by all body cells, and which 
present fragments of foreign proteins, such as those produced by the cell if it is infected with a 
virus. T-helper and regulatory cells only recognise antigens bound to MHC class II molecules 
which are only expressed by professional antigen presenting cells (dendritic cells, 
macrophages, B cells). Antigen recognised by B cells binds to its B cell receptor (a membrane 
bound antibody molecule; BCR) and is engulfed, processed and presented on MHC class II 
surface molecules. Antigen-specific CD4+ T-helper cells that recognise the same antigen and 
have already been activated by dendritic cells, may then recognise antigen presented by B cells 
in the context of MHC class II. The attracted CD4+ T helper cells up-regulation surface 
molecules, providing co-stimulation to the B cell and cytokines, which helps the B cell mature 
and produce antibodies. 
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Legend. This figure demonstrates the interaction following B cell encounter with a matching antigen until the B 
cell matures and becomes capable of releasing antibodies into the blood. 
 
 
Antibodies are Y-shaped molecules which are composed of two identical light chains and two 
identical heavy chains linked by disulfide bonds. Both chains comprise constant (C) and 
variable (V) regions (see Figure 3). It is the type of heavy chain which determines the final 
antibody class or isotype; there are two different light chains (kappa and lambda) and five 
varying heavy chains which correspond to the immunoglobulins IgM, IgD, IgG, IgA and IgE 
(Moser and Leo, 2010). Relevant to allergy and very broadly, IgA molecules are responsible for 
tolerance of ingested food products, whereas IgE molecules are typically responsible for the 
abnormal immune response that results in allergic symptoms and responses (Nagler-Anderson, 
2001). 
 
B cell encounters matching antigen 
B cell engulfs and digests the antigen  
Antigenic fragments are bound to MHC molecules and presented on the cell surface 
Presented antigen attracts an antigen-specific T-cell which secretes  
cytokines to activate the B cell.  
The B cell matures into antibody-secreting plasma cells, which release antibodies into 
 the blood where they bind matching antigens. 
B cell encounters matching antigen 
B cell engulfs and digests the antigen  
Antigenic fragments are bound to HLA molecules and presented on the cell surface 
Presented antigen attracts and is bound by matching T cell, which secretes cytokines to 
activate the B cell.  
The B cell matures into antibody-secreting plasma cells, which release antibodies 
into the blood where they lock onto matching antigens. 
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Legend. The variable region of the IgE antibody molecule enables them to bind to a range of specific antigenic 
peptides. 
 
Immunoglobulin E (IgE) is the antibody responsible for immediate allergic hypersensitivity. The 
secretion of high levels of IgE antibody arise from the predominantly Th2 environment, rich 
with the cytokines IL-4, IL-5 and IL-13 (Moser and Leo, 2010). There are two phases to the 
immunological basis of allergic disease; the sensitisation phase and the effector phase. During 
the sensitisation phase, Th2 effector cells produce IL-4, which promotes class switching to the 
IgE heavy chain and the further production of Th2 cytokines. Allergen-specific IgE then binds to 
high-affinity IgE receptors - known as FcεRI- on mast cell and basophil surfaces, resulting in 
sensitisation. The FcεRI receptor is a receptor complex that binds the Fc section of the IgE 
heavy chain exon, which has a primary role in controlling the allergic response. The effector 
phase occurs when an individual is re-exposed to an allergen and cross-linking of the IgE FcεRI 
complexes on sensitised mast cells results in mast cell activation. Mast cells are present in 
almost all tissues and are often close to epithelial surfaces. Mast cell degranulation results in 
the release of pro-inflammatory mediators (including histamine, heparin, leukotrienes and 











Antigen binding sites 
Variable region 
Constant region 
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1.3 Classification of hypersensitivity reactions  
In 1963 Gell and Coombes described four classes of hypersensitivity based upon the 
mechanisms and timing involved (Gell, 1963). 
Type I: immediate hypersensitivity 
Type I hypersensitivity reactions are known as immediate or anaphylactic reactions. Common 
symptoms include one or more of the following symptoms; angioedema, urticaria, 
bronchoconstriction, rhinitis, conjunctivitis and anaphylactic shock. Following the binding of 
IgE to high-affinity receptors on the surface of mast cells and basophils, cell degranulation 
occurs which results in the release of preformed mediators such as histamine. This is followed 
by the release of newly synthesised mediators (previously known as slow reacting substances 
of anaphylaxis) such as leukotrienes and prostaglandins. 
Type II: antibody-mediated cytotoxic reactions  
Type II hypersensitivity reactions are rare cytotoxic reactions, which are antibody-mediated 
and are usually caused by IgG and IgM antibodies. Type II responses are associated with 
autoimmune diseases, adverse reactions to drugs and transplants. Reactions typically take 
several hours to develop. There are two mechanisms which result in tissue damage: the first 
results from direct action caused by neutrophils, macrophages and eosinophils and the second 
is due to antibody-mediated activation of the complement pathway, resulting in cell lysis. 
Common examples are thrombocytopenia, immunoallergic haemolytic anaemia and 
haemolytic disease of the newborn (Descotes and Choquet-Kastylevsky, 2001). 
Type III: immune complex-mediated reactions  
Immune complexes are responsible for causing tissue damage in type III reactions. Common 
manifestations include serum sickness and systemic lupus erythematosus. The reaction 
between antigen and IgM that can occur in tissue spaces results in the development of micro-
precipitates around small vessels, causing cell damage. If there is an excess of antigen, soluble 
immune complexes develop and are deposited in blood vessel endothelium where they cause 
local inflammation. This culminates in complement activation, attracting macrophages, 
platelets and neutrophils, which further contribute to tissue damage. The primary target 
systems are the lungs, eyes, kidney, joints and the skin (Descotes and Choquet-Kastylevsky, 
2001). 
Type IV: delayed hypersensitivity 
Type IV reactions primarily involve the skin, with contact dermatitis being a common 
manifestation. Symptoms are delayed and often occur 2-14 days after exposure, depending 
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upon previous exposure. Type IV reactions do not involve antibodies but occur following T cell 
sensitisation in conjunction with skin proteins. Reactions occur on subsequent exposure when 
memory T cells proliferate into effector cells (Nosbaum et al., 2009). 
 
1.4 The development of food allergy 
A food allergy is an acquired immunological reaction to a food protein, which can be IgE or 
non-IgE mediated. Allergy is different to other adverse reactions to foods, such as food 
aversion or food intolerance. IgE mediated or ‘Type I food hypersensitivity’, often referred to 
as ‘true food allergy’ occurs when the immune system perceives a harmless protein as 
potentially dangerous and responds accordingly. 
 
The allergic response is an acquired immune response which arises due to the ability of the 
individual’s immune system to remember and recognise a small structural component on the 
surface of an antigen, known as an ‘epitope’. Each epitope is only able to bind with one 
specific IgE antibody. In allergy, the epitope is termed an ‘allergen’. 30%-40% of individuals are 
genetically predisposed to produce specific IgE antibodies to common aeroallergens. These 
individuals are described as being ‘atopic’ or having ‘atopy’. Atopic diseases include eczema, 
asthma, allergic rhinitis and food allergy. In predisposed atopic individuals, the response to an 
innocuous food allergen can be excessive, as the body mistakenly perceives the epitope as a 
threat. In atopic individuals, antigen presenting cells ingest the allergenic protein and present 
it via MHC-class II to CD4+ T-helper cells, adopting a Th2 phenotype that stimulates B cell 
production of IgE. Antigen-presenting cells ingest and process the allergen and display it on 
their surface in conjunction with MHC class II molecules. The antigen-presenting cell then 
migrates to the lymph nodes, where it will present its antigen to a CD4+ T-helper cell that has a 
complementary T cell receptor. The CD4+ T-helper cell may then meet an antigen-specific B 
cell that has already ingested and processed the same antigen, presenting fragments via MHC 
class II. The CD4+ T-helper cell will then activate the B cell, stimulating it to produce allergen-
specific antibodies. IgE antibodies to food allergens are produced by plasma cells and are only 
able to react with the specific allergen responsible for its formation, rather like a lock and key; 
they are therefore known as ‘specific IgE antibodies’ (Sampson, 1999).  
 
Once released, IgE antibodies bind to antigens with the aim of eliminating and neutralising 
their target for removal from the body. As part of this process, IgE is also bound to IgE-specific 
receptors (FcεRI) on the surface of mast cells on mucosal surfaces and basophils in the blood, 
causing sensitisation of the individual. Although no symptoms occur during the sensitisation 
phase, the individual becomes primed for the onset of an allergic reaction. Sensitisation is 
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necessary for an individual to express clinical allergy although sensitised individuals do not 
always express clinical reactivity. In other words, it is not possible to experience an allergic 
reaction to peanut without being sensitised, although some individuals may be sensitised to 
peanut yet be able to ingest it without reaction. It is unclear precisely why some individuals are 
sensitised to specific food allergens but do not experience an allergic reaction following 
ingestion of that food (Sampson and Ho, 1997). 
 
Food allergens are water-soluble glycoproteins, usually less than 70 kiloDaltons (kDa) in mass, 
which are stable to heat, acid and proteases (Astwood, 1996, Deshpande, 1987, Sampson, 
1999, Sicherer and Sampson, 2010). Allergens have several distinct molecular properties. The 
first is the ability to induce the immune system to produce IgE antibody and thus cause 
sensitisation of the individual. The second is the ability to trigger allergic symptoms, known as 
elicitation. Finally the allergen needs to be capable of binding to allergen-specific IgE. 
If exposure to an allergen occurs in an allergic individual, the allergen is able to bind to and 
cross-link the IgE molecules and Fc receptors on the surface of the mast cells. This activates 
the sensitised cell, provoking degranulation. Degranulation results in the release of histamine 
and other pro-inflammatory chemical mediators including interleukins, leukotrienes and 
prostaglandins into the surrounding tissue (Figure 4). Mast cell degranulation also leads to the 
recruitment of additional pro-inflammatory responses (Burbank and Burks, 2015). 
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Legend. Degranulation of the mast cell results in the release of preformed mediators, which culminate in allergic 
symptoms. Adapted from Pawel Kuzniak (Kuzniak, 2006) 
 
 
Ultimately, this culminates in unpleasant and potentially life-threatening clinical symptoms. 
Reactions tend to be acute in onset, often occurring immediately and usually within less than 
two hours. Chemical mediators affect target organs including the skin, gastrointestinal, 
oropharyngeal and respiratory tracts and cardiovascular systems, and reactions may be local 
or systemic (Iweala and Burks, 2016). Responses involving the skin causing rash or swelling are 
the most common and tend to be mild, whereas those involving the respiratory and 
cardiovascular systems are more likely to be severe (Sicherer and Sampson, 2010). The most 
severe form of Type I hypersensitivity is anaphylaxis, defined by the European Academy of 
Allergy and Clinical Immunology (EAACI) as 'a severe, life-threatening, multiple-organ 
hypersensitivity, often dominated by severe asthma and hypotension' (Emmett et al., 1999). 
 
It is known that allergens have some or all of the following characteristics: stability against 
heat and digestive enzymes, solubility (the ability of the allergen to cross the gut mucosal 
barrier), and a structure allowing for surface molecule exposure (Helm, 2003). The six most 
common food allergens in children are milk, egg, soya, fish, wheat and peanut (Sicherer, 2002, 
Burks, 1998). These six foods are responsible for 90% of all reactions, although any food can 
trigger an allergic response. 
 
Mast cell FcεRI receptors 
Release of preformed mediators 
from granules (histamine, heparin) 
Newly formed mediator 
(Prostaglandins, leukotrienes)  
Allergen 
Specific IgE antibodies 
Mast cell 
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1.5 Linear and conformational epitopes 
Food allergens are water-soluble glycoproteins. A globular protein comprises a sequence of 
amino acids creating a protein structure that tends to be folded rather than linear. The cells of 
the immune system recognise ‘epitopes’ rather than complete antigens. An epitope, or 
antigenic determinant, is a sequence of amino acids (Chen, 2012). In food allergy specifically, 
an epitope is a localised area on the surface of the antigen that is recognised by an IgE 
antibody. An epitope may be either linear or conformational (3-dimensional) in structure as 
shown in Figure 5. A linear epitope - also known as a sequential allergenic epitope - is 
recognised by IgE antibodies by its contiguous sequence of five to ten amino acids. A 
conformational epitope has a three-dimensional shape and structure, comprised of several 
non-contiguous residues which are separated in the amino acid chain but which form an 
epitope that results from the folding of the antigen (Hansen et al., 2016, Chen et al., 2016). 
 












Legend. The linear epitope comprises a contiguous amino acid chain whereas the conformational epitope is 
formed by the folding of separate amino acids. Adapted from The Immune System (Parham, 2009). 
 
 
1.6 Natural history of peanut allergy 
Peanut is responsible for the majority of food-induced severe allergic reactions (Macdougall et 
al., 2002). Type I hypersensitivity to the peanut is common, affecting 1-2% of UK school 
children (Tariq et al., 1996, Grundy et al., 2002, Sicherer, 2002). Peanut allergy tends to 
present early in life and, in more than 70% of allergic children, symptoms are present on the 
child’s first known exposure (Sicherer, 1998). However, resolution rates are low in comparison 
with other foods. Approximately 50% of children with egg and milk allergy will experience 
resolution by two years of age (Sicherer et al., 2014, Spergel et al., 2015). Peanut allergy was 




  24 
20% of primary school aged children and up to 25% of adolescents aged 10 to 18 (Lack et al., 
2003b, Hourihane, 2005, Skolnick, 2001, Peters et al., 2015). It is not yet clear how to predict 
which children will eventually outgrow their peanut allergy. Early research suggests that 
resolving children may have lower initial whole peanut-specific IgE concentrations and 
subsequent whole peanut-specific IgE concentrations or skin prick test wheal diameters which 
decrease over time (Ho, 2008). These epidemiological studies demonstrate that the majority of 
peanut allergic children will grow up to be peanut allergic adults and therefore further 
research into prevention and treatment is of prime importance (Iweala and Burks, 2016). 
 
1.7 Egg allergy and eczema - risk factors for peanut allergy 
Clinicians working in allergy have to deal with an important clinical conundrum on a daily basis 
- what should be done with the atopic child who is already being investigated for other allergic 
disease, such as another food allergy or moderate to severe eczema, who is also found to be 
peanut sensitised? (Codreanu et al., 2011). This is a common clinical problem encountered by 
clinicians managing children with egg allergy. The link between egg allergy and peanut 
sensitisation is well established, with a significant proportion of egg allergic children being co-
sensitised to peanut (Du Toit et al., 2008). 
 
The Learning Early About Peanut allergy (LEAP) study confirms this association, reporting the 
presence of egg allergy to be the most important risk factor for peanut sensitisation (Du Toit et 
al., 2008). The LEAP study was the first study to confirm that early peanut introduction 
between the ages of four and ten months may prevent the development of peanut allergy in 
high-risk atopic children. Out of 640 infants who had never consumed peanut with severe 
eczema, egg allergy or both, the prevalence of peanut allergy at age 60 months was 17.2% in 
infants who avoided peanut and 3.2% in children who consumed 2 grams of peanut three 
times per week. This study provides a further important reason for clinicians to be able to 
differentiate between peanut allergy and tolerance in young children as easily and quickly as 
possible. 
 
There were only two inclusion criteria for participation in the LEAP study; severe eczema and 
egg allergy. The authors propose that as egg and peanut are allergenically diverse, this 
association is most likely to be due to shared risk factors rather than cross-sensitisation (Du 
Toit, 2015). Eczema is a known risk factor for peanut allergy, with one postulated mechanism 
for this being the imperfect skin barrier paving the way for sensitisation to occur through the 
skin (Lack et al., 2003a). Lack et al (2003) proposed that sensitisation occurs through the skin 
via an imperfect barrier although at the time of publication the mechanism was unknown. In 
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2006, research identified mutations within the filaggrin gene which result in a filaggrin 
deficiency (Irvine and McLean, 2006). Filaggrin is a genetically regulated hydrating protein that 
is present within the epidermis. A genetic filaggrin deficiency exists in up to 10% of the 
Caucasian population and leads to a defective epithelial barrier leaving individuals prone to 
developing a number of inflammatory skin conditions including atopic eczema (Weidinger et 
al., 2008, Palmer et al., 2006). Individuals with a profilaggrin mutation may experience 
cutaneous dehydration causing an imperfect barrier which allows penetration by allergens 
(Weidinger, 2006). Subsequent studies have identified filaggrin haplo-insufficiency in a murine 
model to be associated with barrier impairment and percutaneous allergen sensitisation 
(Fallon, 2009, Oyoshi, 2009). More recently, research has been undertaken into the 
importance of maintaining skin integrity to prevent the development of peanut and other 
allergies (Brown et al., 2011, Irvine et al., 2011). Brough et al demonstrated that for children 
with filaggrin mutations, each log unit increase in house dust peanut protein level was 
associated with a six-fold increased odds of having peanut sensitisation, and more than a 
three-fold increase of having peanut allergy. No effect was observed in those children without 
filaggrin mutations (Brough et al., 2014). 
 
Clinical practice varies with regard to testing high-risk children - particularly those with egg 
allergy - for peanut sensitisation. Most clinicians feel that it is best practice to actively seek out 
peanut sensitisation in high-risk children to avert the child from potentially having an allergic 
reaction at home. Others find testing for peanut sensitisation to be problematic, particularly in 
smaller centres, as sensitisation then requires further investigation and resources may be 
limited. Nicolaou reported a study in which only 22.4% of egg allergic children who were 
peanut-sensitised were proven to have true peanut allergy on oral provocation challenge 
(Nicolaou et al., 2010b). 
 
Children with a skin prick test wheal diameter or a specific IgE antibody level above the 
previously published 95% positive predictive value for peanut are usually labelled as being 
peanut allergic, whilst those with a negative test should be encouraged to regularly consume 
peanut as the negative predictive value is sufficiently reliable (Burks, 1998). Rance et al 
reported a negative predictive value of 95% (Rance et al., 2002). However, children whose 
results lie within what is commonly acknowledged to be the ‘immunological grey area’ - a 
considerable number of children with a low or borderline skin prick or whole peanut- specific 
IgE test - require an oral provocation challenge to confirm or refute their peanut allergic 
status. If their status is not clarified, then peanut-tolerant children are at risk of developing 
peanut allergy by failing to include peanut in their regular diet whilst peanut-allergic children 
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without a clear diagnosis may not have access to appropriate medications and management 
advice. 
 
It is high-risk children, whose skin prick or whole peanut-specific IgE antibody concentrations 
fall within this immunological grey area, for whom the greatest benefit would accrue from an 
improved diagnostic process, reducing the need for an oral provocation challenge. 280 oral 
food provocation challenges were performed at Bristol Royal Hospital for Children in 2014. 
53(19%) of these were to peanut and only 4(8%) were positive, supporting the need for a 
highly sensitive screening test. This also suggests that referring healthcare professionals in our 
centre have until recently tended to err on the side of caution. Ultimately this means that 
many peanut-sensitised children who have never consumed peanut may not be being referred 
for challenges appropriately and may be being left with an incorrect diagnosis of peanut 
allergy. An effective allergy service could be expected to report a sizeable percentage of 
children who develop symptoms upon oral provocation challenge. A rate of 30-40% would be 
reasonable for a tertiary NHS sercice as this reflects that appropriate patients are being 
selected for the procedure. If all children were experiencing symptoms on oral provocation 
challenge, this would suggest that the centre is selecting the wrong patients for the procedure 
and including those who might be accurately diagnosed by skin prick or specific IgE testing and 
the use of positive predictive values, whilst a centre where most children do not experience 
any reaction are likely to be neglecting to challenge a large number of children who might 
actually not be allergic. For the purpose of this thesis, this group of children who have never 
knowingly consumed peanut will be defined as ‘peanut-naïve’ children although it is 
recognised that these children are likely to have had exposure to peanut in ways other than by 
ingestion, such as percutaneously. 
 
1.8 Diagnosis of peanut allergy 
There are considerable implications associated with a diagnosis of food allergy and establishing 
a child’s peanut allergic status should ideally be undertaken as early as possible with the 
identification of peanut-tolerant children being of prime importance. There are several 
reasons for this; maintaining a good quality of life, the need for allergen avoidance and 
provision of appropriate rescue medication, the benefit of early peanut introduction during 
weaning, the possibility of peanut desensitisation, the inadequacy of current screening 
techniques and the risks associated with an oral provocation challenge. 
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1.8.1 Quality of life 
Peanut is a popular and widely available cheap source of protein and contamination of other 
food products with peanut is common (Remington et al., 2015, Brough et al., 2015). Where 
possible, the sooner tolerance to peanut is ascertained, the sooner a child can enjoy a normal, 
unrestricted diet which alleviates the social and emotional burden associated with a diagnosis 
of food allergy and is important for normal growth and development (Garcia-Ara et al., 2004). 
A diagnosis of peanut allergy often gives rise to substantial parental anxiety from fear of 
anaphylaxis and the constant need for vigilance (Klinnert and Robinson, 2008). Anxiety is a 
frequent problem for both food allergic children and their parents and can be assessed via 
food allergy quality of life assessments (Cummings et al., DunnGalvin et al., 2008, Flokstra-de 
Blok et al., 2008, Flokstra-de Blok et al., 2009, Herbert and Dahlquist, 2008, Hourihane et al., 
2002, Lebovidge et al., 2009). In a nut allergic population, allergic children were found to have 
poorer emotional, social and psychological quality of life scores when compared with healthy 
normative controls (Cummings et al., 2010). 
 
1.8.2 Allergen avoidance and appropriate medication 
Allergen avoidance leads to significant dietary limitations and has implications for care at 
school and out of the home. As peanut allergy often provokes severe life-threatening reactions 
allergen avoidance is the mainstay of treatment. Of additional importance is the provision of 
personalised allergy management plans and emergency medications, as accidental reactions 
are unfortunately common (Muraro et al., 2014). Children without a confirmed diagnosis of 
food allergy may be excluded from school dinners, which can have financial consequences for 
children of low-income families, who then have to provide their children with a packed lunch 
themselves. This can also lead to increased segregation among school children in reception 
and school years one and two (Muraro et al., 2010). 
 
1.8.3 Early introduction of peanut during weaning 
There is increasing evidence to suggest that total peanut avoidance in young children may be 
detrimental and may lead to the development of peanut allergy (Wennergren, 2009). It is 
therefore important to identify children who are not peanut allergic early in life to enable 
parents to introduce peanut into their diets as early as possible to protect them from future 
allergy. Due to the strong correlation between egg allergy and peanut allergy it appears 
judicious to define each egg allergic child’s peanut allergy status before they are accidentally 
exposed in the community and placed at unnecessary risk (Du Toit, 2013). The LEAP study 
identified that to reduce the number of children who will develop peanut allergy, peanut 
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should be introduced to high-risk infants (those with egg allergy or severe eczema) between 
the ages of 4 and 11 months of age (Du Toit, 2015). To ensure the safety of this process, ideally 
high-risk infants would initially be screened via skin prick testing although current national 
allergy service provision makes this difficult. Infants with a negative response could then 
introduce peanut into their diet immediately whilst those with a positive response would need 
to attend hospital as a day case for further clarification by way of a peanut provocation 
challenge. This has phenomenal health care implications both in terms of time and availability 
of screening services and day-case beds. There is therefore an urgent need to best identify the 
diagnosis of peanut allergy (or tolerance) without the need for an oral provocation challenge 
wherever possible. 
 
1.8.4 Peanut desensitisation 
As research into the treatment of peanut allergy continues, specifically with regard to peanut 
desensitisation, it is becoming increasingly important to know an individual’s peanut allergic 
status (Blumchen et al., 2010, Jones et al., 2009, Clark et al., 2009, Kim et al., 2011). Peanut 
desensitisation is beginning to be rolled out and although this is currently only available 
privately in the UK, it is likely to be more widely available within the next few years. Pollen 
desensitisation is highly effective in children and young adults and it may be that early 
intervention may deliver the best outcome; if peanut desensitisation were to prove more 
effective in children than teenagers and adults, then this would present an additional case for 
an accurate early diagnosis. A high predictive value for early sensitisation may also provide an 
opportunity for a future early intervention study (Dean et al., 2007).  
 
1.8.5 Risks associated with an oral provocation challenge 
Double-blind placebo-controlled food challenges are currently the gold standard for the 
diagnosis of food allergy although in routine clinical practice open food provocation challenges 
are more usually performed as they are less resource intensive, given that they only require 
one hospital visit rather than two (Bock et al., 1988). Although definitive, a food provocation 
challenge is time consuming, expensive and carries a risk to the child. Positive oral food 
provocation challenges may provoke acute allergic reactions with potentially life-threatening 
anaphylaxis (Nowak-Wegrzyn et al., 2009). Consequently it is far from being an ideal test as 
there is both a risk to the child and a significant cost implication. Reduction of the need for an 
oral provocation challenge would also have an important effect upon service delivery. Waiting 
lists can be long, staff-to-patient ratio requirements are high and the procedure is costly. The 
cost to the NHS of an oral provocation challenge at Bristol Royal Hospital for Children lies 
between £453 and £1118, depending upon challenge outcome and the child’s co-morbidities. 
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Children who pass incur a charge to Primary Care of £453, those who fail incur a cost of £563 
and for those with a co-existent diagnosis of asthma, the charge is £1118. Establishing a 
simple, reliable test to reduce the number of oral provocation challenges referrals would 
therefore bring considerable health economics benefits. As the burden of allergy increases, the 
waiting lists for such challenge tests grow longer and the need for improved diagnostics 
becomes increasingly important. 
 
1.8.6 Inadequacy of current screening techniques 
A diagnostic screening test for the diagnosis of peanut allergy in high-risk, peanut-naïve infants 
would be extremely useful in clinical practice. Food allergy in children is often parentally 
diagnosed, with the incidence of parentally-perceived food allergy being significantly higher 
than physician-diagnosed food allergy (Eggesbo et al., 1999, Eggesbo et al., 2001, Pyrhonen et 
al., 2009). Several studies have attempted to identify diagnostic markers that can predict the 
likelihood of an allergic reaction during an oral peanut provocation challenge (frequently 
referred to as a positive oral provocation challenge) and thereby lessen the need for the test. 
These studies have investigated the clinical utility of a number of variables, including both 
clinical symptoms and immunological markers such as specific IgE and skin prick test values 
(Hill et al., 2001, Sporik et al., 2000, Hill et al., 2004, Savage et al., 2007, Boyano-Martinez et 
al., 2002). Only one in five children with measurable whole peanut-specific IgE will have clinical 
reactivity on exposure to peanut. 
 
The opportunity to establish safe, reliable in vitro testing for food allergy has been a focus 
since the late 1990s when early work on the development and clinical utility of positive 
predictive values for peanut allergy was published (Sampson and Ho, 1997). Much focus has 
been placed upon the possible role of positive predictive values in the diagnosis of peanut 
allergy. The positive predictive value (PPV) is the proportion of patients with a positive test 
result who prove to be allergic on oral provocation challenge. It reflects the presence of a 
positive screening test successfully identifying the underlying condition being tested for. 
Measures of diagnostic performance also consider sensitivity and specificity (type I and type II 
errors). Sensitivity measures the proportion of children whose peanut allergy is correctly 
diagnosed by their positive test result whilst specificity measures the proportion of negative 
results that are correctly identified by the test. An allergen-specific IgE positive predictive value 
with a threshold of 95% is a cut-off value for allergy-specific IgE that is exhibited by 95% of 
children who undergo an oral provocation challenge and subsequently have a confirmed 
allergic reaction. The validity and clinical utility of previously published positive predictive 
values are examined later in this chapter. Published positive predictive values vary between 
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studies and depend upon the study population, as the positive predictive value is dependent 
upon disease prevalence within a given population. The diagnosis of peanut allergy in a 
peanut-naïve sensitised individual therefore currently continues to be dependent upon an oral 
food provocation challenge as existing in vivo and in vitro testing is insufficiently reliable to 
make an accurate diagnosis in a large number of peanut-sensitised children. 
 
1.9 Assessment of food allergy status 
The current diagnostic approach to any food allergy begins with the taking of an allergy-
focussed clinical history of any symptoms that may be indicative of a Type 1 hypersensitivity 
response. Children may be sensitised to peanut yet remain clinically asymptomatic without 
expressing symptoms of clinical food allergy on ingestion. A diagnosis should therefore be 
based on a positive clinical history in conjunction with the presence of food-specific IgE 
antibodies. The presence of food-specific IgE antibody levels can be determined either in vivo 
(by skin prick testing) and/or in vitro (by measuring food-specific IgE in serum). Component 
testing (i.e., IgE that is specific for sub-components of foods, such as specific proteins within a 
peanut) is currently only routinely available via specialist allergy services and not routinely 
used in smaller hospitals without an in-house immunology laboratory. In the Bristol region, 
access to specific-IgE testing is controlled by the laboratory manager and GPs are forbidden 
from requesting certain tests, including component testing.  This is to restrict costly, 
unnecessary and inappropriate testing within an environment in which the specialist allergy 
knowledge required to interpret such tests is lacking. 
 
1.10 In vitro tests for peanut allergy 
Laboratory testing for whole peanut-specific IgE testing is a standard routine investigation 
recognised globally. As discussed above, work has been conducted on the development and 
clinical utility of positive predictive values for peanut allergy. Predictive cut-off values reported 
in the literature are often lower in infants and small children and increase with age (Benhamou 
et al., 2009). Published 95% positive predictive values for a clinical reaction to peanut are 
depicted in Table 1, highlighting the substantial differences in whole peanut-specific IgE 
positive predictive values between published studies (Peters et al., 2013, Wainstein et al., 
2007, Roberts and Lack, 2005, Rance, 2002).  
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The positive predictive values of 15 kUA/L (kilo-units of antibody per liter) or higher identified 
by Sampson is the most frequently used value in UK clinical practice and the value most usually 
referenced in peanut allergy research papers (Sampson and Ho, 1997). Explanations for the 
differences seen in other studies may include the age of the study population, varying 
selection criteria and varying standards for defining an oral provocation challenge outcome (as 
either a pass or fail). The inclusion of subjective or very mild symptoms as positive has clear 
implications for the diagnostic values. Study populations also vary, and Roberts and Lack 
propose that published values for peanut skin prick testing or whole peanut-specific IgE 
concentrations in children from a tertiary allergy clinic cannot be generalised for use in other 
community-based populations (Roberts, 2005). Benhamou et al suggested that for future 
studies, well-characterised clinical phenotypes and standardized challenge protocols which 
include food preparation might elicit more valuable predictive information (Benhamou et al., 
2009). 
1.11 In vivo tests for peanut allergy 
Skin prick testing is the process whereby a minute quantity of allergen is introduced into the 
epidermis where it is able to interact with specific IgE bound to mast cells (Dreborg, 2001). The 
diameter of the resulting wheal produced in response is measured with a ruler. This is an 
internationally popular diagnostic tool of choice in paediatric allergy clinics as results are 
immediate and the test is cheap and simple to perform. As with allergen-specific IgE tests 
whereby IgE is measured in serum samples, there are limited studies available comparing skin 
prick test wheal diameters with the results of an oral provocation challenge. Of the few studies 
that have been published, the results vary substantially (Sporik et al., 2000, Hill and Hosking, 
2004, Peters et al., 2013, Wainstein et al., 2007, Nolan et al., 2007, Roberts, 2005). Published 
positive predictive skin prick test wheal diameters for whole peanut are shown in Table 2. 
 
 




Cut-off value %PPV 
Peters et al (2003) 2013 438 ≥34 kUA/l 95% 
Wainstein et al (2007)  2007 85 >10 kUA/l 100% 
Roberts et al (2005)  2005 161 ≥15 kUA/l 95% 
Rance et al (2002) 2002 363 >57 kUA/l 100% 
Sampson and Ho (1997)  1997 196 ≥15 kUA/l 95% 
Legend: Positive predictive values vary widely between studies. 












The most frequently quoted skin prick test cut-off value for predicting a clinical reaction to 
peanut in clinical practice is 8mm, although approximately 43% of children with a skin prick 
test wheal diameter below this cut-off value will still experience a reaction during an oral 
provocation challenge. Peters’ systematic review identified two groups of values and reported 
that the higher values were elicited by prick-to-prick testing rather than the conventional 
standardised extracts (Peters et al., 2013). Some studies did not differentiate between 
sensitised and proven allergic children, which may have led to an inaccurate positive predictive 
value calculation. For example, one study assessed the positive predictive values among all 
children with a positive skin prick test to peanut within a tertiary allergy clinic, regardless of 
whether they had any history of a clinical reaction (Wainstein et al., 2007). 
1.12 Component-resolved diagnostics for peanut allergy 
Traditionally, the investigation of food allergy has been by either skin prick testing or 
measuring whole peanut-specific IgE as described above. More recently, due to advances in 
diagnostic testing procedures, it has become possible to test for smaller and more specific 
allergenic parts of food allergens containing different epitopes; this is known as component-
resolved diagnostics (CRD). Component-resolved diagnostics is a method of identifying the 
allergenic sensitisation profile of patient at a pure molecular level by using recombinant 
allergenic molecules instead of allergen extracts (van Veen et al., 2016). Recombinant 
allergens are biotechnologically produced allergenic molecules that have been identified from 
an original allergen extract. They have IgE antibody binding capacity comparable to that of the 
natural allergen and are similar to the original protein with regards to structural features and 
immunological properties. Component testing evaluates the binding of IgE to specific 
allergenic proteins known as components (Valenta et al., 2007). Component testing is deemed 
superior to whole allergen testing as it is essentially cleaner; testing based on natural allergen 
Table 2:  Summary of published positive predictive cut-off values for 
peanut skin prick testing 
Author Date Cut-off value 
Peters et al (2013)  2013 ≥15mm 
Nolan et al (2007)  2007 >7mm 
Wainstein et al (2007)  2007 ≥15mm 
Roberts et al (2005)  2005 ≥8mm 
Hill et al (2004)  2004 ≥8mm 
Sporik et al (2000)  2000 ≥8mm 
Legend: Positive predictive values for skin prick tests vary widely between 
studies. 
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extracts is composed of ill-defined mixtures of major allergens, cross-reactive components and 
non-allergenic material making it more difficult to identify the disease-eliciting allergen 
(Bousquet et al., 1998). 
 
Theoretically, it may be possible to use component-resolved diagnostics to distinguish 
between individuals with a genuine peanut allergy and those who have positive whole peanut-
specific IgE or positive skin prick tests to peanut due to cross-reactivity. As such, they have the 
potential to make it easier to differentiate between peanut allergic and tolerant children 
without the need to subject them to an oral provocation challenge. As described below, some 
peanut allergen components are associated with milder symptoms, others cross-react with 
pollen allergens, whilst the seed storage protein components have a more sinister profile. 
Component testing is currently only routinely available via allergenic component-specific IgE 
measured in serum although skin prick reagents may be made available in the future. 
1.13 Peanut allergens 
The peanut is the fruit of the groundnut plant, which splits into two halves to reveal the 
embryonic plant (plumule). The main body of the peanut, known as the cotyledon, stores 
those nutrients required to support the germinating plant. A cotyledon is the primary or seed 
leaf in the embryo of higher plants. The protein element of the cotyledon is the most allergenic 
part of the peanut and contains the seed storage proteins important to the developing plant. 
Seed storage proteins are highly allergenic, being both heat and digestion stable and not easily 
altered from their most allergenic form (Lehmann et al., 2006). The more stable an epitope, 
the higher the risk of severe allergic reactions (Flinterman et al., 2008). 
 
The terminology of peanut allergenic components relates to the Latin genus and species name 
of the plant (‘Ara h’ for ‘Arachis hypogaea’), with each discrete component being numbered 
sequentially. Thirteen peanut components have been identified to date; the most 
immunologically important are considered to be Ara h 1, 2, 3, 6, 8 and 9 (Becker and Jappe, 
2014). 
 
1.13.1 Seed storage proteins  
Seed storage proteins are digested during germination. Proteins from legumes belong to the 
globulin family of seed storage proteins and are categorised as either legumins (known as 11S 
globulin) or vicilins (known as 7S globulin) (Shewry et al., 1995, Breiteneder and Mills, 2005). 
Globulins are a family of globular proteins that have higher molecular weights than albumins. 
Each globulin has its own particular shape. Together, Ara h 1, 2 and 3 represent more than 30% 
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of the total peanut protein content (Chassaigne, 2007). Storage proteins remain unaltered by 
heat or digestion and are therefore able to cross the gastrointestinal mucosal intact.  
 
Ara h 1 is a glycosylated seed storage protein belonging to the vicilin (7S) family of seed 
storage proteins and a member of the cupin superfamily, in addition to the 11S seed storage 
protein, Ara h 3, which is a peanut glycinin belonging to the legumin (11S) family (Lehmann et 
al., 2006, Koppelman et al., 2003, Koppelman et al., 2001, van Boxtel et al., 2006). Ara h 1 
comprises 12 to 16% of the total peanut protein and to date 23 linear binding epitopes have 
been identified (Burks, 1997). 
 
Ara h 2 is a conglutin seed storage protein related to the 2S albumin family, along with Ara h 6 
and Ara h 7. There is reported to be significant sequence homology between these three 
components (Lange et al., 2014). Ara h 2 is a 17 kDa glycoprotein comprising between 5.9-6.3% 
of the total peanut protein. Like Ara h 2, Ara h 6 is a 2S albumin, sharing several epitopes with 
Ara h 2 and although it rarely exists in isolation it can provoke systemic allergic reactions (Chen 
et al., 2013, Koppelman et al., 2005, Suhr et al., 2004). The exact role for Ara h 2 in peanut 
allergy has not yet been well defined. Ara h 2-specific IgE sensitivity does not appear to have 
the same geographical distribution as Ara h 1;  Ara h 1 sensitivity is recognised in almost all 
North American allergic patients, but in only up to 35% of European allergic populations 
(Burks, 1997). Ara h 2 is known to exist in two isoforms: Ara h 2.0101 and Ara h 2.0201 - 
isoforms being different forms of the same protein structure (Hales, 2004). 
 
1.13.2 Profilin 
Profilins are proteins found in plant species and plant foods, which have extensive cross-
reactivity. Profilin sensitisation is common among pollen-sensitised children with Ara h 5, a 
pollen profilin homologue, being recognised in approximately 10% of peanut allergic children 
(Kleber-Janke, 1999). It is primarily associated with local reactions and many sensitised 
individuals will not react at all when challenged (Pele, 2010). 
 
1.13.3 Bet v 1 homologue pathogenesis-related protein (PR-10) 
A Bet v 1 homologue is a protein that is similar in structure to the birch pollen protein Bet v 1 
(Betula verrucosa), the primary allergen in Silver Birch pollen. Bet v homologues are classified 
as pathogenesis-related proteins, most commonly referred to as PR-10 proteins, and are found 
in plant foods and in tree pollen. They are part of a plant’s defence system against ubiquitous 
pathogens and are activated by infection (Fernandes et al., 2013). There are seventeen families 
of PR proteins, with classification being dependent upon structure. Bet v homologues fall into 
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the family PR-10 (Fernandes et al., 2013, He, 2014). Ara h 8 is a minor allergen, which cross-
reacts with the birch pollen allergen Bet v 1 as a consequence of its similar protein fold 
structure, and sensitisation depends largely upon pollen exposure (Lange et al., 2014). This Bet 
v 1 homologue PR-10 protein is associated with mild to moderate symptoms in individuals with 
concurrent birch-pollen induced hay fever (Asarnoj et al., 2012a, Hurlburt et al., 2013). Ara h 8 
is a labile protein, unstable against digestion and which has low stability when roasted (Mittag 
et al., 2004). The Bet v 1 homologue, Ara h 8, appears to provoke symptoms of the pollen fruit 
syndrome in individuals sensitised to the birch pollen Bet v 1, whilst Ara h 9-specific IgE is most 
common in individuals exposed to pollens from the Fagales plant order (Ebisawa, 2012). The 
minor peanut antigens may be less likely to provoke a severe anaphylactic reaction and more 
commonly associated with oral symptoms. This was demonstrated in a Swedish population 
study of adolescents and adults which identified sensitization to Ara h 1-3 as a risk factor for 
systemic reactions whilst individuals sensitised to either Ara h 8 or 9 did not report severe 
symptoms (Kim and Nowak-Wegrzyn, 2011). A study of peanut component-IgE recognition 
patterns in 11 European countries reported that peanut-tolerant subjects were frequently 
sensitised to Ara h 8 or 9 but not to the seed storage proteins (Ballmer-Weber, 2015). 
However, case reports of severe reactions to Ara h 8 sensitised individuals have been 
published (Glaumann et al., 2013). 
 
1.13.4 Non-specific Lipid transfer protein (Ara h 9) 
Lipid transfer proteins are proteins that are present in plant foods and in tree and weed 
pollens, being most commonly found in fruits, vegetables and nuts. They are fairly stable 
structures and can result in systemic reactions but are regarded as secondary food allergens. 
Ara h 9 is a lipid transfer protein with some cross-reactivity to profilin and is predominantly 
found in Mediterranean individuals (Asero, 2002, Krause et al., 2009). Ara h 9 sensitised 
individuals are often co-sensitised to components Ara h 1-3 which may explain why these 
individuals are also frequently prone to severe systemic reactions, although Ara h 9 also 
possesses some thermal and digestive stability (Moverare et al., 2011, Lauer et al., 2009, Blom 
et al., 2013). 
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1.13.5 Oleosins 
Oleosins are low molecular weight structural plant proteins that are involved in the formation 
of oil bodies; they are potential allergens in legumes, tree nuts and oils. It has been postulated 
that they may be responsible for allergic reactions to peanut oil and potentially cross-react 
with soya although their role in peanut allergy is likely to only affect a small number of peanut 
allergic individuals (Pons et al., 2002, Lange et al., 2014). 
 
1.13.6 Defensins 
Defensins such as Ara h 12 and 13 are low molecular weight allergens and have been recently 
associated with severe clinical allergic reactions to peanut (Petersen et al., 2015). The primary 
molecular characteristics of the peanut components are shown in Table 3 (Matsuo et al., 2015, 
Pele, 2010). 
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1.14 Allergenicity and denaturation of peanut allergens 
Digestive enzymes in the gastrointestinal tract normally degrade food constituents during 
passage between the mouth and the small intestine. In order to cause a reaction, allergenic 
proteins, or fragments of proteins, are absorbed by the gut mucosa, processed by dendritic 
cells and then presented to the immune system. The stability of an allergen is an important 
factor as the longer the significant component of the allergenic protein remains intact, the 
more able it is to trigger an allergic reaction (Astwood, 1996). The more stable a protein, the 
Table 3:  Molecular characteristics of the major peanut allergens 
Nomenclature Protein 
family 
Family type Characteristic Probable implications for 
clinicians? 





Degradable by gastric 
digestion but some 
allergenicity retained 
Associated with severe 
reactions 
Associated with significant 
reactions 




Heat & digestion stable 
Associated with severe 
reactions 
Highly allergenic 
Most important predictor of 
peanut allergy 




Degradable by gastric 
digestion but some 
allergenicity retained 
Associated with severe 
reactions 
Associated with significant 
reactions 
Ara h 3.02 
(previously Ara h 
4) 
Glycinin Cupin (legumin) 
Seed storage 
protein 
Heat & digestion stable 
Associated with severe 
reactions 
Associated with significant 
reactions 
Ara h 5 Profilin Pollen-associated 
allergen 
Highly cross-reactive and 
present in most plants 
Seldom associated with clinical 
symptoms 
 
Ara h 6 2S Albumins Conglutin 
homologue 
protein 




with Ara h 2, but exact role not 
well clarified 
Ara h 7 2S Albumins Conglutin 
homologue 
protein 
Heat & digestion stable 
 
One of the least studied 
allergens 









Heat labile protein 
Cross reacts with birch 
pollen 
Associated with fruit & 
vegetable reactions (pollen 
fruit syndrome) in North 
Europe 
Usually associated with local 
symptoms 




Plant panallergens Heat & digestion stable 
Associated with fruit & 
vegetable reactions (oral 
allergy syndrome – OAS) in 
South Europe 
Possible association with 
systemic, severe reactions in 
addition to OAS. Primarily in 
Mediterranean countries. 
Ara h 10/11 Oleosin Structural protein Low molecular weight 
protein involved in oil 
formation 
May be associated with peanut 
oil reactions 
Ara h 12/13 Plant 
defensins 
Plant proteins Low molecular weight 
proteins 
Recent association with severe 
reactions 
Legend. Identification of an individual’s peanut sensitisation profile may assist in assessment of the risk of 
an individual experiencing a severe systemic reaction. 
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easier it is for it to cross the gastrointestinal mucosa and provoke systemic reactions (Moreno, 
2007). Most allergens enter the body via the mucosal surfaces. The intestinal epithelial layer 
has a complex dual role of facilitating the digestive absorption of nutrients whilst preventing 
access to potential antigens (allergens) and pathogens, aided by ‘tight junctions’ which restrict 
access to all but the smallest molecules (<2kDa). Specialist epithelial cells, known as ‘M cells’, 
transport microbes (and allergens) to antigen presenting cells within the gut-associated 
lymphoid tissue (GALT). Secretory IgA also has a role in excluding access to the gut epithelium 
from antigenic proteins and may have a role in the induction of oral tolerance (Nagler-
Anderson, 2001). 
 
Analysis of highly allergenic food substances has identified biochemical characteristics which 
are shared by many food allergens (Stanley, 1999). Many food allergens contain intramolecular 
disulfide bonds which are of paramount importance to their allergenicity (Taylor, 1996). 
Denaturation is the process by which these disulfide bonds are either altered or destroyed. 
The destruction of these disulfide bonds disrupts the native conformation and changes the 
tertiary structure of the protein (Figure 6). Following protein denaturation the protein shape is 
modified with the consequence that the IgE binding site no longer exists (Siskiyous, 2010). 
Once a protein has been denatured it frequently loses its allergenic potential, as IgE binding to 
the specific epitope is no longer possible. 
 
The majority of epitopes are conformational. Conformational epitopes are generally more 
labile and easily destroyed by heat than linear epitopes. Following denaturation, the amino 
acid sequences of linear epitopes may sometimes still be recognised by the antibody, and 
therefore retain some of their binding capacity. Conformational epitopes are generally unable 
to bind to the antibody after denaturation as unfolding destroys the shape of the amino acid 
sequence. A lack of IgE recognising linear epitopes has been postulated as the likely 
mechanism by which some children experience resolution of peanut allergy (Hourihane, 2005). 
Conformational models of Ara h 2 and Ara h 6 demonstrate almost identical protein structures 
(Lehmann et al., 2006, Flinterman et al., 2007). 
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Figure 6:  The process of globular denaturation  
 
Legend. The process of denaturation alters the shape of the proteins, which subsequently lose their allergenic 
potential due to the inability to bind to the specific epitope. Above, the original protein (1) is altered by heat (2) to 
assume an altered form after denaturation (3) (Scurran15, 2015). 
 
 
Common denaturation parameters include ranges of pH and temperature. Individual peanut 
proteins have differing denaturation parameters; for example, the allergenicity of Ara h 1 has 
been demonstrated to be heat-stable although conformational changes may be induced by 
heat treatment (Koppelman, 1999). Both Ara h 1 and Ara h 3 have been demonstrated to be 
more easily hydrolysed by the digestive enzyme pepsin, whilst Ara h 2 and Ara h 6 remain 
digestion stable (Koppelman et al., 2010). However, although gastric digestion results in rapid 
degradation of Ara h 1 and Ara h 3 into small fragments, it retains some T cell stimulatory and 
IgE-binding properties although in contrast, Ara h 2 is far more stable (Eiwegger et al., 2006, 
Koppelman et al., 2010).  Ara h 2 has been shown to be resistant to acidic environments and 
consequently to digestion by gastrointestinal tract enzymes (Astwood, 1996). 
1.15 Ara h 2 and persistent peanut allergy 
Recent research has identified that the measurement of Ara h 2-specific IgE may be of 
considerable value in distinguishing between children with true clinical allergy and those who 
are merely sensitised. The three dimensional structure of Ara h 2 shown in Figure 7 comprises 
a five-helix bundle stabilised by four disulfide bonds and is similar in structure to many 
amylase and trypsin inhibitors (Mueller et al., 2011). The disulfide bonds are of paramount 
importance to the ability of Ara h 2 to resist denaturation and subsequently to its ultimate 
stability as described above (Sen, 2002). Mapping of the Ara h 2 epitope-binding sites has 
identified ten epitopes (Barre et al., 2008). Ara h 2 has been identified as being a more potent 
allergen than either Ara h 1 or 3 (Palmer, 2002, Koppelman, 2004). 
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Figure 7: Ribbon diagram of the peanut component Ara h 2 
 
 
Legend. The glycoprotein, Ara h 2, is a three-dimensional conformation comprising a five-helix bundle stabilised 
by four disulfide bridges which accounts for 5.9-6.3% of the total peanut protein. To date, ten epitopes have been 
mapped on the molecular surface (Barre, 2005). 
 
 
As Ara h 2 retains it allergenic properties despite digestion and extensive heating, the 
measurement of specific IgE antibodies to Ara h 2 has been suggested to be of value in the 
identification of peanut-sensitised children who are allergic to peanut, eliminating unnecessary 
challenges and risk (Klemans et al., 2015, Klemans, 2013, Dang et al., 2012). More than 95% of 
American peanut-allergic individuals have positive Ara h 2-specific IgE concentrations 
(Koppelman et al., 2001, Palmer et al., 2005). 
 
A literature review to identify relevant articles related to Ara h 2-specific IgE testing in the 
diagnosis of peanut allergy is presented in Chapter 2. An increasing number of medical 
practitioners working in the field of paediatric allergy are beginning to consider the 
measurement of Ara h 2-specific IgE concentrations as a useful adjunct to their existing 
practice and clinical decision-making. The literature review aims to establish what is currently 
known about the clinical utility of Ara h 2-specific IgE testing in peanut allergy diagnosis and to 
ascertain where knowledge is lacking and further research may be required. 
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2.1 Search methods for Identification of relevant literature related to peanut and 
Ara h 2  
This review searched the PubMed Databases for articles published between 2010 to June 
2016. This is because component-resolved diagnostic testing is a relatively new concept and 
searching earlier databases was unlikely to have identified relevant papers. The initial 
literature review was conducted on 19.05.2015 but was repeated on 27.06.2016 following 
completion of the study after several additional relevant articles were published. This later 
review identified an additional 9 articles of potential interest. The search terms used in this 
literature review are shown in Table 4. No language restrictions were made to maximize 
international coverage although search was restricted to journal articles only, with 
presentation abstracts being excluded. Abstracts were searched by hand for relevance and the 
full text of relevant papers was acquired and read. Salient points of the abstract were noted 
and important references obtained. A search of the term ‘Ara h 2’ (search 7) identified 158 
titles and abstracts in the PubMed database published between 2010 and June 2016; 21 of 
these were relevant. After the exclusion of duplicate papers, a second search using the terms 
‘peanut allergy (search 3) and diagnosis (search 6) identified only 1 additional paper. A further 
additional paper was obtained from the hand-search of reference lists. Other search terms 
were employed as outlined below but no additional papers were found. 
 
Table 4: PubMed Search History (27.06.2016) 
Search No: Search History Results 
1 Hypersensitivity 31520 
2 Peanut hypersensitivity 127 
3 Peanut allergy 936 
4 Screening 182676 
5 Component resolved diagnostics 50 
6 Diagnosis 475013 
7 Ara h 2 158 (21) 
8 3 and 5 13(0) 
10 3 and 6  150 (1) 
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The breakdown of the search history is depicted in Figure 8. After exclusion of duplicate 
articles and those deemed irrelevant by title, 23 papers were obtained. Hand searching of 
reference lists identified 1 additional relevant paper. After the papers had been read, they 
were scored using the QUADAS-2 (Quality Assessment Diagnostic Accuracy Study) scoring 
system, a tool for assessing the quality of diagnostic accuracy tests (Whiting, 2011). The 
QUADAS tool has been utilised in several systematic reviews and recommended by the 
National Institute for Clinical Excellence (NICE). 
 



































Excluded papers following 
QUADAS-2 review  
n=6 (See Section 2.4) 
 
Included papers scored using QUADAS-2 
n=14 
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2.1.1 Papers excluded by abstract 
4 papers were excluded by abstract. Tuano et al published an instructive article on component-
resolved diagnostic methodology, Bernard et al investigated the relative contributions and 
allergenicity of linear and conformational epitopes of Ara h 2, Kukkonen et al aimed to utilise 
Ara h 2-specific IgE to distinguish between mild and moderate-to-severe peanut allergy in a 
birch-pollen endemic area and Namork looked at age-related differences in peanut-
sensitisation patterns in a cohort of patients voluntarily reported to the Norweigan Food 
Allergy Register with no reference to oral provocation challenges (Namork and Stensby, 2015, 
Kukkonen et al., 2015, Bernard et al., 2015, Tuano and Davis, 2015). 
 
2.2 Literature review methods 
A systematic literature review was performed of all relevant identified papers describing the 
clinical utility of measuring Ara h 2-specific IgE for the diagnosis of peanut allergy in children. 
The quality of the included studies was assessed using the QUADAS-2 checklist (see Table 5). 
QUADAS-2 is a validated tool designed to evaluate the risk of bias and applicability of primary 
diagnostic accuracy studies through four phases. The first phase produces a review question 
based on the patients studied, the index test and the reference standard and reference 
condition. This is similar to the PICO process, used as the simplistic basis for this review. The 
PICO process is used in evidence-based practice to examine a clinical care-related question. 
The acronym stands for:  P – patient or study population, I – intervention, C – comparison and 
O – outcome (Huang et al., 2006).  Studies were included if they focused on children with 
either suspected peanut allergy or peanut sensitisation (based on skin prick or specific IgE 
testing) as these are the study populations examined within this thesis. There were no studies 
found specifically examining the clinical utility of Ara h 2-specific IgE concentrations for the 
diagnosis of peanut allergy in egg allergic children. 
 
The phase one PICO question was utilised as follows: 
 
Patients:   Children with suspected peanut allergy  
Intervention (Index Test): Ara h 2-specific IgE measured 
Comparison Test:  Oral Provocation Challenge  
Outcome:   Confirmed peanut allergic status 
 
Phase two examines the construction of signalling questions to be used to assess study 
validity, phase three aims to review the flow diagram for the primary study and phase four is 
designed to apply judgments regarding study bias and applicability. This review focuses 
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primarily upon phases one and four. Following the literature review, eligibility criteria for 
selected studies were developed and are listed in Table 5. 
 
Table 5:  Study inclusion and exclusion criteria 
Inclusion criteria: Exclusion criteria: 
Articles only Non-English language 
Suspected peanut allergy Published pre- 2010  
Index test performed Other Index Test 
OPC in 20% of study population Systematic review or review article 
Paediatric population No paediatric subjects 
 
 
The QUADAS-2 scoring assessment tool depicted in Table 6 is relevant to phase four of the 
QUADAS-2 process; papers are assessed for risk of bias (sub-domain A) and concerns regarding 
test applicability (sub-domain B) through focusing on 4 key domains: patient selection; use of 
the index test; use of the reference standard, and flow and timing. 
 
Table 6:  QUADAS-2 Scoring Assessment Tool 
Risk of Bias Domain 
Patient selection  Patients were not randomly or consecutively selected; case-control design 
was used; non-comparable cohorts were used 
Index test  Cut-off value not specified in the paper 
Reference standard  An open challenge rather than a DBPCFC was performed on more than 
50% of study population 
Flow and timing  The reference standard was not performed in >5% the study population 
Applicability Concern Domain 
Patient selection  Non-secondary or tertiary care centre; diagnosis based on sensitization 
regardless of clinical history 
Index test  Non standardized / commercially available test performed 
Reference standard  Weak criteria for categorization of OPC result, which may allow for 
misclassification of diagnosis 
  
   Low Risk    High Risk     ? Unclear Risk  
 
Studies deemed eligible and subjected to a QUADAS-2 quality assessment are summarised in 
Table 7 and Figure 9, formatted using recommended QUADAS-2 resources 
(http://www.bristol.ac.uk/social-community-medicine/projects/quadas/quadas-2/) (QUADAS-
2, 2016). 
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Figure 9 clearly summarises the studies assessed in Table 7. It is clearly evident that the 
domain with the highest risk of bias was the patient selection domain, followed by the 
reference standard domain. Risk of bias was lowest in the index test and flow and timing 
domains. 14 included studies are synopsised individually in Section 2.3 using the QUADAS-2 
scoring assessment tool outlined above in Table 6. Six selected studies which did not fulfil the 
eligibility criteria but which still report findings of interest regarding the diagnostic utility of 
Ara h 2-specific IgE concentrations are described separately at the end of the chapter in 
Section 2.4. 
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Table 7:  Quality assessment of eligible articles using QUADAS-2 
Study 















Kim, 2016        
van Veen, 2016        
Martinet, 2016        
Beyer, 2015        
Ebisawa, 2015    ?   ? 
Leo, 2015    ?    
Eller, 2013        
Klemans, 2013        
Lieberman, 2013        
Lopes de Oliveira, 2013        
Surtannon, 2013        
Dang, 2012        
Ebisawa, 2012        
Nicolaou, 2010         
Legend: Low Risk High Risk  ? Unclear Risk  Most studies had bias in the patient selection domain and many within the reference and flow 
and timing domains.  No study introduced bias within the index test domain. 
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Legend:       Low Risk      High Risk       Unclear Risk 
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2.3 The diagnostic utility of detecting Ara h 2-specific IgE: Selected articles 
identified from the literature search 
Peanut comprises several discrete allergenic proteins. The development of component-
resolved diagnostics for peanut, where component-specific IgE concentration levels are 
measured, is anticipated to be a valuable tool in the diagnosis of peanut allergy. Ara h 2 has 
been proposed as the immunodominant allergen in peanut allergy and subsequently a 
potential superior diagnostic test (Nicolaou 2010). A review of the literature highlights both 
the paucity of published research that investigates the diagnostic value of Ara h 2-specific IgE 
concentrations in predicting peanut allergy in peanut-naïve infants and young children; and 
also the high degree of bias in available studies. Similarly, studies of specific subgroups of 
allergic children, such as those with eczema or egg allergy, do not exist. Selected studies that 
fulfilled the QUADAS-2 inclusion criteria are summarised in Table 8 and subsequently discussed 
individually.
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Table 8: Outline of QUADAS-2 scored included studies 
Authors  Type of study Number of subjects & 
inclusion criteria 
Primary outcome Key Findings 
Kim, 2016 Retrospective study of peanut-
specific IgE and components in 
Korean children in two study centres 
48 children had OPC (22 
proven allergic) 
5 children with recent 
anaphylaxis and detectable 
specific IgE not challenged 
To construct diagnostic 
decision points for 
peanut-specific IgE and 
evaluate the value of Ara 
h 1,2,3,8&9 in diagnosis 
 The 100% PPV for peanut-specific IgE was 10.3kU/L 
 The 100% PPV for Ara h 2 was 4.0kUA/L 
 The AUC for Ara h 2 was 0.83 
 Measurement of Ara h 2 had no additional benefit 
van Veen, 
2016  
Prospective cohort study of utility of 
Ara h 1,2,3,6,8 & 9 in 62 children 
attending a Dutch tertiary clinic 
between 2012-2013 
Children had either a history 
of previous reaction to peanut 
or were peanut-sensitised and 
peanut-naïve. 
To evaluate utility of CRD 
in predicting a) DBPCFC 
outcomes b) the eliciting 
dose and c) reaction 
severity 
 Ara h 2 best predictor of peanut allergy but no 
better at predicting DBPCFC outcome than whole 
peanut 
 A negative peanut-specific IgE level to peanut had a 
100% NPV removing the need to challenge this 
subgroup of children 
 CRD had no value in the prediction of the eliciting 
dose or the severity of the reaction 
Martinet, 
2016 
Retrospective study of Ara h 2 and 
Ara h 8 in children attending a French 
tertiary allergy centre 
81/268 children had adequate 
data recorded including a 
previous OPC. 
To establish a diagnostic 
decision point for Ara h 2 
and Ara h 8 in the 
diagnosis of peanut allergy 
 The optimal cut-off point for whole peanut-SpIgE 
was 0.5kUA/L; specificity 76% and PPV 85% 
 For Ara h 2, a cut-off of 1.0kUA/L had a 100% PPV 
and a 93% NPV 
 Children with Ara h 2<0.44 kUA/L were at low risk of 
anaphylaxis and those >14kUA/L were at high risk 
 Ara h 8 was useful for birch-pollen cross-reactivity 
Beyer, 2015 Prospective study of peanut 
components in German children with 
suspected peanut allergy 
210 children had OPC (90 
proven allergic) 
To prospectively 
investigate the role of 
peanut component-
specific IgE in the 
diagnosis of peanut allergy 
 A cut-off value for Ara h 2 of 14.4kUA/L had a 90% 
probability for peanut allergy 
 The 95% probability was 42.2kUA/L. 
 The AUC was 0.92 
Ebisawa, 
2015 
Retrospective study of children 
attending 2 Japanese centres 
between 2005-2010 
165 children included (35 
allergic and 86 tolerant on 
OPC; 36 with positive history 
and 8 with negative history 
To study the association 
between SpIgE to peanut 
and Ara h 2 in the 
diagnosis of peanut allergy 
 Ara h 2 cut-off value of 4.0 kUA/L gave 91.3% PPV 
 SpIgE concentrations for Ara h 2 were lower than for 
peanut  
 There is a relationship between a positive Ara h 2 
level and peanut allergy 
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Table 8: Outline of QUADAS-2 scored included studies (page 2) 
Authors  Type of study Number of subjects & 
inclusion criteria 
Primary outcome Key Findings 
Leo, 2015 Prospective Canadian study of the 
predictive value of Ara h 2 in 
Canadian children 2011-2013 
137 children included (20/47 
failed OPC); 90 were not 
challenged due to high Ara h 
2-SpIgE 
To review the clinical 
utility of Ara h 2-specific 
IgE concentrations in 
predicting of peanut 
allergy in peanut-
sensitised children 
 95% PPV for Ara h 2 was between 2 & 3 kUA/L AUC 
for Ara h 2 was 0.75 at 0.5 and 0.75 kUA/L  Two 
patients with negative Ara h 2-SpIgE concentrations 
failed OPC; one had anaphylaxis Ara h 2 is an 





Peanut OPC outcomes correlated 
with specific IgE concentrations to 
whole peanut and peanut 
components Ara h1-3, h8 & h9) 
175 peanut OPC positive & 30 
OPC negative individuals (aged 
1-26; mean age 5.6 years) 
To correlate IgE values 
with OPC outcomes 
 Best correlation was found for Ara h2  Cut-off value 
for Ara h2 of 1.63 kUA/L yielded specificity of 100% 
and sensitivity of 70%  
Klemans, 
2013 
Retrospective study of Dutch children 
with suspected peanut allergy 
evaluated between 2008 and 2010 
100 of 200 eligible patients 
randomly selected for OPC; 47 
allergic, 53 tolerant (DBPCFC 
n=81; Open n=19) 
To develop a new peanut 
allergy prediction model 
based on sIgE to 
components 
 Ara h 2 most useful component  Cut-off value for 
Ara h 2 of 0.35 kUA/L resulted in 88% sensitivity and 
84% specificity The AUC 0.84 PPV was best at 94% 
Lieberman, 
2013 
Prospective study of 4 cohorts of 
patients from the US and Sweden 
167 children completed an 
OPC; 106 proved allergic 
To evaluate the utility of 
peanut component testing 
in the diagnosis of peanut 
allergy in children with 
suspected allergy 
 Ara h 2 was the best diagnostic test in patients with 
suspected peanut allergy May be useful in the 
reduction of OPCs PPV 94% Sensitivity 80% and 




Prospective study of German children 
with suspected peanut allergy 
Open OPC in 61 children 
referred to a tertiary centre  
To investigate the role of 
specific IgE concentrations 




allergy from peanut 
tolerance. 
 94% of allergic and 26% of tolerant children were 
sensitised to Ara h 2 Neither whole peanut or Ara h 
2 SpIgE concentrations were able to clearly 
differentiate between allergy and tolerance 
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Table 8: Outline of QUADAS-2 scored included studies (page 3) 
Authors  Type of study Number of subjects & 
inclusion criteria 
Primary outcome Key Findings 
Surtannon, 
2013 
Cross-sectional study of peanut 
sensitised Thai patients between 
2008 and 2010 
40 peanut-sensitised 
individuals; clinical reactions 
determined by clinical history 
or OPC 
To investigate the utility 
of CRD to differentiate 
between allergy and 
tolerance in a low-
prevalence country 
 Ara h 2 cut-off <0.35kUA/L with sensitivity 68% and 
specificity 95% 
 Ara h 2 cut-off of 0.35kUA/L PV 92% and NPV 77% 
 The AUC was 0.82 
Dang, 2012 Prospective Australian birth cohort 
study of one year old children 
Random stratified sample of a 
population-based birth cohort 
study of 1-year olds; 100 with 
peanut allergy and 100 
controls (58 of whom were 
peanut-sensitised). All open 
challenged  
To ascertain whether sIgE 
to Ara h 2 might improve 
the accuracy of peanut 
allergy diagnosis in a 
general population of 
infants 
 Measuring SpIgE to whole peanut followed by Ara h 2, 
reduced the number of OPCs by two thirds 
 Cut-off value for Ara h2 of 1.19 kUA/L detected 60% of 
children with PA 
 Cut-off value of 0.10 kUA/L for Ara h2 identified 87% of 
peanut tolerant children 
 At a cut-off of 0.10kUA/L, sensitivity was 95% and 
specificity was 86% 
 The AUC was 0.95. 
Ebisawa, 
2012 
A prospective study of 57 Japanese 
children referred for investigation of 
peanut allergy 
57 Japanese children (2-13 yrs) 
attending specialist allergy clinic 
with previously primary care 
diagnosed peanut allergy; 31 
proven peanut positive on open 
OPC & 26 negative 
To evaluate utility of IgE to 
peanut allergens in diagnosis of 
peanut allergy in Japanese 
children 
 Ara h2 was superior to whole PN 
 Using the cut-off value of >0.35kUA/L, sensitivity & 
specificity were 88% and 84% 
 PPV 82% & unlikely to be useful as a sole tool for 
diagnosis in the absence of clinical history 
 AUC 0.91 
Nicolaou, 
2010 
Prospective UK birth cohort study of 
8 year old children 
A population-based birth cohort of 
933 8 year olds tested; 110 (11.8%) 
sensitised. 19 not challenged (no 
consent); 12 with known allergy 
were considered allergic without 
challenge. 
79 children had an OPC and 7 
were positive. 
To establish the proportion of 
sensitised children with true 
allergy 
To investigate the utility 
of components to 
distinguish between 
allergy and tolerance 
 Prevalence of true allergy among sensitised 8 year olds 
estimated as 22.4% 
 Ara h2 most important predictor 
 Cut-off value >0.35kUA/L had sensitivity of 1.00 and 
specificity of 0.96 
Legend:  DBPCFC, Double-blind placebo-controlled food challenge; OPC, Oral provocation challenge; PPV, Positive predictive value; NPV, Negative predictive value; AUC, Area under the curve; 




This retrospective study recruited Korean children with suspected peanut allergy in two 
centres between 2011 and 2013. The primary aim was to establish diagnostic decision points 
for whole peanut-specific IgE in the diagnosis of peanut allergy. The secondary aim was to 
evaluate the clinical utility of measuring specific IgE concentrations to the peanut components 
Ara h 1,2,3, 8 and 9 in confirming the diagnosis of peanut allergy. The study population was 
small; 48 children were recruited and 22 reacted upon open oral provocation challenge, the 
use of the latter inducing a high risk of bias in the patient selection domain according to the 
QUADAS-2 criteria. An additional 5 children with a clear history of anaphylaxis and detectable 
whole peanut-specific IgE within the last twelve months were included in the statistical 
analysis. Bias concerns regarding the index test were low as the study published cut-off values. 
There was a high level of bias regarding the reference standard domain, which used an 
unusual protocol - roasting peanuts for ten minutes at 170 degrees. All children, except those 
excluded for safety reasons, underwent an oral provocation challenge as per routine clinical 
care and therefore there were no bias concerns regarding study flow and timing. There was a 
high level of concern regarding study applicability and patient selection, as it is unclear 
whether all children were tertiary clinic patients. 
 
Summary:  Sensitisation to Ara h 2 was higher in peanut allergic children but there were no 
differences between groups for other components. The 100% positive predictive value was 
10.3 kUA/L for whole peanut-specific IgE with a sensitivity of 31.8%, specificity of 100% and 
negative predictive value of 63.4%. For Ara h 2-specific IgE, the 100% positive predictive value 
was 4.0 kUA/L. The area under the curve (AUC) for whole peanut-specific IgE antibody levels 
was 0.91 and for Ara h 2-specific IgE was 0.83. The authors concluded that Ara h 2-specific IgE 
did not provide any additional diagnostic information and was of little benefit (Kim, 2016). 
van Veen, 2016 
This prospective cohort study reviewed 62 consecutive children attending a Dutch tertiary 
allergy clinic between 2012 and 2013. Children had either a history of a previous allergic 
reaction to peanut, or were peanut-sensitised and peanut-naïve. The study aimed to measure 
specific IgE concentrations to the peanut components Ara h 1, 2, 3, 6, 8 & 9 and to use these 
results to predict (a) peanut double-blind placebo-controlled food challenge outcomes, (b) the 
eliciting dose and (c) the severity of the reaction. The risk of patient selection, index test and 
reference testing bias was low as subjects were recruited prospectively and were all subjected 
to a double-blind placebo-controlled food challenge in a single centre within three months of 
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serological testing. This meant that the risk of flow and timing bias was also low. 33(53%) 
children reacted with challenge outcomes being strictly scored using Sampson’s scoring 
system. There was a low level of concern with regard to patient selection applicability as 
children included in this tertiary centre study were either peanut-sensitised and peanut-naïve 
or had a confirmed history of peanut allergy supported by serological testing. The present 
thesis examines similar groups of children although refines the study population further to 
only include children with a history of egg allergy. 
 
Summary: Ara h 2-specific IgE testing was identified as the best predictor of peanut allergy, 
although peanut component-specific IgE concentrations were no better at predicting double-
blind placebo-controlled food challenge outcome, eliciting dose or reaction severity than 
existing specific IgE or skin prick tests to whole peanut. A negative whole peanut-specific IgE 
level had a 100% negative predictive value and was superior to that of peanut components. 
The paper therefore proposed that children with a negative whole specific IgE test need not be 
subjected to an oral provocation challenge. Components were of no value in predicting either 
the eliciting dose or the severity of any reaction (van Veen et al., 2016). 
Martinet, 2016 
This retrospective review of 81 children attending a French tertiary allergy clinic aimed to 
evaluate the diagnostic decision point for Ara h 2- and Ara h 8-specific IgE testing in the 
diagnosis of peanut allergy. 81/268 children with adequate data recorded were included in the 
study analysis. This, combined with the study being retrospective, introduced a high risk of 
patient selection bias. There was also a high risk of bias for the reference standard as all 
children were subjected to an open oral provocation challenge, and for flow and timing as it is 
unclear when children were reviewed. However, bias in the applicability concern domain was 
low with the majority of patients undergoing an oral provocation challenge scored using the 
European Academy of Allergy and Clinical Immunology (EAACI) taskforce on anaphylaxis 
scoring. 
 
Summary:  The optimum cut-off value for whole peanut was 0.5kU/L with poor specificity at 
76% and a positive predictive value of 85%. Ara h 2-specific IgE level measurements had a 93% 
negative predictive value and a 100% positive predictive value at a cut-off value of 1.0 kUA/L. 
An Ara h 2-specific IgE level of <0.44 kUA/L was associated with a low risk of anaphylaxis and a 
level of >14kU/L with a high risk. Ara h 8 was recommended for evaluation of birch pollen 
cross-reactivity (Martinet et al., 2016). 
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Beyer et al, 2015 
This study aimed to prospectively investigate the role of peanut and hazelnut components in 
the diagnosis of German children with suspected allergy being referred to 7 tertiary paediatric 
hospitals. This review focuses on the peanut allergy section of the study. 210 children with 
suspected peanut allergy undergoing oral provocation challenges were prospectively recruited. 
The risk of patient selection bias and index and reference testing bias was low as all children 
were prospectively challenged, with one third undergoing a double-blind placebo-controlled 
food challenge rather than an open challenge. There was also a low level of bias within the 
flow and timing domain as blood was drawn for component testing on the same day as the 
oral provocation challenge. Specific IgE concentrations were measured for peanut and Ara h 1, 
2, 3 and 8. Ninety children (43%) had proven peanut allergy following oral provocation 
challenge. There was a low level of concern regarding applicability of the study in terms of 
patient selection, as all patients were tertiary centre patients. It is important that all included 
study populations are similar to enable comparisons to be made but also, oral provocation 
challenges are rarely conducted outside the secondary and tertiary setting. 
 
Summary: The best diagnostic test was Ara h 2-specific IgE. A 90% probability for a positive 
peanut oral provocation challenge was calculated at a cut-off value of 14.4 kUA/L. A 95% 
probability could only be estimated for Ara h 2-specific IgE concentrations at a cut-off value of 
42.2 kUA/L. An area under the curve for Ara h 2-specific IgE was calculated as 0.92 (Beyer, 
2015). 
Ebisawa, 2015 
This study aimed to look at the relationship between whole peanut- and Ara h 2-specific IgE 
concentrations and peanut allergy in Japanese schoolchildren. A diagnosis of peanut allergy 
was based on either a positive oral provocation challenge or a convincing positive case history. 
It is unclear whether the latter was confirmed by testing, placing the study at high risk of 
patient selection bias as the peanut allergic group is very likely to include children who are not 
allergic. The risk of bias in the flow and timing domain is unclear as there is no description of 
the time interval between the index test and the reference standard (oral provocation 
challenge) taking place although it is likely that the oral provocation challenge was conducted 
first, given the date of the introduction of component testing. There are concerns regarding 
patient selection applicability given the study inclusion criteria and high risk of bias together 
with an unclear level of concern regarding the reference standard, as the scoring criteria are 
not clearly defined. Therefore the prevalence of peanut allergy in more than 5% of the study 
population is likely to be misrepresented. 
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Summary:  An Ara h 2-specific IgE cut-off of 4.0 kUA/L had a positive predictive value of 91.3%. 
For each doubling of specific IgE antibody level, the diagnosis of peanut allergy increased by an 
odds ratio of 1.74 for Ara h 2- and 1.68 for whole peanut-specific IgE. Ara h 2-specific IgE 
concentrations were lower than for whole peanut (Ebisawa et al., 2015). 
Leo, 2015 
This study of 147 peanut-sensitised Canadian children aimed to evaluate whether Ara h 2-
specific IgE concentrations are useful in predicting peanut allergy. Recruited children either 
had a convincing clinical history of peanut allergy or were peanut-naïve. 47 children with an 
Ara h 2-specific IgE level of ≥10 kUA/L (regardless of whole peanut-specific IgE level) were 
invited for an open oral provocation challenge; 20 failed (10 with anaphylaxis) and 10 
completed the challenge without reaction. This study was at high risk of bias in several 
domains. In the domain of patient selection bias, patients who were invited for an oral 
provocation challenge were not selected on the basis of previously published positive 
predictive values for Ara h 2-specific IgE concentrations as none currently exist; in the 
reference standard domain, all challenged patients followed an open protocol and in the flow 
and timing domain, the interval between the index test and reference standard test is unclear. 
In view of the above, patient applicability concerns also exist as most allergic patients were 
included on the basis of sensitisation rather than challenge-proven allergy. The scoring system 
was robust for the classification of challenged children, but this group comprised a small 
minority of the study population and groups were not analysed separately. 
 
Summary:  This study reported that an Ara h 2-specific IgE cut-off value of 0.75 kUA/L (AUC 
0.75) was twice as predictive as using a combination of a whole peanut-specific IgE level of 
more than 2 kUA/L with a positive skin prick test >3mm. Two patients with negative Ara h 2-
specific IgE levels failed the oral provocation challenge; one with anaphylaxis (Leo et al., 2015). 
Eller, 2013 
This paper aimed to correlate specific IgE values to peanut components with peanut oral 
provocation challenge (OPC) outcomes. Retrospective data from 175 positive and 30 negative 
OPCs in Danish children and adults aged 1 to 26 years were correlated with specific IgE levels 
to whole peanut and peanut components. 
 
There was a high risk of selection bias as patients were retrospectively recruited over a six year 
period (2003-2009). There was also a high risk of bias in the reference standard domain as the 
majority of OPCs performed were open challenges. Children three years of age or under were 
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subject to an open challenge (n=165) whilst older children and adults underwent FBPCFC 
(n=40). Only 158 of the 165 positive OPCs were described as having had objective symptoms. 
There is no differentiation between results for children and results for adults introducing a 
high level of concern regarding the applicability of the study into paediatric clinical practice. 
Another significant limitation of this study is data concerning the small number of subjects 
proven to be peanut tolerant (30/205). 
 
Summary:  This study concluded Ara h 2 to be the most important peanut component in the 
prediction of peanut allergy with an ODP of 1.63 kUA/L (specificity 1.00; sensitivity >70). The 
authors reported that using this cut-off value would have reduced the number of OPCs from 
205 to 92 concluding that Ara h 2 can significantly improve diagnostic accuracy but cannot 
completely replace the need for an OPC (Eller and Bindslev-Jensen, 2013). 
Klemans, 2013 
Klemans compared the utility of Ara h 2-specific IgE testing with an existing model for the 
prediction of peanut allergy incorporating sex, history, age, skin prick test and specific IgE 
concentrations to whole peanut and total IgE minus specific IgE to whole peanut. The aim of 
the study was to improve and update the existing model by adding additional clinical 
symptoms and peanut component testing. 100 of 200 eligible patients in the Netherlands were 
randomly selected for inclusion. All patients had been referred with suspected peanut allergy 
based on a positive history regardless of sensitisation data. This is different to the study 
population in the present study, which includes only high-risk patients, many of whom are 
peanut-naive. There is a high level of concern regarding patient selection applicability, as the 
patient study group in this paper is not directly comparable with the subgroup population of 
high-risk atopic infants examined in the present study. It may however, be comparable with 
the tertiary clinic population as a whole in terms of the evaluation of children referred with 
suspected peanut allergy. All children were challenged; 81 underwent double-blind placebo-
controlled food challenges and 19 (mostly younger) children were subject to open challenges. 
 
Summary:  The discriminative ability of Ara h 2-specific IgE in predicting peanut allergy was 
found to be comparable with the updated prediction model. This adds to the accruing 
evidence suggesting that Ara h 2-specific IgE is the most useful peanut component in the 
diagnosis of peanut allergy (Klemans, 2013). 
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Lieberman et al, 2013   
Lieberman et al compared whole peanut-specific IgE concentrations with the recombinant 
allergens Ara h 1, 2, 3 and 8 in 167 children with suspected peanut allergy undergoing an oral 
peanut provocation challenge in the US or Sweden. There was a high level of patient selection 
bias with individuals being recruited from four different cohorts within the two countries, with 
varying degrees of suspicion of peanut allergy. This also introduces a high level of concern 
regarding study applicability under the patient selection domain. 
 
All patients were subjected to an oral provocation challenge, which in the majority were 
double-blind placebo-controlled food challenges, and blood was taken immediately prior to 
the procedure. Overall, 63.5% patients reacted. Specific IgE concentrations to components and 
whole peanut were compared between peanut allergic and tolerant groups. Subgroup analysis 
between the four cohorts was also conducted. Ara h 2-specific IgE was the most specific test 
for peanut allergy with specificities ranging from 85% to 95% between subgroups. 
 
Summary: Ara h 2-specific IgE was the most specific test among the combined groups with the 
best positive predictive value (0.94). Receiver-operating characteristic curve analysis 
demonstrated an area under the curve of 0.84. Ara h 2-specific IgE may have a role in the 
reduction of the number of oral provocation challenges required in clinical practice and is 
particularly of value when combined with whole peanut-specific IgE testing to peanut in a 
stepwise approach (Lieberman, 2015) 
Lopes des Oliveira et al, 2013 
Lopes des Oliveira et al investigated the diagnostic value of specific IgE to whole peanut and 
the components Ara h 1, 2, 3, 6 and 8 among 61 German children. The risks of patient 
selection bias and level of applicability concern were both low. All children had been referred 
to a tertiary centre and all were challenged regardless of whole peanut-specific IgE level. The 
index test of Ara h 2-specific IgE concentration measurements was different in this study to all 
of the others as it was ascertained by using the ISAC chip microarray immunoassay. This is a 
solid-phase assay that enables the measurement of specific IgE antibodies to multiple 
allergenic components using only 20µ of serum. There was a high risk of bias with the 
reference standard as all oral provocation challenges were open challenges. 25 children had a 
whole peanut-specific IgE level to above the published cut-off value of 15kUA/L, although 
7(28%) of these were peanut tolerant on oral provocation challenge giving a false positive rate 
of 28%. 34/61(56%) children were proven allergic. 94% of peanut allergic children were 




Summary: Ara h 2-specific IgE measurements did not clearly differentiate between clinical 
allergy and clinical tolerance and reliance upon the test is likely to lead to misclassification. An 
oral provocation challenge remains necessary in order to make an accurate diagnosis (Lopes 
de Oliveira, 2013). 
Suratannon et al, 2013 
This study aimed to investigate the role of component-resolved diagnostics in the evaluation 
of peanut allergy among peanut-sensitised individuals in Thailand. There was a high risk of 
patient selection bias as individuals were included based on peanut sensitisation and clinical 
history alone. The sample size of only 40 patients (19 proven allergic and 21 proven tolerant) 
was small. Double-blind placebo-controlled food challenges were only performed if oral 
provocation challenge symptoms were subjective, which introduced a high risk of bias in the 
reference standard domain. It is unclear how many of the study children were challenged and 
how many had a diagnosis based on history and sensitisation alone, which identifies a high risk 
of flow and timing bias. 
 
Summary: Ara h 2-specific IgE was the most prevalent component in individuals with peanut 
allergy (68%) but was lower than in many other studies. Ara h 2-specific IgE was also 
associated with peanut allergy and anaphylaxis. A ratio of Ara h 2- to whole peanut-specific IgE 
was associated with the identification of children at risk of anaphylaxis. At a cut-off of 
<0.35kUA/L, sensitivity was 68% and specificity was 95%. The area under the curve was 0.82 
(Surtannon, 2013). 
Dang et al, 2012 
This study investigated the role of measuring Ara h 2-specific IgE concentrations in the 
reduction of oral food challenges for the diagnosis of peanut allergy. Children received skin 
prick testing to peanut, followed by whole peanut- and Ara h 2-specific IgE testing. Skin prick 
testing was regarded as positive if the measured wheal diameter was ≥1mm. This is an 
unusually low cut-off value. The study utilised a population-based cohort of one-year old 
Australian infants and included 100 infants with peanut allergy and 100 peanut tolerant 
infants, 42 of whom were non-peanut sensitised atopic controls leading to a high risk of 
patient selection bias. There is little indication for measuring Ara h 2-specific IgE 
concentrations in non-peanut sensitised atopic controls as these infants do not require any 
further clinical evaluation given that the negative predictive value of routine whole peanut 
testing is so good.  Such children are unlikely to be undergoing clinical review for potential 
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peanut allergy in a tertiary allergy clinic. As a population-based birth cohort, these children 
would not all be at risk of allergic disease, and so these results cannot be extrapolated into the 
clinical environment. QUADAS-2 identifies this as a high level of concern regarding the 
applicability of the findings to clinical practice. All children were one year of age, which tells us 
little about the sensitisation profile in children from other age groups. Additionally, 
population-based cohorts do not reflect tertiary clinical practice, as the pre-test probability is 
different to those children routinely encountered in clinical practice. There was a high risk of 
bias in the reference standard domain as the scoring system for mild reactions was weak and 
could have led to the inclusion of non-allergic infants. 
 
Summary:  A cut-off value of 1.19kUA/L for Ara h 2-specific IgE testing was more accurate in 
predicting peanut allergy than skin prick testing or specific IgE testing to whole peanut, and 
could potentially reduce the number of oral provocation challenges by two thirds. A negative 
predictive cut-off value of 0.10 kUA/L identified 87% of peanut-tolerant infants (Dang et al., 
2012). 
Ebisawa et al, 2012 
This study reported a consecutively recruited cohort of 57 Japanese children, aged two to 
thirteen years, with previous doctor-diagnosed peanut allergy undergoing a peanut oral 
provocation challenge. All children had either a positive clinical history or positive sensitisation 
and were recruited consecutively. The initial peanut allergy diagnosis had been given in 
primary care and was largely based on self-reported symptoms. Some of the children included 
in the peanut-tolerant group were likely to have never been previously allergic and therefore 
not eligible for inclusion in this study, creating a high level of concern in the patient selection 
domain. 26(46%) children were proven peanut-allergic, and 54% proven to be peanut-tolerant 
on oral provocation. There was a high risk of bias in the reference standard domain as all oral 
provocation challenges were open challenges. Using the manufacturer’s cut-off value of <0.35 
kUA/L, Ara h 2-specific IgE was demonstrated to be the superior diagnostic test with a 
sensitivity of 88% and a specificity of 84%. The area under the curve was 0.91. Specificity was 
increased to 94% when Ara h 2-specific IgE testing was performed in conjunction with testing 
to Ara h 1 and h 3.  
 
Summary:  Japanese children are frequently sensitised to the peanut component Ara h 2, 
which performed better than whole peanut-specific IgE concentrations for the diagnosis of 
peanut allergy. The optimal decision point was 0.66 kUA/L (Ebisawa, 2012). 
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Nicolaou et al, 2010 
This study measured whole peanut-specific IgE concentrations in a population-based birth 
cohort of 933 8 year-old children to ascertain whether peanut allergy could be distinguished 
from peanut sensitisation. As with the HealthNuts study, there were significant limitations to 
using the findings of a population-based birth cohort in clinical practice, which raises a high 
concern regarding the applicability of the reference standard to secondary or tertiary care. 
Studies that include children without a clinical suspicion of peanut allergy are at high risk of 
patient selection bias by virtue of the fact that they focus on individuals who would not 
routinely be investigated for peanut allergy. 110(11.8%) children were sensitised to peanut 
using the conventional test. 12 with a convincing clinical history of a previous reaction were 
considered peanut allergic without further investigation. 79 children underwent oral 
provocation challenge; 7 of whom were proven peanut allergic. More than 50% of oral 
provocation challenges were open rather than being a double-blind placebo-controlled food 
challenge. This potentially introduces a high risk of reference standard bias due to the 
potential for observer bias. Peanut allergic subjects had increased sensitivity to peanut 
components Ara h1, 2 and 3. Peanut tolerant subjects were primarily sensitised to pollen 
allergens. 
 
Summary:  The prevalence of peanut allergy among peanut-sensitised children was estimated 
to be 22.4%. The majority of children considered peanut-sensitised using standard tests do not 
have true peanut allergy. A positive Ara h 2-specific IgE concentration was the most important 
predictor of true allergy (Nicolaou et al., 2010). 
 
2.4 Minor studies excluded by QUADAS-2 
Excluded papers with poor methodological quality were identified. Six select articles that did 
not fulfil the designated eligibility criteria following QUADAS-2 scoring but which are notable 
are summarised in Table 9 and described briefly below. 
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Table 9:  Outline of useful minor studies which were excluded by QUADAS-2 scoring review 
Authors Reason for exclusion  Type of study Number of subjects & inclusion criteria Primary outcome Key Findings 
Grabenhenrich, 
2016 
This study population was 
previously presented in the 
paper by Beyer et al described 
in Table 8 and discussed above 
Prospective 9-
multicentre study, using 
data previously 
published 
207 children undergoing their first 
clinical review for exclusion or 
confirmation of peanut or hazelnut 
allergy 
To examine whether the ratio of 
component or specific IgE 
measurements to total serum IgE 
concentrations could improve the 
prediction of OPC outcome 
 Ara h 2 best diagnostic test with AUC of 
0.93 





Only 15% of study population 
were subject to an OPC which 
is below the QUADAS-2 cut-off 
for inclusion 
Peanut component 
population profile study 
Children not subjected to an OP had a 
diagnosis based on history and SPT or 
SpIgE (but PPV not used so high risk of 
false positive results) 
To investigate peanut component 
profile of French Mediterranean 
children with suspected PA 
 Ara h 6 best predictor of PA 
 Ara h 2 cut-off value 0.13kUA/L (PPV 
86%) 
 AUC 0.78 for Ara h 6 and 0.74 for Ara h 2 
Ballmer-Weber, 
2015 
The atopic controls included 
were  pollen-sensitised 
individuals not a comparable 
cohort 
Peanut component 
population profile study 
in 11 European 
countries 
68 PA individuals and 82 atopic (pollen-
sensitised) and non-atopic controls 
28 of 54 challenges were DBPCFC 
Combination of children and adults 
To study molecular peanut 
sensitisation patterns among 
individuals with PA 
 Ara h 2 major allergen in children 
presenting under 14 yrs 
 Ara h 2 SpIgE level of ≥1.0kUA/L had 97% 
probability of a systemic reaction  
Trendelenburg, 
2014 
No control group 
No cut-off values published 
Weak criteria for 
categorisation of OPC outcome 
Retrospective study in a 
German tertiary allergy 
clinic 2007-2011 
53 peanut-naïve sensitised children 
with eczema identified but clinical 
relevance data only available on 24 
(45%)  
To investigate an allergen profile of 
peanut-sensitised peanut-naïve 
infants and young children with 
eczema and assess clinical 
relevance 
 Ara h 1 was the immunodominant 
allergen, followed by Ara h 2 and 3 
respectively 
 Ara h 2 was not detected in 43% of 
children with proven peanut allergy 
Keet, 2013 Unclear whether patients were 
randomly or consecutively 
included 
Retrospective review in 
a single US centre 
60 children: 26 with a history of peanut 
allergy and 35 peanut-sensitised, 
peanut-naïve children. 
To assess the applicability of 
previously published Ara h 2-
specific cut-off values to a general 
paediatric allergy clinic population. 
 There were high misclassification rates 
with most cut-off values. 
 Ara h 2 did not replace an allergy-
focussed history with oral provocation 
challenge 
Codreanu, 2011 Case-control study utilising 
non-comparable controls 
A case-control study in 
two French allergy 
clinics 
166 patients with proven PA 
61 pollen sensitised peanut tolerant 
patients 
10 non-allergic controls 
 
To investigate the diagnostic 
performance of SpIgE to peanut 
components to reduce need for 
OPC 
 Ara h 2 had 96% sensitivity & 85% 
specificity with a cut-off value of 0.10 
 Optimal decision point of 0.23 gave 93% 
sensitivity & 96% specificity 
  Measurement of Ara h 2 increased test 
specificity and reduced OPC referrals 







This was a prospective multicentre study of 207 children undergoing their first evaluation for 
confirmation or exclusion of peanut or hazelnut allergy in nine German centres. The aim was 
to examine whether the ratio of either component or specific IgE measurements to total 
serum IgE concentrations could improve the prediction of oral provocation challenge outcome 
in children. Both peanut and hazelnut-specific IgE concentrations were measured together 
with the relevant components although the hazelnut data is excluded from this present 
review. The study population was the same study population previously included in the paper 
by Beyer et al below (Beyer, 2015). 
 
Summary: The best diagnostic test was Ara h 2-specific IgE testing with an area under the 
curve (AUC) of 0.93. The probability of a positive peanut provocation challenge was 16%. The 
calculation of ratio measures failed to improve diagnostic prediction. Cut-off values were those 
reported separately by Beyer et al (Beyer, 2015, Grabenhenrich et al., 2016). 
Agabriel et al, 2015 
This study of 181 children referred to a French tertiary allergy clinic with suspected peanut 
allergy aimed to describe the component profile of their Mediterranean population. There was 
a high risk of bias in their patient selection with only 15% of the study population being 
subjected to an open food challenge. Other children were categorised as allergic on the basis 
of a recent positive clinical history of a reaction and either a positive skin prick test of 4mm or 
a specific IgE level to whole peanut above 1 kUA/L, which is very low and increases the risk of 
false positives. 
 
Summary:  French Mediterranean children had a lower prevalence of seed storage protein 
sensitisation than other studied populations. The highest prevalence of 64% was to Ara h 6, 
followed by Ara h 2 at 63%. The best predictor of peanut allergy was Ara h 6- (positive 
predictive value 96%) followed by Ara h 2-specific IgE testing (positive predictive value 86%) at 
a cut-off value of 0.11kUA/L. The area under the curve was 0.78 for Ara h 6 and 0.74 for Ara h 
2-specific IgE concentrations. The predictive performance of peanut was not discussed. Ara h 
2-specific IgE testing was not found to be discriminant with respect to the development of 
tolerance (Agabriel, 2014). 
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Ballmer-Weber et al, 2015 
This study included 68 peanut allergic and 82 atopic and non-atopic controls from 11 European 
countries in a study of molecular peanut sensitisation patterns among peanut allergic 
individuals – the EuroPrevall study. The study additionally examined age at onset of allergy. 
Allergy was confirmed by double-blind placebo-controlled food challenge in 28 of 54 
challenged subjects with no history of previous anaphylaxis. There was a high risk of selection 
bias as subjects were acquired via mixed cohorts from varied background settings. 
Additionally, the atopic controls had never been suspected of having peanut allergy but were 
pollen-sensitised individuals. Among those 54 individuals who did undergo a double-blind 
placebo-controlled food challenge, Ara h 2-specific IgE testing had a sensitivity of 45% and a 
specificity of 100%. 
 
Summary: Ara h 2 was the major allergen recognised by the peanut allergic subjects. 
Sensitisation to Ara h 1 and 2 almost exclusively occurred in children who presented with 
allergy prior to 14 years of age. Ara h 8 or 9 were the predominantly recognised allergens 
among tolerant subjects and adult peanut allergic individuals. Subjects with Ara h 2-specific IgE 
concentrations of ≥1.0 kUA/L had a 97% probability of experiencing a systemic reaction 
(Ballmer-Weber, 2015). 
Trendelenburg, 2014 
This study aimed to investigate the component-resolved diagnostic profile of peanut 
sensitisation in peanut-naïve infants and young children with eczema attending a German 
tertiary allergy centre, and to assess its clinical relevance. This was a retrospective study and 
ineligible for inclusion as it had no control group. It also had a high risk of bias in both domains, 
as it produced no cut-off values and did not clearly score oral provocation challenge outcome. 
The study is notable and relevant to this thesis as it is the only study which evaluated a 
particular subgroup of peanut-naïve peanut-sensitised children; those with eczema. The 
present thesis evaluates a different subgroup, children with egg allergy.  
 
Summary: Seed storage proteins were the immunodominant allergens in this study 
population, with Ara h 1 being recognised in the majority of children followed by Ara h 2 and 
then Ara h 3. However, Ara h 2 was not detected in 43% of children with proven peanut allergy 




This US study was a retrospective review of 60 children who had been subjected to an open 
diagnostic peanut oral provocation challenge between 2003 and 2010. It aimed to investigate 
the applicability of published Ara h 2-specific IgE cut-off values to a general paediatric allergy 
clinic population. There were two groups of children included; 26 with a positive clinical 
history and 34 who were peanut-sensitised and peanut-naïve. 26 children reacted on oral 
provocation challenge but it is not clear to which group they had been assigned prior to oral 
provocation challenge. One child was challenged twice, and passed a second oral provocation 
challenge two years after failing the first. The risk of patient selection bias was high as it is not 
specified how children were selected. It is unclear whether only children with banked serum 
were included or whether inclusion was appropriately random or consecutive. The use of 
banked serum may lead to patient selection bias as serum may only be available for select 
groups of patients rather than random inclusion. This has the potential consequence that the 
reported diagnostic outcome measures may not accurately reflect the study population as a 
whole as if all eligible subjects had been included. There was also bias in the use of the index 
test as the study did not identify and report its own cut-off values. There was a high risk of bias 
with the index reference standard as it was performed several years after the oral provocation 
challenge and used banked samples. In addition, children were challenged with a non-
standardised peanut-containing food of their preference. 
 
Summary:  The study reported a high rate of misclassification when applying previously 
published Ara h 2-specific IgE concentrations to their general paediatric allergy clinic 
population: 26% at 0.23 kUA/L, 21% at the manufacturer’s cut-off 0.35 kUA/L, 36% at 2.0 
kUA/L and 21% at 0.3 kUA/L. Children also reacted on oral provocation challenge with a 
negative Ara h 2-specific IgE level below 0.35 kUA/L. Ara h 2-specific IgE testing was not able to 
replace an allergy-focussed clinical history in conjunction with an oral provocation challenge 
(Keet et al., 2013). 
Codreanu et al, 2011 
Codreanu et al evaluated the diagnostic performance of specific IgE to peanut components. 
Specific IgE to whole peanut and peanut components were measured in 3 groups of patients; 
those with proven peanut allergy (n=166), pollen-sensitised peanut tolerant patients (n=61) 
and non-allergic controls (n=10). This study was not included as it was a case-control design 
using non-comparable controls, who have never been investigated for suspected peanut 
allergy and therefore at high risk of patient selection bias. This includes controls who regularly 
consume peanut without reaction. The best predictor of peanut allergy was found for Ara h 2-
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specific IgE testing which was 96% sensitive and 85% specific, with a cut-off value of 0.10 
kUA/L. An optimal decision point of 0.23 kUA/L gave 93% sensitivity and 96% specificity. 
Unfortunately results were combined for children and adults, making the results less easily 
extrapolated to a purely paediatric population.  
 
Summary: The measurement of Ara h 2-specific IgE can be used to diagnose peanut allergy 
with an acceptable degree of precision, increasing test specificity and reducing oral 
provocation challenges for the majority of children (Codreanu et al., 2011). 
 
2.5 Synopsis of Review of Relevant Articles 
Component-resolved diagnostics (CRD) is a new and evolving field. Published optimal decision 
points for Ara h 2-specific IgE concentrations do exist but vary considerably between studies. 
Nicolaou et al suggest the prevalence of peanut allergy among peanut sensitised children 
within a general population birth cohort study to be low at 22.4%, which intensifies the need 
to find an accurate screening tool to predict clinical peanut allergy with acceptable sensitivity 
and specificity (Nicolaou et al., 2010a). All studies were prone to bias, primarily within the 
patient selection domain as inclusion criteria varied between studies. Some studies included 
children who were peanut-sensitised without any clinical history of a reaction and others 
included children with both a clinical history and peanut sensitisation. Other studies included 
patients who reported peanut allergy but failed to confirm it via serological or skin prick 
testing. Many studies included children with peanut skin prick or specific IgE test values above 
a commonly published positive predicted value primarily for safety reasons, although it should 
also be noted that parents are frequently unwilling to consent to an oral provocation challenge 
with significantly elevated test results. Additionally, many studies were conducted 
retrospectively. There was often also bias within the reference standard domain as many 
studies operated open oral provocation challenges rather than double-blind placebo-
controlled food challenges. However, this is likely to be because open challenges are routine in 
clinical practice with double-blind placebo-controlled food challenges being more common in a 
research setting. The measurement of Ara h 2-specific IgE concentrations was proposed as the 
best test for the diagnosis of peanut allergy in almost all selected studies although there was 
some variation between sensitivity (80 to 100%) and specificity (60-97%) as shown in Table 8. 
 
A systematic review of the diagnostic accuracy of specific IgE components in diagnosing 
peanut allergy was conducted by Klemans et al (2013) and based on the diagnosis of allergy in 
those patients suspected of being peanut allergic. The aim was to establish how to best 
manage those individuals with either a positive clinical history regardless of sensitisation or 
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individuals who were peanut-sensitised but peanut-naïve. This population varies from that 
within the present study, which aims to quantify the management of a specific high-risk group 
of peanut-sensitised atopic children – those with egg allergy. The pre-test probability of being 
peanut allergic within this cohort of infants will be higher than that addressed by Klemans. 
However, Klemans reported that studies with different inclusion criteria were demonstrated to 
have very little variation in their sensitivity and specificity values (Klemans, 2015).  
 
The selected studies described above are not directly comparable. Despite this, in the majority 
of studies study, Ara h 2-specific IgE testing was found to have the best diagnostic accuracy 
compared with the standard diagnostic tests of whole peanut-specific IgE testing or skin prick 
testing. However, the more recent studies by van Veen et al and Kim et al in 2016 did not find 
Ara h 2-specific IgE testing to be superior to whole peanut-specific IgE testing in predicting oral 
provocation challenge outcome (van Veen et al., 2016, Kim, 2016). Many studies also 
investigated other peanut components, which proved to be of limited clinical value. Martinet 
et al described Ara h 8 to be useful for identifying birch pollen cross-reactivity (Martinet et al., 
2016). Several studies published diagnostic cut-off specific IgE and SPT values, although the 
criteria for establishing these cut-off points varied between studies. Some studies used 90% or 
95% positive predictive values which are dependent on the composition of the study 
population, whereas others used the specific IgE level representing the 95% specificity of the 
test which is not dependent upon prevalence of the disease. Cut-off values are depicted in 
Table 10 and are presented with associated published data such as optimal decision points 
where available. Some studies looked at more than one cut-off value and therefore appear in 
the table more than once. 
 
The majority of included studies were conducted in secondary or tertiary allergy centres. 5 of 
these were within Europe, 2 in the United States, 4 in Asia, 1 in the UK, 1 in Australia and 1 in 
Canada. Despite this geographical variation, Ara h 2-specific IgE testing remained the optimal 
clinical test. Apart from one study, all used the same method to measure whole peanut-
specific IgE concentrations (ImmunoCap, Thermofisher, Sweden). Ara h 8-specific IgE testing 
was of some value in two studies but remained suboptimal compared with Ara h 2-specific IgE 
testing and was best suited to identifying birch pollen cross-reactivity. Most of the European 
studies were from northern Europe and it would be interesting to establish if Ara h 2 is the 
predominant allergen in southern Europe, given that several papers have identified the LTP 
protein Ara h 9 as an immunodominant allergen in this population. However, patients under 




Table 10:  Summary table of the clinical utility of specific IgE for peanut component allergens from 
included studies 
First author, Year Cut-off (kUA/L) 
Area under the 
curve (AUC) 
Sensitivity (%) Specificity (%) 
Beyer, 2015 0.1 0.92 86 86 
Lieberman, 2015 0.35 0.84 80 92 
Eller, 2013 0.35 - 89 60 
Eller, 2013 1.28 0.90 91 72 
Klemans, 2013 0.35 0.90 91 72 
Lopes de Oliveira, 2013 0.30 - 94 74 
Suratannon, 2013 0.35 0.82 68 95 
Dang, 2012 0.1 0.95 95 86 
Dang, 2012 0.35 - 81 88 
Ebisawa, 2012 0.35 0.91 88 84 
Nicolaou, 2010 0.35 0.99 100 96 
Nicolaou, 2010 0.23 - 93 97 
Nicolaou, 2010 1.28 0.90 76 97 
Legend. *Optimal cut-off point.  Some studies reported more than one cut-off point. 
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2.6 Conclusions following review of relevant articles 
There are important clinical implications to finding an improved measure for predicting a 
positive reaction on oral peanut provocation challenge as described above. Many young 
children undergo oral provocation challenges in order to ascertain whether they have 
definitive peanut allergy rather than mere peanut-sensitisation. The current diagnostic 
approach comprises the taking of a detailed allergy-focussed clinical history combined with the 
measurement of either skin prick tests or whole peanut-specific IgE measurements, with 
current diagnostic techniques being unacceptably inadequate in children (Eigenmann and 
Sampson, 1998). 
 
In routine clinical practice at Bristol Royal Hospital for Children in 2014, 280 oral provocation 
challenges were performed. As described above, 53(19%) of these were to peanut, following 
routine whole peanut-specific IgE and peanut skin prick testing in the paediatric outpatient 
clinic. Despite following evidence-based, published diagnostic guidelines, only 4(8%) of these 
peanut oral provocation challenges were positive. The low positive rate suggests that many 
children may not be being fully investigated and that there appears to be a high degree of 
clinical reticence to challenge children with a positive skin test. It is likely that there are many 
children, labelled as peanut allergic, who actually are tolerant. A peanut oral provocation 
challenge is currently the only definitive way to ascertain a child’s current peanut allergy 
status. The role of Ara h 2-specific IgE testing may be an important one; it may allow clinicians 
to change their clinical practice to ensure that those children who are extremely likely to react 
are not challenged, whilst also encouraging clinicians to fully investigate those children within 
the immunological grey area rather than simply labelling them as peanut allergic and running 
the risk of misclassification. If proven to be extremely valuable in the diagnosis of peanut 
allergy in high-risk children, then the measurement of Ara h 2-specific IgE concentrations may 
be able to replace the oral provocation challenge for a significant proportion of children. 
 
Protecting children from harm is of paramount importance. Despite clear, published guidelines 
on performing a food peanut oral provocation challenge, these do imply a potential risk to 
children and incur the potential risk of provoking a life-threatening allergic reaction (Sampson, 
2001). There are also important issues for service delivery and staffing concentrations. Waiting 
lists for peanut oral provocation challenges can be many weeks long and establishing a reliable 
and simple clinical test to reduce the number of children waiting for tests would be valuable, 
particularly from a health-economics perspective. It is important that such a screening test has 
sufficient sensitivity and specificity to ensure that peanut tolerant children do not miss the 
opportunity of being offered a peanut oral provocation challenge that would demonstrate that 
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they do not have peanut allergy, and that allergic children are not placed at unnecessary risk. 
Clearly the development of positive predictive values will be helpful in the management of egg 
and peanut allergic children within the allergy clinic setting. A positive predictive value of 95% 
suggests that there is no need to subject a child for a peanut oral provocation challenge as 
they are highly likely to react with less than 5% of children who will be falsely labelled as 
allergic. Ethical approval to challenge this group of children would also be difficult to secure. 
Positive predictive values did vary between the studies discussed above although some studies 
concurred. Sampson’s positive predictive values for the measurement of whole peanut-specific 
IgE are perhaps the most frequently quoted, and were confirmed by Roberts and Lack in 2005, 
who found them to be generalizable to different populations of children undergoing clinical 
review (Roberts and Lack, 2005). It is notable however, that not all studies found this 95% cut-
off value useful and in one study, the misclassification rate for the diagnosis of peanut allergy 
was high with 25(28%) of peanut tolerant children having a whole peanut-specific IgE level of 
greater than 15kUA/L (Lopes de Oliveira, 2013). This study did not look at higher positive 
predictive values such as those proposed by other studies. Dang’s study calculated the 
misclassification rate utilising these same positive predictive values and found it to be 
extremely low at only 3% or less (Dang et al., 2012). 43(43%) peanut allergic children had a 
skin prick test wheal diameter of <8mm which placed them in what is commonly regarded as 
‘the immunological grey area’, necessitating a provocation challenge. As described above, up 
to 43% of children with a skin prick test of less than 8mm will still react on oral provocation 
challenge, but this is currently the only way to give a child a definitive diagnosis. The use of an 
improved diagnostic test would be very useful in clinical practice within Bristol Children’s 
Hospital. Standards for the management of egg allergic children, who are at high-risk of peanut 
allergy, are currently not clearly outlined, with clinicians of varying levels of seniority managing 
children in different ways according to their own preferred criteria.  
 
This study will investigate the hypothesis that specific sensitisation to the peanut component 
Ara h 2 is associated with a diagnosis of clinical peanut allergy in egg-allergic children. 
Consequently, Ara h 2-specific IgE testing may have a better diagnostic performance than 
whole peanut-specific IgE testing in predicting which children will react during their oral 
provocation challenge. This may ultimately mean that unnecessary oral provocation challenges 
in children with peanut allergy could be potentially reduced or avoided. 
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3.1 Aims and objectives 
1. To investigate the diagnostic value of Ara h 2-specific IgE measured in serum in 
predicting a clinical reaction to peanut in peanut-sensitised, peanut-naïve children with 
a history of egg allergy. 
 
2. To evaluate whether the measurement of Ara h 2-specific IgE concentrations is 
clinically useful in the management of peanut-naïve, egg allergic children who are 
sensitised to peanut. 
 
3. To develop a post hoc diagnostic algorithm model for the use of Ara h 2-specific IgE. 
 
3.2 Objectives 
 Recruit a population of egg allergic children with sensitisation to 
peanut; 
 Perform whole peanut- and Ara h 2-specific IgE testing, and skin prick 
testing to peanut prior to peanut oral provocation challenge; 
 Define two groups of children with clinical peanut allergy versus 
clinical tolerance on the basis of either oral provocation challenge 
outcome or skin prick test wheal diameter above previously 
published 95% positive predictive values for peanut allergy; 
 Include an additional control group of egg allergic children with 
previously confirmed peanut allergy; 
 Compare the performance of whole peanut- and Ara h 2-specific IgE 
testing and peanut skin prick testing in the diagnosis of clinical 
peanut allergy in egg allergic children; 
 Develop a diagnostic algorithm to optimise the clinical utility of all 
available tests.  
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3.3 Null hypothesis 
The hypothesis of the study is that there is no relationship between a positive Ara h 2-specific 
IgE antibody concentration and clinical peanut allergy in a cohort of high-risk egg allergic 
children.  
 
3.4 Study Design 
 
This was a prospective, observational study comparing the measurement of Ara h 2-specific IgE 
concentration testing in addition to routine conventional whole peanut-specific IgE 
concentration testing. Children with a history of egg allergy who were sensitised to peanut 
were subject to an oral peanut provocation challenge as per usual care. The oral provocation 
challenge outcomes were related to peanut- and Ara h 2-specific IgE concentrations and to 
skin prick test wheal diameters. 
 
3.5 Recruitment strategy 
Parents or carers of eligible children were informed about the study by an Allergy Clinical 
Nurse Specialist as outlined below: 
 
1. Where possible, parents of all eligible children were sent a Parent Information 
Sheet through the post in advance of their clinic appointment (Appendix 1: Parent 
Information Sheet; Appendix 2: Child Participant Information Sheet) 
2. The Clinical Nurse Specialist discussed the study with the family on arrival at the 
clinic. 
3. If the child had egg allergy and peanut sensitisation on skin prick testing and the 
parent was happy for them to participate in the study, written informed consent 
was taken prior to routine blood testing. 
 
A copy of the consent form was filed in the patient records and the original was given to the 
parents (Appendix 3: Consent Form). A letter to the GP was sent informing them of the child’s 





All peanut-sensitised, egg allergic children aged between 12 months and 17 years of age 
referred to the Paediatric Allergy Clinics at Bristol Royal Hospital for Children for review of egg 
allergy over an eighteen month period were invited to participate in the study. Those willing to 
participate and whose parent or guardian gave informed consent were enrolled in the study. 
The period of recruitment ran from January 2015 to June 2016. Inclusion was performed 
consecutively.  
 
All children had either ongoing egg allergy or a previous confirmed diagnosis of egg allergy that 
had resolved, and a positive peanut skin prick test or whole peanut-specific IgE concentration. 
Egg allergy was confirmed by a positive clinical history of a convincing type I hypersensitivity 
reaction to egg and a recorded positive specific IgE level or skin prick test to egg white.  
 
Peanut-naïve children with a whole peanut-specific IgE concentration or skin prick test wheal 
diameter of less than previously published 95% positive predictive values for peanut allergy of 
≥15kUA/L and ≥8mm were each referred for a peanut oral provocation challenge in line with 
routine clinical practice to determine their current peanut allergic status (Sampson and Ho, 
1997, Sporik et al., 2000). Children with positive predictive values above the 95% cut-off point 
were allocated into the peanut allergic group. Children with known peanut allergy confirmed 
by positive whole peanut-specific IgE testing also had Ara h 2-specific IgE concentrations 
measured but did not undergo an oral provocation challenge but were included and analysed 
separately. 
 
3.7 Inclusion and exclusion criteria 
Children were eligible if they had a history of egg allergy confirmed by either a positive skin 
prick test to egg or a positive egg white-specific IgE concentration above 0.35kUA/L, and 
sensitisation to whole peanut-specific IgE or skin prick testing together with written, informed 
parental consent. Children were excluded if they had any chronic disease requiring 
intervention or therapy with the exception of the atopic co-morbidities, wheeze, asthma, 
eczema, other food allergy or rhinitis. Children without any confirmed documentation of a 




3.7.1 Comparator groups 
Children with known and confirmed peanut allergy 
In addition to peanut-naïve infants and children, children undergoing review who had a history 
of egg allergy with confirmed and documented peanut allergy were also included. These 
children had peanut allergy confirmed by skin prick test or whole peanut-specific IgE testing 
supported by either a positive food challenge in hospital or a documented clinical allergic 
reaction to peanut. Data from these children were included in some of the analyses but this 
subgroup were also analysed separately. When analysed separately these children were 
allocated to the known peanut allergy subgroup. 
Children identified with resolved peanut allergy 
There was a small subgroup children who had been referred to clinic for review of possible 
peanut allergy resolution and who passed their oral provocation challenge without reaction, 
despite continuing to have positive whole peanut-specific IgE concentrations or skin prick 
tests. All these children had been reviewed in this centre previously where peanut allergy had 
been confirmed and documented. One of these children had previously failed a peanut oral 
provocation challenge two years previously with clear documentation of this in their medical 




3.8 Study visits  
The study required two patient visits as shown in Figure 10 below. 
 




























Children attending the outpatient clinic were subject to skin prick testing to peanut and 
venepuncture to facilitate the measurement of total IgE concentrations and concentrations to 
whole peanut- and Ara h 2-specific IgE. Written informed consent was taken from parents and 
carers at this initial visit, and assent forms were also completed where applicable. Children 
No reaction on OPC 
PEANUT TOLERANT 
Reaction on OPC 
PEANUT ALLERGIC 
Outpatient clinic review 
Skin prick test  
to peanut 




Specific IgE for 
Peanut and Ara h 2 
Peanut oral provocation 
challenge 
History of egg allergy 
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who had a whole peanut-specific IgE concentration of less than 15kU/L were invited for a 
peanut oral provocation challenge as per routine care. Outcome measures are listed in Table 
11. 
 
3.9 Measurement of whole peanut-specific and Ara h 2-specific IgE in serum 
Total IgE, whole peanut-specific IgE and Ara h 2-specific IgE were determined by singleplex 
ImmunoCAP fluorescence enzyme immunoassay (Thermofisher Scientific, Uppsala, Sweden). 
Serum samples from all children were taken at the outpatient review by a paediatric 
phlebotomist, using the standard paediatric technique of using a tourniquet on either the 
child’s upper or lower arm and drawing blood using a retractable butterfly from the 
antecubital fossa or the back of the hand. Samples were collected into a gold-top serum-
separator tube. An additional 0.5ml serum was taken for the measurement of Ara h 2-specific 
IgE antibody concentrations in addition to routine whole peanut-specific IgE testing. Samples 
were left to clot prior to being centrifuged for 15 minutes. Samples were subsequently 
aspirated into aliquots and stored at -20˚C. During processing, the allergen placed within the 
assay reacts with any specific IgE in the individual serum sample. Non-specific IgE is then 
washed away and enzyme-antibodies against IgE are added to create a complex. Following 
incubation, any unbound enzyme-anti-IgE is washed away and the bound complex is incubated 
further with a developing agent. This is then completed by the introduction of a stopping 
solution and the fluorescence of the remaining product is measured and transformed to a 
standard concentration using a calibration curve (Phadia, 2014). Specific IgE was measured in 
kilounits of antibody per litre (kUA/L) with a lower detection limit of 0.35 kUA/L and a 
maximum limit of 100 kUA/L and results were recorded. Values  0.35 kUA/L to whole peanut 
and to Ara h 2 were considered positive according to the manufacturer’s instructions and 
recorded as a continuous variable.  
Table 11:  Outcome measures 
Method of measurement: Description: 
Sensitisation to whole peanut via skin prick test Wheal diameter of ≥3mm to whole peanut 
Sensitisation to peanut via whole-peanut 
specific IgE antibody concentration 
≥0.35 kUA/L – Positive according to 
manufacturer’s instructions 
Sensitisation to Ara h 2 via Ara h 2-specific IgE 
antibody concentration 
≥0.35 kUA/L – Positive according to 
manufacturer’s instructions 
Peanut allergy status 
As confirmed by oral provocation challenge or 





3.10 Skin Prick Testing  
Allergen skin prick tests were performed using a commercial one-prick lancet technique, using 
commercially available extracts of peanut using a 1:20 (wt/vol) solution (Soluprick, ALK, 
Uppsala, Sweden). All tests were performed by a specialist paediatric allergy nurse. Histamine 
dihydrochloride (10mg/mL, ALK-Abello A/S, Horsholm, Denmark) was used as a positive 
control and saline (Soluprick SQ, ALK-Abello) was used as a negative control. Skin tests were 
performed on the volar aspect of the forearm. The maximal skin wheal diameter (mm) was 
measured with a ruler after 15 minutes and recorded. A reaction was considered positive if the 
resultant wheal was ≥3mm in diameter in the presence of a reaction to histamine of at least 
3mm in diameter and a negative response to the saline negative control. A skin prick test 
wheal diameter of ≥3mm has been recommended as a marker of hypersensitivity to foods in 
many North American and European centres.(Dreborg, 1993, Bock et al., 1977). 
 
3.11 Sensitisation to peanut  
All children had either skin prick testing and/or specific IgE antibody concentrations measured 
to peanut. Both tests were performed in almost all children except in select cases were 
children were unable to discontinue their antihistamines or where the laboratory had an 
insufficient sample for full analysis. Ara h 2-specific IgE and total IgE concentrations were also 
measured. Children were considered peanut sensitised and eligible for study inclusion if they 
had a skin prick test wheal diameter of 3mm or greater and/or a specific level to peanut of 
≥0.35 kUA/L according to the manufacturer’s instructions. Specific IgE concentrations were 
measured between 0.35 and 100 kUA/L. For the purposes of statistical analysis concentrations 
below <0.35 KUA/L were recorded as 0.34 and those >100 were recorded as 101 kUA/L. 
 
3.12 Oral provocation challenge  
Children were referred for a routine open peanut oral provocation challenge in the usual 
manner. The decision to challenge was made as per routine clinical practice by the physician or 
specialist nurse in the allergy clinic and was not affected by the child’s participation in the 
study. Challenges are indicated when an allergy-focussed clinical history together with skin 
prick or whole peanut-specific IgE testing gives insufficient information for the reviewing 
clinician to diagnose an individual with peanut allergy or peanut tolerance. Challenges 
occurred between one and five months later due to the length of the food challenge waiting 
list and were performed under medical supervision on the day care unit at Bristol Royal 
Hospital for Children. Open challenges, where the family are aware that each challenge dose 
contains peanut, were performed in preference to double-blind placebo-controlled food 
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challenges due to both clinical service pressures and because this study was an evaluation of 
routine clinical care outcomes. 
 
All eligible children were challenged with either ground peanuts or Bamba peanut snack 
(peanut puff crisps). Both foods contain demonstrable Ara h 2 (James Hindley, Indoor 
Biotechnologies Limited, personal communication, June 11 2010, European Academy of Allergy 
and Clinical Immunology, Vienna). Ground peanut was mixed in 110g Petit Filous chocolate 
dessert (Yoplait, Uxbridge). For all subjects the initial dose was 0.25g of peanut. The highest 
dose was 10g for children aged 3 years or younger and 15g for older children. For Bamba, 
doses ranged between 0.85g and 17g for children 3 years or younger and 34g for older 
children. Doses were given every 15 minutes. Patients were observed on the paediatric day 
care ward for two hours after the final dose. Reactions occurring within one hour were 
considered immediate and reactions occurring after one hour were considered late reactions. 
Challenge doses are shown below in Table 13 and protocols are included in Appendix 5. One 
peanut contains approximately 200mg of protein (Goldman, 1998). 
 
Results were recorded as positive (any two objective allergic symptoms on or within 2 hours) 
or negative (no reaction). Symptoms were recorded and classified by body system and in terms 
of severity using a validated scoring system (Bock et al., 1988). Reactions were classified into 
skin, upper and lower respiratory, gastrointestinal and cardiovascular reactions. Children with 
a positive reaction to peanut following oral provocation challenge were allocated to the 
Peanut Allergic group whilst those proven peanut tolerant were allocated to the Peanut 
Tolerant group. The outcomes of the challenges were related to the serum concentration of 











Table 12: Oral peanut provocation challenge doses 







Legend. Bamba is a soft peanut puff which can be easily fed to very 




3.13 Classification of Symptoms 
There are many symptom classification systems for type I hypersensitivity reactions. The first 
study to classify symptoms was devised by Mueller for the grading of systemic allergic 
reactions to insect venom (Mueller, 1959). This system has been commonly used either in its 
original form or adapted for use in descriptions of food anaphylaxis. In this study, reactions 
were scored using the Oral Food Challenge Symptom Score Sheet in Appendix 6 (Bock et al., 
1988). This scoring chart is straightforward for use by allergy ward staff and ensures that each 
symptom can be easily recorded. It also ensures that oral challenges are not discontinued due 
to subjective symptoms. 
 
3.14 Data recording 
Skin prick test results, whole peanut- and Ara h 2-specific IgE concentrations and peanut 
provocation challenge outcomes were recorded on an anonymised, password-protected 
database, kept in a locked office. Hard copies of all paperwork were kept in a separate 
location. 
 
3.15 Ethics and R&D Approvals 
The University of Bath undertook the study sponsorship role. The Proportionate Review Sub-
Committee of the Camden and Islington Research Ethics Committee granted ethical Approval 
for the study in October 2014. The University of Bath Research Ethics Approval Committee for 
Health and the UHBristol Research & Innovation Department approved the study protocol 
(Appendix 7). This study was conducted in accordance with the Research Governance 
Framework for Health and Social Care and Good Clinical Practice. 
 
3.16 Provision for dealing with attrition 
It was anticipated that some families would choose not to have a peanut provocation 
challenge and that others might fail to complete the entire peanut provocation challenge. 
Recruited children who elected not to proceed with the challenge were removed from the final 
analysis as were children whom the managing clinician elected not to challenge. Other 
anticipated reasons for attrition were lost or insufficient samples for full analysis. It was 
decided to include children if they had an Ara h 2-specific IgE measurement available together 






3.17 Power Calculation    
Previous studies have published various optimal decision point cut-off values for predicting 
peanut allergy using both whole peanut and various peanut components. Calculations using 
the primary outcome measure of Ara h2-specific IgE concentrations are based on a study by 
Dang et al 2012, which reported a mean (SD) Ara h2-specific IgE concentration of 7.11 kUA/L 
(11.49) in peanut allergic Australian infants and a mean (SD) Ara h2-specific IgE concentration 
of 0.25 kUA/L (0.53) in peanut tolerant infants (Dang et al, 2012). The minimal important 
difference was therefore calculated as 6.86. Using these figures and an employing a 1-sided 
significance level, for the study to have 80% power to detect the minimal important difference 
a total of 72 patients would be required. Assuming an attrition rate of 10%, 80 patients would 
need to be recruited. A secondary analysis looked at receiver operating characteristic (ROC) 
curves, constructed to test the difference between the predictive ability of skin prick test 
wheal diameters to peanut, and whole peanut and Ara h 2-specific IgE concentrations. 
Null Hypothesis:  There is no relationship between a positive Ara h 2-specific IgE 




Analyses were conducted to compare the likelihood of a positive peanut oral provocation 
challenge following each of the three screening tests: Skin prick test to peanut, whole peanut-
specific IgE concentration and Ara h 2-specific IgE concentration testing. Skin prick test wheal 
diameters were normally distributed and differences between groups were examined using 
analysis of variance (ANOVA). Specific IgE concentrations were not normally distributed 
continuous variables and the Kruskal-Wallis test was used for non-parametric group 
comparisons. Differences in median specific IgE concentrations were analysed using the Mann-
Whitney U test and dichotomous variables (such as peanut allergy status) using Fisher’s Exact 
test. A p value of <0.05 was considered statistically significant for all tests. 
 
Logistic regression analysis was performed to ascertain the effects of Ara h 2-specific IgE 
concentrations on the likelihood of a child having peanut allergy. Receiver-operator 
characteristic curves were constructed. An area under the curve of greater than 80% suggests 
that the test is a good diagnostic test with clinical utility. In practice this means that if a 
clinician were to take two children, one allergic and one tolerant and perform the selected test 
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on them, then the child with the abnormal test result should be the child from the peanut 
allergic group. 2 by 2 contingency tables were used to calculate sensitivity and specificity for 
specific IgE and skin prick test cut-off values. Likelihood ratios were calculated to assist the 
clinician to calculate an individual child’s post-test probability of having peanut allergy. 
Statistical analyses were conducted with IBM SPSS Statistics for Macintosh, Version 22  





















George Washington Carver, 1906. 
Carver promoted alternative food crops to enable poor farmers to grow alternative crops 
as a source of their own food and of other products to improve their quality of life. He 
wrote 105 recipes that included peanuts. He also developed and promoted more than 
100 products made from peanuts useful for the house and farm, including cosmetics, dyes 
and plastics. 
This image is available from the United States Library of Congress' Prints and Photographs 







RESULTS SECTION 1: DATA PRESENTATION 
4.1 Subjects 
During the study period 105 peanut-sensitised, peanut-naïve children (with consent provided 
by a parent or guardian) were enrolled and listed for a peanut oral provocation challenge as 
per routine care (Figure 11). The parents of an additional child, whose peanut allergy status 
was known and for whom all data was available, declined to give their consent for inclusion of 
their results and outcome in the study. This may have been due to a language barrier. 54 
children with a whole peanut-specific IgE test value, or skin prick test wheal diameter 
equivalent to, or above previously published positive predictive values of 15kUA/L or 8mm 
were not challenged. Additionally, 11 egg allergic children had a previous documented allergic 
reaction to peanut confirmed. Four of 105 children were not included in the final analysis; two 
children did not undergo an oral provocation challenge due to parental anxiety and two 
children with results below the positive predictive value were not challenged as per their 
managing consultant’s clinical decision. In a smaller centre such as Bristol, there is some 
variability between clinicians regarding their clinical management decisions. 101 children were 
therefore included in the study analysis. 36 children were subject to a peanut oral provocation 
challenge. No children had inconclusive challenges. There were two sets of siblings included. 
58 children were male and 43 were female. 14 infants were less than 2 years of age and 87 
children were aged 2 years of age and above. The pathway of the subjects through the study is 




















Legend. Peanut allergic children are shown in pink and peanut tolerant children are shown in green. OPC, oral provocation challenge; PPV, positive 
predictive value; SPT, skin prick test; SpIgE, Specific IgE, PN, Peanut.  
 
 
Parental OPC consent refused 
n=2 
 




























































PN SPT/SpIgE ≥PPV 
n=54 
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4.2 Outcome groups 
The children were divided into two outcome groups – peanut allergic and peanut tolerant. 
Each group was subdivided into further outcome groups as described in Table 13; challenge-
proven peanut allergy, values above previously published 95% positive predictive values, 
known peanut allergy and resolved peanut allergy. Throughout the results chapter, the focus 
will be upon the analysis of the two primary groups of allergic and tolerant groups of children. 














4.2.1 Children with known peanut allergy  
11 peanut-sensitised egg-allergic children reported a history of a previous reaction at home. 
Previous confirmation by either a peanut skin prick test or whole peanut-specific IgE 
concentration was available. Only one child had contacted acute emergency services. 10(90%) 
were treated with antihistamine. No children had been treated with Salbutamol or 
intramuscular adrenaline. One child was particularly unwell with urticaria, reduced 
consciousness, and recurrent diarrhoea and vomiting for several hours. This child was not 
brought for medical help and did not take any rescue medications. The precipitating dose is 
more difficult to quantity for this group of children although 8(73%) children reported 
reactions following contact with a small amount of peanut. All reactions occurred within 1 
hour of ingestion and no child experienced a delayed reaction. One child did experience a 
prolonged reaction but this was largely due to lack of medical intervention. 








Total Peanut Tolerant: 31 6.6  [1.1-17.9] 16:15 
Resolved Peanut Allergy 3 8.2  [5.7-11.4] 1:2 
Total Peanut Allergic: 70 6.4  [1.2-16.0] 42:18 
De Novo Peanut Allergic: 62 6.2 [1.2-13.5] 38:14 
Challenge proven allergy 8 5.7  [1.2-13.0] 3:5 
Values ≥PPV 54 6.2  [1.9-13.7] 35:19 
Known Peanut Allergy 8 8.2  [1.4-12.0] 4:4 
Legend. Primary outcome groups are shown in bold. 
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4.2.2 Children with resolved peanut allergy  
Three children with a previous history of peanut allergy confirmed by previous clinical 
correspondence and previous positive whole peanut-specific IgE testing completed an oral 
provocation challenge without reaction. One of these children had failed a peanut oral 
provocation challenge two years previously in our centre. These children were all subject to a 
routine peanut oral provocation challenge due to falling levels of whole peanut-specific IgE 
with no reaction over the last two years. 
 
4.3 Reactions on peanut oral provocation challenge  
36 children completed a peanut oral provocation challenge. 28 children completed the 
challenge without reaction whilst 8 demonstrated Type I hypersensitivity symptoms. 8 children 
had symptoms on oral provocation challenge, with the provoking dose ranging between 0.25g 
and 4g. Reactions were recorded using a validated symptom score system which classifies 
reactions by body system into skin, upper and lower respiratory, gastrointestinal and 
cardiovascular reactions. Reactions were assessed and managed by a ward allergy support 
nurse under the supervision of an Allergy Specialist Nurse or a Consultant Paediatrician 
specialising in allergy. All symptoms developed within 20 minutes of the previous ingested 
dose and resolved within the two-hour post challenge observation period. There were no late 
phase reactions and no child experienced a delayed reaction following discharge. All children 
received oral antihistamines; one child was prescribed additional Prednisolone by an 
inexperienced junior doctor due to lack of response to antihistamine. No children required 
Salbutamol or intramuscular adrenaline. Reactions on oral provocation challenge are 
summarised in Table 14.








Type Stage Symptoms Score Treatment 
1 (M) 13 Peanut 1 Facial urticaria; Oral pruritus 2 Cetirizine 
2 (F) 2 Peanut 2 Perioral erythema; Vomit x2; Contact urticaria on 
hands 
4 Cetirizine 
3 (F) 1.3 Bamba 1 Moderate rhinorrhoea; Hives x4; Facial 
erythema; Conjunctival pruritus; Cough;Fractious 
6 Cetirizine 
4 (F) 6 Peanut 2 Vomit x 2; Moderate abdominal pain 4 Cetirizine 
5 (M) 6 Bamba 4 Facial urticaria x1; Sneezing; Conjunctival 
pruritus 
1 hr Post Cetirizine: Nausea; Diarrhoea x5; 




6 (M) 3.5 Peanut 1 >3 Perioral hives; Oral pruritus; Excessive 
drooling 
4 Cetirizine 
7 (M) 4.5 Bamba 1 Widespread urticaria; Pruritus 5 Cetirizine 
8 (F) 7.5 Bamba 3 3 Hives; Vomit x 1; Rhinorrhoea; Minimal cough 5 Cetirizine 
Legend. Reactions were scored using a validated scoring system published by Bock et al (Bock et al., 1988) 
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Figure 12 depicts the severity of reactions. The most common symptoms elicited occurring in 
88% of children were cutaneous. 4 (50%) children developed gastrointestinal symptoms. Most 
children reacted early in the peanut oral provocation challenge although one child reacted 
after the fourth dose and then continued to develop further symptoms despite being given 
oral antihistamine. The mean dose provoking a reaction was 1 gram. This does not differ from 
threshold doses published in the literature (Taylor et al., 2009). 
 
No child experienced clear cardiovascular, respiratory or laryngeal symptoms although two 
children were allocated positive scores under the laryngeal criteria for occasional cough. Of 
these, one young child who complained of oral symptoms had extreme excessive drooling but 
was too young to be able to describe his symptoms clearly. His only other symptom was mild 
facial urticaria. Another infant developed significant rhinorrhoea and conjunctival symptoms 
together with minimal facial urticaria (4 hives) and erythema. This child was reported to have 
minimal cough although no wheeze. It was hard to ascertain whether the child was coughing 
due to oral symptoms or whether the cough resulted from airway compromise as no other 
airway signs were present and her oxygen saturations were normal. This child was too young 
to be able to define her symptoms clearly. 
 




Legend: Severity was classified according to a validated scoring system which classified reactions in terms of 
severity, increasing in severity from 1 to 7. 
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4.4 Primary analysis of peanut allergic and peanut tolerant children 
The primary analysis within this study is to make comparisons between the two groups of 
peanut allergic and peanut tolerant children for the three tests: peanut skin prick testing, and 
measurement of whole peanut- and Ara h 2-specific IgE concentrations. Table 16 shows 
median whole peanut- and Ara h 2-specific IgE concentrations and mean skin prick test wheal 
diameters to peanut for each outcome group. Each test will subsequently be described 
separately. 
 
4.4.1 Skin prick test wheal diameters compared with peanut oral provocation challenge 
outcomes for peanut allergic and peanut tolerant children 
The primary outcome of this study is to examine the clinical utility of Ara h 2-specific IgE 
between groups of peanut allergic and peanut tolerant children. As skin prick testing is the 
most frequently utilised test in the paediatric allergy clinic, it is necessary to examine its 
clinical utility as a basis for comparison with Ara h 2-specific IgE. Skin prick test reactivity to 
peanut was therefore examined in relation to peanut oral provocation challenge outcomes in 
97 children. The differences in wheal diameters for peanut allergic and peanut tolerant 
children are demonstrated in Figure 13.  
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Legend: Children were divided into subgroups of allergic and tolerant children. 
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Peanut tolerant children had a mean wheal diameter to peanut of 4mm (SD± 2.5, range 0-11) 
whilst peanut allergic children had a mean wheal diameter of 10mm (SD± 4.1, range 0-22). 
There is no overlap of the interquartile ranges, reflecting a real difference between the two 
groups. Whilst the number of children with a positive skin prick test result to peanut above the 
manufacturer’s cut-off value of 3mm was not significantly different between groups (67/67 
(100%) vs 25/30 (83%) (Fisher’s Exact p=45.11), 2 (7%) tolerant children had a skin prick test 
wheal diameter above the positive predictive value compared with 47 (70%) of allergic 
children. This was confirmed to be significant (Fisher’s Exact test p<0.05). 
 




Legend: The study population was divided into two primary outcome groups; those who were peanut allergic and 
those who were peanut tolerant. Skin prick test wheal diameter was significantly larger in peanut allergic 
children (Fisher’s Exact test; p<0.05) 
 
 
4.4.2 Whole-peanut and Ara h 2-specific IgE concentrations in two groups of peanut allergic 
and peanut tolerant children 
In order to establish whether Ara h 2-specific IgE is a useful test clinically, a comparison was 
made between whole-peanut specific IgE and Ara h 2-specific IgE concentrations (Figure 14). 
Whole-peanut specific IgE concentrations 
Whole peanut-specific IgE concentrations were available for 99 subjects and were collected as 
per routine care. 83(84%) subjects had both positive skin prick test results and elevated whole 
peanut-specific IgE concentrations ≥0.35kUA/L. 22(22%) children had discordant results: 
13(13%) subjects were sensitised on skin prick testing but not on whole-specific IgE testing; 9 
of these children proved peanut tolerant. 3(3%) subjects were sensitised on specific IgE level 
testing only; 2 were peanut tolerant. 
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Ara h 2-specific IgE concentrations 
Ara h 2-specific IgE concentrations were available for 101 children. 5 of 8(63%) children with 
challenge-proven peanut allergy had negative Ara h 2-specific IgE concentrations. 58(57%) 
children had positive Ara h 2-specific IgE concentrations of ≥0.35 kUA/L; of these only 2(3%) 
were peanut tolerant. 1 child with challenge-proven peanut allergy had discordant results 
having a positive Ara h 2-specific IgE concentration and a negative whole peanut-specific IgE 
concentration. 
Comparison of whole peanut- and Ara h 2-specific IgE concentrations 
Whole peanut- and Ara h 2-specific IgE concentrations are presented in Figure 14. The range 
of detectable whole peanut-specific IgE was greater in peanut allergic than peanut tolerant 
children with the median being 11.6 kUA/L (IQR 74.4, 0.34-101). For peanut tolerant children 
the median was less at 0.63 kUA/L (IQR 1.98, 0.34-51.6). Ara h 2-specific IgE concentrations 
were lower than those for whole peanut. The median Ara h 2-specific IgE for tolerant 
children was 0.34 kUA/L (IQR 0, 0.34-1.54) compared with 4.8 kUA/L (IQR 28.4, 0.34-101) for 
allergic children.
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Figure 14:  Comparison between whole peanut-specific IgE and Ara h 2-specific IgE concentrations in peanut allergic and tolerant children 





Legend: The study population was divided into two primary outcome groups; those who were peanut allergic and those who were peanut tolerant. Whole peanut and Ara h 2 
specific IgE concentrations were significantly higher in peanut allergic children (Fisher’s Exact test; p<0.05
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4.5 Secondary analysis of subgroups of peanut allergic and peanut tolerant 
children 
The secondary analysis within this study is to make comparisons between the subgroups of 
peanut allergic children; those with challenge-proven peanut allergy, those with whole peanut-
specific IgE or skin prick test values above previously published positive predictive values and 
those who have experienced a previous confirmed allergic reaction to peanut. The most 
clinically useful finding would be to identify tests able to distinguish between children with 
challenge-proven allergy or tolerance. 
 
4.5.1 Subgroup analysis of the clinical utility of peanut skin prick test wheal diameters in the 
prediction of peanut allergy status 
Figure 15 depicts differences in skin prick test wheal diameters between the separate oral 
provocation challenge outcome subgroups. The mean peanut wheal diameter was 4mm 
(SD±1.5, range 2-6) for children in with challenge-proven peanut allergy, 7mm (SD±3.5, range 
4-13) for children with known peanut allergy, 11mm (SD±3.7, range 0-22) for children with 
values above the positive predictive value, 4mm (SD±2.6, range 0-11) for tolerant children and 
4mm (SD±1.2, range 3-5) for children with resolved allergy. A one-way ANOVA demonstrated 
that at least one group was significantly different to the others [F(4,90)=22.36, p<0.0001]. Post 
hoc multiple pairwise comparisons using the Bonferroni correction indicated that the mean 
wheal diameter for children within the positive predictive value subgroup was significantly 
different than the mean wheal diameter for children in the challenge-proven peanut allergy or 
challenge-proven peanut tolerance subgroups. There was no significant difference for any 
other group comparisons (Figure 15). 
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Legend: Peanut allergic and tolerant children were further divided into subgroups; Challenge-proven peanut 
tolerance, challenge-proven peanut allergy, known peanut allergy, positive predictive value or resolved peanut 
allergy. The mean wheal diameter for children within the positive predictive value subgroup was significantly 
higher than children with challenge proven allergy or tolerance.  
 
 
4.5.2 Subgroup analysis of whole peanut- and Ara h 2-specific IgE concentrations 
compared with peanut oral provocation challenge outcomes 
Whole-peanut specific IgE concentrations 
A Kruskal-Wallis test was performed to examine differences between the subgroups depicted 
in Figure 16; challenge-proven peanut allergic, known peanut allergy, test values above 
previously published 95% positive predictive values, challenge-proven peanut tolerance and 
resolved peanut allergy. This demonstrated that at least one group was significantly different 
from the others (p<0.0001). Median whole peanut-specific IgE values were highest in 
children with known peanut allergy at 47.8 KUA/L (IQR 99.1, 0.70-101) and in children in the 
positive predictive value subgroup at 18 KUA/L (IQR 38.9,0.34-101). However, there was no 
clear difference in median whole peanut-specific IgE values between children who were 
tolerant and children with challenge proven peanut allergy. The median whole peanut-
specific IgE was 1.0 KUA/L (IQR 2.7,0.34-51.6) for tolerant children and 1.2 KUA/L (IQR 
1.44,0.34-2.55) for challenge proven allergic children. Outliers existed in the tolerant group 
rather than the allergic group. 
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A series of post hoc Mann-Whitney U non-parametric tests were performed to compare 
differences between subgroups. Median whole peanut-specific IgE were significantly higher 
for children in the positive predictive value subgroup than for children with challenge-proven 
peanut allergy (U=55.5, z=-3.321, p<0.0001), resolved peanut allergy (U=7.0, z=-2.636, 
p<0.01) or peanut tolerance (U=222.5, z=-5.110, p<0.0001). There was also a significant 
difference in median whole peanut-specific IgE between children with known peanut allergy 
and challenge-proven peanut allergy (U=9.0, z=-2.423, p<0.05) or tolerance (U=35.0,  
z=-2.954, p<0.005). Applying the Bonferroni correction identifies that only values less than 
0.005 were significant as ten pairwise comparisons were made. 
Ara h 2-specific IgE concentrations 
A Kruskal-Wallis test identified a difference for at least one group (p<0.0001)(see Figure 16). 
Children with known peanut allergy and those with a test value above the positive predictive 
value had median Ara h 2-specific IgE concentrations of 28.2 kUA/L (IQR 97.9, 0.53-101) and 
8.5 kUA/L (IQR 27.8, 0.34-101) respectively. Five post hoc Mann-Whitney U comparisons 
were made between children with known peanut allergy and challenge-proven peanut 
allergy (U=3.0,z=-3.130, p<0.005) and tolerance  (U=3.0,z=-5.253, p<0.0001); positive 
predictive value and challenge-proven peanut allergy  (U=53.5,z=-3.434, p<0.001) and 
tolerance  (U=128.5,z=-6.368, p<0.0001) and, and children with challenge-proven peanut 
allergy and tolerance  (U=91.0,z=-1.464, p>0.1).  There was no significant difference when 
comparing median Ara h 2-specific IgE concentrations in de novo children with challenge 
proven allergy and peanut tolerant children; median 0.34kUA/L (IQR 0.12, 0.34-2.66) versus 
0.34 kUA/L (IQR 0,0.34-1.54). 
Comparison of whole peanut- and Ara h 2-specific IgE concentrations 
Ara h 2-specific IgE concentrations tend to be lower than whole peanut-specific 
concentrations although the distribution of results was similar. Figure 16 compares whole 
peanut- and Ara h 2-specific IgE outcomes for the five subgroups. This highlights the 
significant difference between children in the positive predictive value and known peanut 
allergy subgroups and the other subgroups. 
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Figure 16:  Whole peanut- and Ara h 2-specific IgE concentrations according to oral provocation 




Ara h 2-specific IgE 
Whole peanut-specific IgE 
 
Peanut allergic and tolerant children were further divided into subgroups; Challenge-proven peanut tolerance, 
challenge-proven peanut allergy, known peanut allergy, positive predictive value or resolved peanut allergy. 
Median whole peanut and Ara h 2 specific IgE values were highest for children with known peanut allergy and 
those in the positive predictive value subgroup (Kruskal-Wallis test; p<0.0001). 
 
 
4.5.3 Summary of the comparison of peanut skin prick testing and whole peanut- and Ara h 
2-specific IgE testing for the diagnosis of peanut allergy in egg-allergic, peanut-
sensitised children 
These analyses have demonstrated that all three tests are of limited value in distinguishing 
between peanut allergy and tolerance in peanut-naïve individuals whose test values lie within 
the immunological grey area below the published positive predictive value. For peanut skin 
prick testing, there was a difference in mean peanut skin prick test wheal diameter between 
the two groups, but this was only significant for the diagnosis of peanut allergy in children with 
a wheal diameter equal to or above the positive predictive value of 8mm. As there was no 
difference in the number of children with a positive skin prick test, then this test is only really 
useful in the identification of egg-allergic, peanut-naïve children who are at risk of peanut 
allergy. Subgroup analysis revealed results to be skewed by the inclusion of children with a 
wheal diameter above the previously published positive predictive value and those with 
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known peanut allergy. Skin prick testing was unhelpful if the differentiation of children with 
challenge-proven allergy or tolerance. However, a negative skin prick test is useful to screen 
out peanut tolerant children without the need for further investigation. 
 
Analysis of both peanut- and Ara h 2-specific IgE testing identified a significant difference in 
the number of children with a positive test result between peanut allergic and peanut tolerant 
children but this was again skewed by children with known peanut allergy or whole peanut 
test values above the positive predictive value. The measurement of whole peanut-specific IgE 
concentrations and Ara h 2-specific IgE concentrations was, like skin testing, unable to 
discriminate between challenge-proven allergy and tolerance. This highlights the limited value 
of whole peanut-specific IgE concentrations in the diagnosis of peanut allergy in children with 
test values below the positive predictive value. There was a stronger association between 
having a positive Ara h 2-specific IgE concentration and peanut allergy, than having a positive 
whole-peanut specific IgE concentration and peanut allergy. A negative Ara h 2-specific IgE 
concentration increased the probability of tolerance but was insufficiently reliable and 
compared unfavourably with the peanut skin prick test for this purpose. Children with a 
negative Ara h 2-specific IgE concentration require further investigation in the form of an oral 
provocation challenge. All children with a positive Ara h 2-specific IgE concentration of Grade 3 
or above were allergic. 
 
4.6 Influence of the co-variables; persistent egg allergy, total IgE concentrations 
and age on oral provocation challenge outcomes 
It is important to consider the presence of factors that may be associated with the prediction 
of either peanut allergy or peanut tolerance, as these may be valuable in the development of a 
diagnostic algorithm. It is also important to consider factors that might confound the analysis. 
Factors of potential interest identified in this study were the presence of persistent egg allergy, 
eczema, total IgE concentrations and the age range of included children. 
 
4.6.1 Persistent egg allergy 
54(77%) peanut allergic children had persistent egg allergy compared with 16 (52%) peanut 
tolerant children (Fisher’s Exact, p<0.05). The presence of persistent egg allergy may be 
associated with an increased risk of a child being peanut allergic rather than peanut tolerant. 
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4.6.2 Eczema 
All peanut allergic and peanut tolerant children had a history of current or previous eczema. 
The presence of eczema was not associated with an increased risk of a child being peanut 
allergic rather than peanut tolerant in this high-risk cohort of children with egg allergy. 
 
4.6.3 Total IgE concentrations in allergic and tolerant children 
It is possible that peanut- and Ara h 2-specific IgE values may have been affected by 
differences in total IgE concentrations between peanut allergic and peanut tolerant children. 
Therefore, total IgE concentrations were compared between these two groups but no 
difference was found. Figure 18 shows total IgE concentrations for children in the peanut 
allergic and tolerant groups. The median total IgE was 359 kUA/L (IQR 932, 11-11702) in 
children with peanut allergy and 302 kUA/L (IQR 1054, 6-4584) in peanut tolerant children, 
showing no difference between the two groups (Figure 17). 
 




Legend: The study population was divided into two primary outcome groups; those who were peanut allergic 
and those who were peanut tolerant. There was no difference in total IgE concentration between allergic and 
tolerant children (p>0.05). 
 
 
4.6.4 Analysis of peanut skin prick tests and the measurement of whole peanut- and Ara h 
2-specific IgE concentrations when study children are categorised according to age  
Differences in food-specific IgE concentrations have been described for children aged below 
and over two years of age as described above and the ages of subjects in this study has been 
examined accordingly. The majority of children were older than two years of age. 14(14%) 
children were less than two years of age and 87(86%) were two years of age or older. The 
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sample of infants was small and therefore it is difficult to analyse the available data. Among 
the infants, no peanut tolerant child had a positive Ara h 2-specific IgE concentration although 
the tolerant child with a high whole peanut-specific IgE of Grade 5 was an infant. Most tolerant 
children also had low Ara h 2 grades but many allergic children also had low grade or negative 
whole peanut- and Ara h 2-specific IgE concentrations. 
 
Figure 18 depicts graded whole peanut- and Ara h 2-specific IgE classifications separately for 
infants and children. Children were not found to have higher median specific IgE values than 
infants as has often been previously reported. Peanut allergic infants had median whole 
peanut-specific IgE concentrations of 48.9 kUA/L (IQR 100, 0-101) compared with allergic 
children 11.6 kUA/L (IQR 63, 0-101). Peanut tolerant children had median whole peanut-
specific IgE concentrations of 0.5 kUA/L (IQR 2, 0-11) compared with tolerant infants 0.9 kUA/L 
(IQR 4, 0-52). Median Ara h 2-specific IgE concentrations were lower than whole peanut-
specific IgE concentrations for allergic and tolerant infants and children. Peanut allergic infants 
had median Ara h 2-specific IgE concentrations of 0.8 kUA/L (IQR 76, 0-101) compared with 
allergic children 5.6 kUA/L (IQR 28, 0-101). Both peanut tolerant infants and children had 
median Ara h 2-specific IgE concentrations of 0.34 kUA/L. 
 
4.6.5 Conclusion of analysis of co-variables on oral provocation challenge outcome 
There was no discernible difference in test results between infants and children. As the sample 
size of infants was smaller than anticipated, no further analyses have been completed 
separating children by age. Total IgE concentrations also had no effect upon peanut allergy 
status. There was an association between persistent egg allergy and a diagnosis of peanut 
allergy, and this will be considered during logistic regression modelling in Section 4.7. 
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Legend: The study population was divided into primary outcome groups; those who were peanut allergic and those who were peanut tolerant. Children were not found to 
have higher median specific IgE values than infants. Children less than two years of age were classified as infants. 
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4.7 Logistic Regression to predict the probability of peanut allergy being detected 
by peanut skin prick testing, or whole peanut- or Ara h 2-specific IgE concentrations  
Logistic regression is applicable to a continuous measurement (food-specific IgE antibody 
concentration) and the nominal categorical (binary) variable of being peanut allergic or 
tolerant. Logistic regression enables the prediction of the probability of the nominal variable 
(peanut allergy status) being based on the independent variables. This was performed to 
predict the probability of peanut allergy being detected by either a peanut skin prick test, or 
whole peanut- or Ara h 2-specific IgE concentration. Logistic regression was performed 




The logistic regression model based on a positive Ara h 2-specific IgE concentration of ≥0.35 
kUA/L was statistically significant, p<0.0005. Based on the Nagelkerke R2, the model only 
explained 57% of the variance in peanut allergy with the other 43% of factors being 
unidentified. Children with a positive Ara h 2-specific IgE concentration had an odds ratio of 
18. Therefore the risk of being peanut allergic increased by 18 for each unit change in Ara h 2-
specific IgE which was statistically significant despite having wide 95% confidence intervals. 
Given these wide margins of error, the precision of the measurement of Ara h 2-specific IgE 
concentrations is low. The logistic regression model for whole peanut-specific IgE and a 
positive peanut skin prick test had lower odds ratios of 1.085 and 1.665 respectively but also 
have far smaller 95% confidence intervals meaning that these tests are more precise. Skin 
prick test wheal diameters to peanut were indicated to be an important factor (p<0.05) with 
the independent odds ratio of being peanut allergic increasing by 1.7 for each mm increase in 
wheal diameter with the 95% confidence interval ranging from 1.34 to 2.06. The logistic 
regression model for persistent egg allergy similarly demonstrated a lower odds ratio than for 
Table 16: Logistic regression predicting likelihood of peanut allergy based on 
measurement of peanut SPT wheal diameter and whole peanut- and Ara h 2-specific IgE 
concentrations 
Test B (SE) p Odds ratio 95% CI for Odds Ratio 
    Lower Upper 
Ara h 2-Specific IgE 2.90 (1.32) 0.03 18.3 1.37 245.4 
Peanut-Specific IgE 0.08 (0.34) 0.02 1.09 1.01 1.16 
Peanut-Skin prick test 0.51 (0.11) <0.0001 1.67 1.34 2.06 
Persistent egg allergy 1.15 (0.46) 0.01 3.16 1.29 7.77 
Legend: Persistent egg allergy was included in the model as it had been identified as being 
associated with a diagnosis of peanut allergy in Section 4.6 
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a positive Ara h 2-specific IgE concentration, being 3.164 (95% CI: 1.288-7.771), although the 
95% confidence intervals here were slightly wider reflecting decreased precision. 
 
A series of logistic regression models have all demonstrated a significant relationship between 
either a positive skin prick test to peanut, a positive whole peanut-specific IgE level or a 
positive Ara h 2-specific IgE level and peanut allergy although the extent to which these can be 
relied upon varies due to their varying degrees of statistical significance. Logistic regression 
modelling confirms the significant relationship between a child having persistent egg allergy 
and peanut allergy. 
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 4.8 Likelihood Ratios to examine the clinical utility of peanut skin prick testing, 
whole peanut- and Ara h 2-specific IgE measurements in predicting peanut allergy in 
egg-allergic peanut-sensitised children 
Sensitivity and specificity are not helpful in practical terms but can be combined to produce a 
likelihood ratio that is useful when reviewing an individual patient. Table 18 shows likelihood 
ratios for both the two groups of peanut allergic and tolerant children and the further 
subgroups. 
 
4.8.1 Likelihood ratios for two groups of peanut allergic and peanut tolerant children 
The pre-test probability of a child chosen at random from a group of egg-allergic children being 
reviewed in the tertiary paediatric allergy clinic having peanut allergy is 0.69 (70/101). The 
specificity and sensitivity for the three tests: peanut skin prick test, whole peanut-specific IgE 
and Ara h 2-specific IgE were calculated using the manufacturer’s recommended cut-off values 
using this pre-test probability. Sensitivity for Ara h 2-specific IgE testing was inferior to that of 
both whole peanut-specific IgE at 94% and skin prick testing at 96%. A positive Ara h 2-specific 
IgE concentration had a 97% positive predictive value for the diagnosis of peanut allergy with a 
negative predictive value of 69%. Ara h 2-specific IgE concentrations had the highest likelihood 
ratio with highest post-test odds of having peanut allergy with a positive Ara h 2-specific IgE 
concentration result being 97% (Table 18). The Fagan’s nomogram used to calculate post-test 
odds is included in Appendix 8.  
 
4.8.2 Likelihood ratios calculated for subgroups of peanut allergic and tolerant children 
Children subjected to an oral provocation challenge had a pre-test probability of 0.21 (8/36) 
for having peanut allergy. In this analysis of children with challenge-proven allergy or 
tolerance, the sensitivity for Ara h 2-specific IgE concentrations falls notably from the previous 
analysis of two groups of allergic and tolerant children (Table 18). Specificity remains highest 
for Ara h 2-specific IgE concentrations at 94%. The positive predictive values for all tests are 
poor. The negative predictive values performed better in this analysis. Ara h 2-specific IgE 
concentrations still produced the highest positive likelihood ratio of 5.81 and had the highest 
post-test odds of 60%. In this subgroup analysis, a child with positive Ara h 2-specific IgE has an 
increased probability of having peanut allergy raised from the pre-test probability of 21% to 
post-test probability of 60%. 
 
The pre-test probability for children with known allergy was also 0.21 (8/36) (Table 18). All 
three tests had a sensitivity of 100%. Specificity was similar to that for challenged children, 
being highest for the measurement of Ara h 2-specific IgE at 94%. The positive predictive value 
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was also highest for a positive Ara h 2-specific IgE concentration at 80% and all three tests had 
a 100% negative predictive value. Ara h 2-specific IgE had the highest positive likelihood ratio 
of 15.5 compared with values just below 1.5 for both peanut tests. Post-test odds remained 
highest for Ara h 2-specific IgE concentrations. A child with a positive Ara h 2-specific IgE 
concentration had an increased probability of peanut allergy, raised from the pre-test 
probability of 21% to post-test probability of 79%. 
 
The pre-test probability in the subgroup of children with whole peanut-specific IgE or skin prick 
tests above previously published 95% positive predictive values was 0.64 (Table 18). Sensitivity 
was good for all three tests but specificity was better for Ara h 2-specfic IgE concentrations at 
94%. Again, Ara h 2-specific IgE concentrations yielded the highest positive predictive value at 
96%. All three groups had comparable negative predictive values. The highest positive 
likelihood ratio was for Ara h 2-specific IgE testing at 13.2. A child with positive Ara h 2-specific 
IgE in this subgroup has an increased probability of having peanut allergy raised from the pre-
test probability of 64% to post-test probability of 96%. 
 
4.8.3 Summary of likelihood ratio analysis 
In summary, out of all three available tests, the measurement of Ara h 2-specific IgE 
concentrations had the best clinical utility (Table 18). A child with positive Ara h 2-specific IgE 
has an increased probability of having peanut allergy raised from the pre-test probability of 
69% to post-test probability of 97%. For all analyses, including subgroup analyses, a positive 
Ara h 2-specific IgE concentration increased the post-test odds of a child having peanut allergy 
to a greater extent than for either of the other two tests. Sensitivity tended to be higher for 
whole peanut-specific IgE and skin prick tests although Ara h 2-specific IgE testing had the best 
specificity in the majority of the above analyses. It is important to consider where the balance 
between sensitivity and specificity should lie to achieve optimum clinical utility when selecting 
a diagnostic test. This will be taken into consideration when constructing receiver-operator 
characteristic curves in Section 4.9. 
  





Table 17:  Sensitivity, specificity, positive predictive values and negative predictive values for cohorts of peanut allergic and tolerant children 















+ Test -Test 
Ara h 2-specific IgE Full study population 81% 94% 97% 69% 12.62 0.20 97% 31% 
Whole peanut-specific IgE Full study population 94% 32% 75% 71% 1.39 0.18 75% 28% 
Peanut skin prick test Full study population 96% 23% 74% 70% 1.25 0.19 74% 30% 
Ara h 2-specific IgE Challenge-proven population 38% 94% 60% 85% 5.81 0.67 60% 15% 
Whole peanut-specific IgE Challenge-proven population 88% 32% 25% 91% 1.29 0.39 25% 9% 
Peanut skin prick test Challenge-proven population 88% 23% 23% 88% 1.14 0.54 23% 13% 
Ara h 2-specific IgE Positive predictive value 85% 94% 96% 78% 13.2 0.16 96% 22% 
Whole peanut-specific IgE Positive predictive value 94% 32% 70% 77% 1.39 0.18 70% 23% 
Peanut skin prick test Positive predictive value 96% 23% 69% 78% 1.26 0.16 69% 22% 
 
Legend: Sensitivity and specificity are not helpful in practical terms but can be combined to produce a likelihood ratio. A positive likelihood ratio of 1 means that a positive test is 
more likely to occur in a child with peanut allergy rather than a tolerant child. Likelihood ratios can be used in conjunction with the pre-test probability of a child having peanut 
allergy to calculate their post test probability of being peanut allergic  
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4.9 Receiver Operator Characteristic Curves to compare the accuracy of the three 
diagnostic tests; the peanut skin prick test and the measurement of whole peanut- 
and Ara h 2-specific IgE concentrations 
The receiver operating characteristic (ROC) curve is obtained by plotting the sensitivity of a 
test against 1-specificity. The area under the ROC curve provides a measure by which to 
compare the accuracy of diagnostic tests (Akobeng, 2007). Receiver operator curves (ROC) 
were constructed to compare the diagnostic utility of each test:  peanut skin prick test wheal 
diameters, whole peanut-specific IgE concentrations and Ara h 2-specific IgE concentrations 
(Figure 19).  
 
Figure 19: Receiver-operator characteristic curves showing the performance of the three screening 
tests in children with peanut allergy and tolerance in predicting peanut allergy  
 
Legend. The ROC curve is obtained by calculating the sensitivity and specificity of a test at every possible cut-off 
point, and plotting sensitivity against 1-specificity. An area under the curve of greater than 80% suggests that the 
test is a good diagnostic test with clinical utility. In practice this means that if a clinician were to take two 
children, one allergic and one tolerant and perform the selected test on them, then the child with the abnormal 
test result should be the child from the peanut allergic group. Ara h 2 is the component with the highest accuracy 
for discriminating between peanut allergy or tolerance. 
 
The area under the curve calculations are presented in Table 19. The receiver-operator 
characteristic curve for Ara h 2-specific IgE concentrations revealed an area under the curve of 
0.88 (95% CI 0.88-0.95) (p<0.0005). This compares with other studies; Kim reported an area 
under the curve of 82% and a recent systematic review identified a range of area under the 
curve values for Ara h 2-specific IgE of between 0.90 and 0.99 (Klemans, 2015, Eller and 
Bindslev-Jensen, 2013). However, the other tests also both had equivalent clinical utility. 
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Whole peanut-specific IgE had an area under the curve of 0.82 (95% CI 0.73-0.90) (p<0.0005) 
and the peanut skin prick test had an area under the curve of 0.88 (95% CI 0.82-0.95) 
(p<0.0005). Therefore although Ara h 2-specific IgE was demonstrated to have the best 
diagnostic accuracy for the prediction of clinical peanut allergy the area under the curve was 







4.9.1 The selection of optimal cut-off values from the receiver operator characteristic curve 
for the prediction of peanut allergy in the study population 
The selection of optimal cut-off values for a diagnostic test depends upon the desired balance 
between sensitivity and specificity. Several cut-off values are examined below selected by 
utilising the following in turn: (1) the Youden Index, (2) the manufacturer’s cut-off value, (3) 
previously published 95% positive predictive values, (4) those giving the highest sensitivity, (5) 
those giving the highest specificity and (6) those where both sensitivity and specificity were as 
close to 80% as possible (Table 20).  
 
The selection of cut-off values using the Youden Index assumes that both false positive and 
false negative diagnoses are equally undesirable. Although these may be the best fit cut-off 
values identified from the receiver operator characteristic curve, they have reduced utility in 
the clinical setting due to the risk of leading to more false negative results than is acceptable. 
The manufacturer’s cut-off values were analysed, as it is important to establish the 
applicability of the manufacturer’s cut-off value to the study population. General practitioners 
who have access to specific IgE laboratory testing often base their decision on these cut-off 
values. Cut-off values calculated using previously published 95% positive predictive values 
were also examined. The 8mm cut-off value for peanut skin prick test performed better than 
whole peanut-specific IgE testing, having 73% sensitivity and 90% specificity. Sampson’s 95% 
positive predictive value for whole peanut-specific IgE had good specificity at 97% but 
surprisingly poor sensitivity in this study population at 46%. Those cut-off values that yielded 
Table 18:  Area under the curve for skin prick test to peanut, whole peanut-specific 
IgE concentrations and Ara h 2-specific IgE concentrations 
Test AUC   [95% CI) p value 
Ara h 2-specific IgE 0.88 [0.81-0.95] <0.0005 
Peanut-specific IgE 0.81 [0.73-0.90] <0.0005 
Peanut skin prick test 0.88 [0.82-0.95] <0.0005 
 
Legend. Ara h 2 was demonstrated to have the best diagnostic accuracy for the prediction of 
peanut allergy but values were similar for all three tests 
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the highest sensitivity were identified followed by those that produced the highest specificity. 
These results demonstrated giving priority to one test to be at the expense of the other, 
although Ara h 2-specific IgE concentrations offered the best performance confirmed by the 
highest Youden Index. False negatives would place the child at risk of experiencing a 
potentially severe reaction in an unsafe environment. Therefore a test with good sensitivity at 
the expense of good specificity is far from ideal. Specificity is of prime importance. It is more 
desirable to have more children with false positive tests as opposed to false negative tests for 
safety reasons. The ideal scenario is to establish a test that eliminates the need for an oral 
provocation challenge. 
 
A secondary aim of the study was to identify optimal decision points. The identification of cut-
off values close to 80% is an attempt to achieve this balance. Ara h 2-specific IgE testing had a 
low optimal cut-off value of 0.39 kUA/L with sensitivity of 79% and good specificity of 93%. The 
present study did not find Ara h 2 to be as good a test as has been previously reported. A study 
of UK schoolchildren reported a similar cut-off value of 0.35kUA/L to classify all peanut allergic 
children correctly, with 100% sensitivity and 96% specificity (Nicolaou et al., 2011). However, 
the study population in the latter study had originated from a birth cohort study. In the 
present study, cut-off values for optimal peanut skin prick test wheal diameters and specific 
IgE concentrations were higher than for Ara h 2-specific IgE concentrations. For whole peanut-
specific IgE a cut-off value of 1.08 kUA/L gave 81% sensitivity although at the expense of 57% 
specificity. To achieve a specificity of 80%, the cut-off value needed to be raised to 3.36 kUA/L 
although corresponding sensitivity fell to 67%. For peanut skin prick testing, a 6mm wheal 
diameter gave reasonable sensitivity and specificity of 84% and 80% respectively. 
 
4.9.2 Conclusion of the construction of receiver operator characteristic curves for the 
comparison of diagnostic accuracy and the identification of optimal cut-off values for 
the three tests 
In summary, although all three tests have a similar area under the curve, when considering the 
balance of sensitivity and specificity, the measurement of Ara h 2-specific IgE concentrations 
had the best performance for all of the proposed cut-off values presented above. The optimal 
decision points identified in this analysis will be used in Chapter 5 to construct a model 
proposing a diagnostic algorithm. 
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Table 19:  Area under the curve and optimal cut-off values for the diagnosis of peanut allergy constructed for skin prick test to 
peanut, whole peanut-specific IgE concentrations and Ara h 2-specific IgE concentrations based on the Youden Index 
Test 
Factors determining the 
selected cut-off value 
Selected 




Ara h 2-specific IgE Youden Index 0.45 kUA/L 78% 97% 0.74 
Whole peanut-specific IgE Youden Index 5.99 kUA/L 62% 93% 0.46 
Peanut skin prick test Youden Index 7.5 mm 73% 90% 0.66 
Ara h 2-specific IgE Manufacturer’s cut-off values 0.35 kUA/L 79% 93% 0.73 
Whole peanut-specific IgE Manufacturer’s cut-off values 0.35 kUA/L 94% 37% 0.30 
Peanut skin prick test Manufacturer’s cut-off values 3 mm 94% 50% 0.40 
Whole peanut-specific IgE 95% positive predictive value 15 kUA/L 46% 97% 0.43 
Peanut skin prick test 95% positive predictive value 8mm 73% 90% 0.66 
Ara h 2-specific IgE Priority to sensitivity 0.39 kUA/L 79% 93% 0.73 
Ara h 2-specific IgE Priority to specificity 1.77 kUA/L 62% 100% 0.62 
Whole peanut-specific IgE Priority to sensitivity 0.35 kUA/L 94% 37% 0.30 
Whole peanut-specific IgE Priority to specificity 54.96 kUA/L 29% 100% 0.29 
Peanut skin prick test Priority to sensitivity 3 mm 94% 50% 0.40 
Peanut skin prick test Priority to specificity 10 mm 37% 100% 0.33 
Ara h 2-specific IgE Optimal decision point 0.39 kUA/L* 79% 93% 0.73 
Whole peanut-specific IgE Optimal decision point 1.08 kUA/L* 81% 57% 0.38 
Whole peanut-specific IgE Optimal decision point 3.36 kUA/L* 67% 80% 0.47 
Peanut skin prick test Optimal decision point 6mm* 84% 80% 0.61 
Legend. There is no 95% positive predictive value available for Ara h 2-specific IgE concentrations. Cut-off values were selected based upon the 
best balance of sensitivity and specificity, considering the clinical need for safety. This balance leans towards a false positive test being 






















Peanut vendor, Bangkok 2015 
Peanut vendors are still common today in Asia. 











RESULTS SECTION 2: DATA INTERPRETATION AND APPLICATION 
5.1 Introduction 
The secondary aim of this study was to evaluate whether the measurement of Ara h 2-specific 
IgE concentrations is clinically useful in the management of peanut-naïve, peanut-sensitised 
children with a history of egg allergy, and to construct optimal cut-off values for the three 
examined tests: peanut skin prick testing, whole peanut-specific IgE concentrations and Ara h 
2-specific IgE concentrations. An ideal cut-off value for the diagnosis of peanut allergy in egg-
allergic, peanut-sensitised children is one that will reduce the need for a child to be subjected 
to an oral provocation challenge. Current testing using peanut skin prick tests and/or whole 
peanut-specific IgE concentrations leaves a large number of children with test values below 
previously published positive predictive values sitting within the immunological grey area. 
Given that the option of leaving a child without a definitive diagnosis is no longer acceptable, if 
indeed it ever has been, this population of children require an oral provocation challenge 
which is time-consuming, labour-intensive, costly, and stressful for children and families. 
Optimal clinical decision points were identified from the ROC curve analysis for the three tests 
by selecting cut-off values that had both sensitivity and specificity as close to 80% as possible, 
as discussed in Chapter 4. Using these criteria the best cut-off values were: ≥6mm for peanut 
skin prick testing, ≥1.08kUA/L for whole peanut-specific IgE testing and ≥0.39kUA/L for Ara h 2-
specific IgE. 
 
5.2 Examination of a potential stepwise approach diagnostic algorithm 
Examination of the clinical utility of whole peanut- and Ara h 2-specific IgE concentrations and 
peanut skin prick tests has highlighted a high diagnostic error rate. The measurement of Ara h 
2-specific IgE concentrations was superior to both whole peanut-specific IgE and peanut skin 
prick testing in the present study but their use as a replacement for the gold standard oral 
provocation challenge is limited. Ara h 2-specific IgE testing is not yet at the stage where it can 
be used to replace the oral provocation challenge. Using the identified cut-off values, an 
attempt was made to identify a stepwise approach to identify those children most at risk of 
peanut allergy and to subsequently reduce the number of children requiring a peanut 
provocation challenge. 4 separate models are examined. 
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5.2.1 Model 1: Whole peanut-specific IgE concentration testing followed by Ara h 2-specific 
IgE concentration testing 
The first model approach examined a two-step approach commencing with a whole peanut-
specific IgE concentration utilising a cut-off of 1.08 kUA/L and identified 69 children from the 
entire cohort (Figure 20). Children without whole peanut-specific IgE measurements available 
were excluded. This model assumes that children with a whole peanut-specific IgE 
concentration below 1.08 kUA/L would be peanut tolerant and would have led to 9 (13%) 
peanut allergic children being misclassified as peanut tolerant and 11 (16%) being correctly 
classified as tolerant. For the second step of the algorithm, the 20 children with an Ara h 2-
specific IgE concentration of less than 0.39 were then excluded and presumed tolerant. This 
led to 11 (16%) children being correctly classified as tolerant and 9 (13%) peanut allergic 
children being misclassified as peanut tolerant, which is clearly a potentially dangerous 
situation. The remaining 49 (71%) children all had an Ara h 2-specific IgE concentration of 0.39 
or above, the presumed allergic group. Within this group, 47 (68%) children were correctly 
classified as peanut allergic whilst only 2 peanut tolerant children were misclassified as 
allergic. This is an acceptable misclassification rate as it does not pose a risk to children and the 
rate of being falsely labelled peanut allergic is not very high. Overall, Model 1 misclassified 11 
children. Children with an Ara h 2-specific IgE concentration below the 0.39kUA/L cut-off value 
need to be challenged rather than being labelled as tolerant but overall, use of this model 
reduces the number of oral provocation challenges from 69 to 20. 
 
Figure 20:  Model 1:  A two-step diagnostic algorithm utilising whole peanut-specific IgE 












Legend. Acceptable misclassified children appear in green; unacceptable misclassified children appear in red. 






























Ara h 2-specific IgE 
<0.39 kUA/L 
n=20 
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A similar approach of measuring whole peanut-specific IgE concentrations followed by Ara h 2-
specific IgE concentrations was undertaken within the HealthNuts birth cohort population and 
was reported to reduce the number of children requiring a confirmatory oral provocation 
challenge by two thirds (Dang et al., 2012). The HealthNuts study identified a 15kUA/L positive 
predictive value for whole peanut-specific IgE to have a corresponding specificity of 98% and a 
sensitivity of 26%. The current study identified a better performance with whole peanut-
specific IgE concentrations having 97% specificity and 46% sensitivity. At the equivalent 
specificity of 98%, the current study identified the sensitivity of Ara h 2-specific IgE testing to 
be 77%, compared with 60% within the HealthNuts study. Therefore, Ara h 2-specific IgE 
concentrations correctly identify a higher proportion of children with peanut allergy than 
whole peanut-specific IgE. 
 
5.2.2 Model 2: Skin prick testing followed by Ara h 2-specific IgE concentration testing 
In model 2, the initial step of measuring whole peanut-specific IgE concentrations was 
replaced by a skin prick test utilising a cut-off value of ≥6mm. According to this model, children 
with a wheal diameter below 6mm would be considered peanut tolerant. (A possible strategy 
for the management of these children is discussed later in Chapter 6). Children on 
antihistamines who did not undergo skin testing were excluded. 61 children were identified 
(Figure 21). For the second step of the algorithm, the 15 children with an Ara h 2-specific IgE 
concentration of less than 0.39 kUA/L were then excluded and presumed tolerant. This led to 
10 children being correctly classified as tolerant and 5 peanut allergic children being 
misclassified as peanut tolerant, which like Model 1 again does not yield an acceptable 
misclassification rate. The remaining 46 children all had an Ara h 2-specific IgE concentration of 
0.39 or above and comprise the presumed allergic group. Within this group, 44 children were 
correctly classified as peanut allergic whilst only 2 peanut tolerant children were misclassified 
as allergic which is a similar acceptable misclassification rate to that above in Model 1. Overall, 
Model 2 misclassified 12 children with 10 (13%) being unacceptably misclassified. As above in 
Model 1, children with an Ara h 2-specific IgE concentration below the 0.39kUA/L cut-off value 
need to be challenged. In the study population, 15 children would have required an oral 
provocation challenge under this model. Model 2 is potentially more useful than Model 1, as 
the skin prick test is a quicker and easier screening method and due to its high negative 
predictive value, enables the clinician to safely eliminate peanut allergy in a large number of 
egg-allergic children without the need for venepuncture or other further investigation. 
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Figure 21:  Model 2 - A two-step diagnostic algorithm utilising peanut skin prick test followed by Ara h 


















Legend. Acceptable misclassified children appear in green; unacceptable misclassified children appear in red. 
Outcomes in black and bold are correctly classified. 
 
 
Neither Model 1 nor Model 2 were good at classifying tolerance in children although did have 
reasonable classification rates for diagnosing peanut allergy which will reduce the 
immunological grey area. An improved method of confirming peanut tolerance for children 
with positive whole peanut-specific IgE concentrations or peanut skin prick test wheal 
diameters is needed to eliminate the need for a peanut oral provocation challenge. However, 
this two-step stepwise approach appears to have clinical utility for the diagnosis of peanut 
allergy in egg-allergic, peanut-sensitised children. 
 
5.2.3 Model 3: Peanut skin prick testing followed by whole peanut-specific IgE concentration 
testing followed by Ara h 2-specific IgE concentration testing  
A further stepwise approach model was constructed to add in a third diagnostic step (Figure 
22). Skin prick test was used as the initial screening measure, being the easiest to perform in 
the majority of children attending clinic. Whole peanut-specific IgE concentrations were then 
added in as the second step to create two subgroups of children; those with whole peanut-
specific IgE concentrations (a) below and (b) above the 1.08 kUA/L cut-off value. 49(80%) 
children had test results of ≥1.08 kUA/L and 12(20%) children had values less than this cut-off. 
The third step was to add in Ara h 2-specific IgE concentrations ≥0.39 kUA/L for the analysis of 
children in both whole peanut-specific IgE subgroups. This created four further subgroups; 























Peanut skin prick test 
≥6mm 
n=61 
Ara h 2-specific IgE 
≥0.39 kUA/L 
n=46 
Ara h 2-specific IgE 
<0.39 kUA/L 
n=15 
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peanut ≥1.08 kUA/L and Ara h 2-specific IgE ≥0.39 kUA/L, (C) whole peanut-specific IgE <1.08 
kUA/L and Ara h 2-specific IgE ≥0.39 kUA/L, and (D) whole peanut-specific IgE <1.08 and Ara h 
2-specific IgE <0.39 kUA/L. 
 
Figure 22:  Model 3 - A stepwise approach for the diagnosis of peanut allergy using study generated 

















Legend. Acceptable misclassified children appear in green; unacceptable misclassified children appear in red. 
Outcomes in black and bold are correctly classified. OPC, oral provocation challenge. 
 
 
Among children with a negative whole peanut-specific IgE and a positive Ara h 2-specific IgE 
concentration (C), all 5 (9%) children were classified correctly as peanut allergic. The next best 
performance was for children with both a positive whole peanut- and a positive Ara h 2-
specific IgE concentration (B) which correctly identified 39 (64%) allergic children and 
misclassified only 2 (3%) children as peanut-allergic rather than peanut-tolerant. This 
misclassification would be acceptable in clinical practice as it does not place any children at 
risk and does not give a positive diagnosis to many children. 3 (5%) children with negative test 
results to both tests (D) were misclassified as tolerant when they were allergic. 7 (11%) of 
allergic children with a positive peanut but a negative Ara h 2-specific IgE concentration (A) 
and were misclassified as tolerant. 
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Overall, 12 (20%) children were misclassified when following Model 3 which is comparable to 
the misclassification rates for both earlier models. The classification profile was similar to the 
above models with positive Ara h 2-specific IgE concentrations performing well in children with 
a peanut skin prick test wheal diameter of ≥6mm, regardless of whole peanut-specific IgE 
concentration. Again, negative Ara h 2-specific IgE concentrations were unreliable and placed 
children at potential risk. This suggests that there is no advantage to the more complex and 
expensive three-step model. 
 
5.2.4 Model 4: Children with a peanut screening skin prick test wheal diameter <6mm 
Children with a skin prick test wheal diameter of <6mm are not included in the above stepwise 
models and require further evaluation via a separate stepwise approach (Model 4). 10 peanut 
allergic children within the study fell into this category; 5 with challenge-proven peanut 
allergy, 2 with known peanut allergy and 3 with a whole peanut-specific IgE of ≥15kUA/L. As 
most children with a whole peanut-specific IgE concentration above 15 kUA/L are routinely 
excluded for oral provocation challenges for safety reasons, this leaves 7 of the 10 children 
requiring further investigation. 23 peanut tolerant children also had a skin prick test diameter 
of less than 6mm; 3 of whom had an entirely negative test, leaving 21 tolerant children 
requiring further investigation. 
 
A total of 27 (28%) children would fall into an immunological grey area by virtue of their low 
skin prick test diameters. Most of these children proved tolerant but it is not easy to 
discriminate between allergic and tolerant children, meaning that most of them will require 
further investigation. As discussed earlier, the performance of the three tests between 
children with challenge-proven peanut allergy and challenge proven tolerance was unhelpful. 
 
Close scrutiny of the data revealed that if children with a peanut skin prick test wheal diameter 
of <4mm were labelled as peanut tolerant, then 21 would be correctly identified as tolerant. 
(These children also had a negative Ara h 2-specific-IgE concentration <0.39kUA/L). Challenging 
children with a negative skin prick test of <4mm and a negative Ara h 2-specific IgE 
concentration would result in the need for 23 challenges, which places a significant drain upon 
hospital resources given that in this cohort of children only 2 of the 23 challenged children 
reacted. Therefore the model needs to be further refined. 
 
If a 4mm cut-off value for skin prick testing were to be applied to the current cohort of peanut 
allergic children, then 3 children would be misclassified as being tolerant. This could be refined 
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by including an Ara h 2-specific IgE <0.39 kUA/L cut-off value as a second step, as in Model 4. 
Utilising this model, only 2 allergic children with both skin prick tests wheal diameters to whole 
peanut and negative Ara h 2-specfic IgE concentrations would be then be misclassified as 
peanut tolerant (Figure 23). Children with an Ara h 2-specific IgE concentration above 0.39 
kUA/L in this Model could be diagnosed as peanut allergic without the need for an oral 
provocation challenge. Model 4 does reduce the number of children who would require a 
peanut oral provocation challenge down to 3 - these being children with a skin prick test to 
peanut greater than 4mm but a negative Ara h 2-specific IgE concentration - but did also place 
2 children at risk given that 2 children having both a skin prick test to whole peanut below 
4mm and an Ara h 2-specific IgE concentration of less than 0.39 kUA/L reacted upon peanut 
oral provocation challenge. 
 
Model 4 demonstrates that most peanut allergic children continued to have a positive Ara h 2-
specific IgE concentration ≥0.39kUA/L. All 5 children with a positive Ara h 2-specific IgE 
concentration were peanut allergic so this group of children may not need to be challenged. 
Three children with a negative Ara h 2-specific IgE concentration proved allergic; 1 of these 
had a skin prick test ≥4mm. 
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Figure 23:  Model 4: A two-step diagnostic algorithm for the evaluation of peanut-sensitised children 
















Legend. Acceptable misclassified children appear in green; unacceptable misclassified children appear in red. 
Outcomes in black and bold are correctly classified. OPC, oral provocation challenge. 
 
 
5.3 Summary of stepwise approach 
Neither of the existing widely used whole peanut-specific IgE and skin prick tests, nor the Ara h 
2-specific IgE test alone are sufficient to confirm or refute a diagnosis of peanut allergy in a 
tertiary allergy clinic population of peanut-sensitised, peanut-naïve children with a history of 
egg allergy. However, Ara h 2-specific IgE testing does improve clinical utility when used in 
combination and can help reduce the number of children who require an oral provocation 
challenge. 
Recommendations 
Children with a skin prick test wheal diameter ≥6mm or a whole peanut-specific IgE 
concentration of ≥1.08 kUA/ L in conjunction with a positive Ara h 2-specific IgE concentration 
of ≥0.39 kUA/L could potentially be excluded from a peanut oral provocation challenge and be 
diagnosed as peanut allergic. Children with a skin prick test wheal diameter <6mm require 
further investigation, which can be optimised using Model 4 above. The classification of all 
children with both a peanut skin prick test wheal diameter of <6mm and an Ara h 2-specific IgE 
concentration of <0.39 kUA/L as peanut tolerant may significantly reduce the number of 
Peanut skin prick test  
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Whole peanut skin prick test 
<4mm 
n=25 
Whole peanut skin prick 
test ≥4mm 
n=6 
Ara h 2-specific IgE  
<0.39 
n=3 



















    
 122 
children in this group of children who would require an oral provocation challenge, although 
this would place a small percentage of children at risk. The identification of other factors 
associated with a diagnosis of peanut allergy to help elucidate the peanut allergic status of this 
group of children, such as persistent egg allergy, are a potential focus for future research. 
 




















Jimmy Carter, US President 1977-81 was a peanut farmer. The 












DISCUSSION AND CONCLUSIONS 
6.1 General discussion 
This prospective study aimed to investigate the diagnostic value of measuring Ara h 2-specific 
IgE concentrations in predicting a clinical reaction to peanut in peanut-naïve children with a 
history of egg allergy. The performance of whole peanut- and Ara h 2-specific IgE 
concentrations and peanut skin prick test results in the diagnosis of peanut allergy were 
compared in a study of 101 children peanut-sensitised children with a history of egg allergy 
attending a tertiary paediatric allergy clinic. This is the first study to examine the performance 
of Ara h 2-specific IgE concentrations within this frequently encountered high-risk population. 
Analyses were conducted for the two primary groups, peanut allergic and peanut tolerant 
children. These groups were further divided into subgroups of peanut allergic children; those 
with challenge-proven allergy or tolerance, known peanut allergy, whole peanut test results 
above previously published 95% positive predictive values and resolved peanut allergy. The 
major finding of this study was that the measurement of Ara h 2-specific IgE concentrations 
performed better than whole peanut-specific IgE concentrations and skin prick testing in the 
diagnosis of peanut allergy in this study population of egg-allergic, peanut-sensitised children 
attending a tertiary paediatric allergy clinic. The performance was less helpful for the analysis 
of subgroups within the immunological grey area. However, Ara h 2-specific IgE concentration 
testing was best employed as part of a two-step approach diagnostic algorithm in conjunction 
with peanut skin prick testing. 
 
The prevalence of peanut allergy in the Bristol egg-allergic study population was 31%. The 
association between egg allergy and peanut allergy is well recognised. In the LEAP study egg 
allergy was recognised to be the most important risk factor for the development of peanut 
allergy (Du Toit et al., 2008). Egg allergy is common in infants and young children and therefore 
the burden placed upon allergy services by this population is considerable (Savage et al., 
2007). The three most common ways in which egg-allergic, peanut-sensitised children may 
present has been described as 1) following an adverse reaction associated with peanut 
consumption; 2) with peanut-sensitisation being an incidental finding on a mixed food 
allergen-specific IgE panel in primary care or 3) via referral for a clinic review to exclude peanut 
allergy in children with eczema or other food allergy prior to introduction (Lange et al., 2014). 
Recent changes in management aimed at the prevention of peanut allergy have prompted a 
need to clarify a child’s peanut allergy status as early in life as possible (Du Toit et al., 2008, Du 
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Toit, 2015, Perkin et al., 2016). Currently, parents of children with negative tests to whole 
peanut are advised to cautiously introduce peanut into their child’s diet and to ensure regular 
ingestion approximately three times per week to prevent the development of sensitisation and 
allergy. Considerable clinical acumen is necessary to addressing the diagnosis and 
management of possible peanut allergy in high-risk, egg allergic children. Children with whole 
peanut-specific IgE concentrations above the widely accepted 95% positive predictive value 
are advised that they are highly likely to be peanut allergic and are diagnosed as such and 
managed accordingly. Children over 12 months of age who are identified as peanut-sensitised 
and have skin prick test wheal diameters between 3mm and 7mm are counselled and offered 
an oral peanut provocation challenge. There is an urgent need to identify diagnostic tests that 
may assist in optimising the existing clinical service. 
 
6.2 The NutCracker Study findings  
In the present study, findings were in line with most other studies suggesting Ara h 2-specific 
IgE concentrations to be better than whole peanut-specific IgE concentrations and peanut skin 
prick testing at discriminating between peanut allergic and peanut tolerant children (Asarnoj 
et al., 2010a, Ebisawa et al., 2015, Ebisawa, 2012, van Erp et al., 2016, Codreanu et al., 2011, 
Pedrosa et al., 2012, Vereda et al., 2011). One UK study reported Ara h 2-specific IgE testing to 
have an area under the curve of 0.99 using the manufacturer’s cut-off value of 0.35kUA/L 
(Nicolaou et al., 2011). Another study identified the threshold of 0.29kUA/L as having 93% 
sensitivity and 96% specificity (Codreanu et al., 2011). In contrast, some studies have reported 
peanut-specific IgE concentrations to be superior with a higher area under the curve (Kim, 
2016). 
 
Children assigned to the peanut allergy group were those with challenge-proven peanut 
allergy, a previous allergic reaction to peanut confirmed by skin prick or whole peanut-specific 
IgE testing, or a positive peanut skin prick test or whole-peanut specific IgE concentration 
above previously published positive predictive values. 56(80%) of allergic children had a 
positive Ara h 2-specific IgE concentration compared with only 6% of tolerant children. Allergic 
children had a median Ara h 2-specific IgE concentration of 4.8kUA/L compared with 
0.34kUA/L for tolerant children. A higher median Ara h 2-specific IgE concentration compared 
with whole peanut-specific IgE has been previously reported (Kim, 2016). Median Ara h 2-
specific concentrations in the current study were influenced by two subgroups; children with 
known peanut allergy (28.2kUA/L) and those with whole peanut test results above previously 
published positive predictive values (8.kUA/L) 28.2 kUA/L. Ara h2-testing had the highest 
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positive likelihood ratio of all three tests at 12.62 which translates to a child with clinically 
relevant peanut allergy being approximately 12 times more likely to have a positive Ara h-2 
specific IgE concentration than an asymptomatic peanut-sensitised child. This compares 
favourably with the positive likelihood ratios for peanut skin prick testing and whole peanut-
specific IgE concentrations, which were 1.25 and 1.32 respectively. A systematic review of 21 
paediatric studies by Klemans et al also reported Ara h 2-specific IgE testing to have the 
highest positive likelihood ratio, and found equivalent negative likelihood ratios for all three 
tests as found in this study population (Klemans et al., 2015). The lowest subgroup positive 
likelihood ratio for Ara h 2-specific IgE concentrations was for children with challenge-proven 
peanut allergy, although at 5.81 this remained superior to those for whole peanut tests. 
 
Some tolerant children did have positive Ara h 2-specific IgE concentrations, which has been 
the finding in previous studies. A study of UK peanut-sensitised schoolchildren identified 80 
out of 81 children to have positive specific IgE concentrations to Ara h 2 (Nicolaou et al., 2011). 
A further study reported 26% of sensitised, tolerant subjects to have positive Ara h 2-specific 
IgE whilst another reported this figure to be 10% whilst another study has reported that no 
tolerant subject demonstrated positive specific IgE to any seed storage protein (Lopes de 
Oliveira, 2013, Ackerbauer et al., 2015, Astier et al., 2006). In the present study, a negative 
result increased the probability of a child being tolerant but could not be relied upon to predict 
peanut tolerance as several allergic children also had a negative result. Children with a 
negative Ara h 2-specific IgE concentration therefore require further investigation which may 
include the measurement of specific IgE to other peanut components but which in many cases 
remains likely to culminate in an oral provocation challenge. The clinical utility of measuring 
whole peanut-specific IgE concentrations was found to be limited. All peanut-tolerant children 
had Ara h 2-specific IgE concentrations of Grade 2 or below which may be helpful when 
reviewing a child in clinic. 
 
In the present study, analysis of whole peanut-specific IgE concentrations identified that a 
concentration of Grade 4 or above is likely to indicate peanut allergy. This compares with 
previously published 95% positive predictive values, with the cut-off point for a Grade 4 
serum-specific IgE classification being 15.49 kUA/L (Sampson and Ho, 1997, Kim, 2016). A 
previous UK study has also identified this cut-off value to be applicable to their study 
population, yielding 96.2% specificity (Nicolaou et al., 2011). Children with a whole peanut-
specific IgE above 15kUA/L should be excluded from oral provocation challenge unless their 
individual sensitisation profile prompts further investigation. All peanut tolerant children, with 
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the exception of a single outlier, had a level of Grade 3 or below. 39(57%) of peanut allergic 
children also had concentrations of Grade 3 or below. This confirms the reduced diagnostic 
accuracy of whole peanut-specific IgE concentrations compared with Ara h 2-specific IgE 
concentrations in discriminating peanut allergy fro tolerance in peanut-naïve individuals with 
test values below the published positive predictive value. Additionally, many peanut tolerant 
children had a positive whole peanut-specific IgE level, which equates with the findings of 
other studies. Ackerbauer et al reported 75% of tolerant individual patients to have positive 
whole peanut-specific IgE concentrations (Ackerbauer et al., 2015). Allergic children had a 
median whole peanut-specific IgE concentration of 11.6 kUA/L compared with tolerant 
children who had a median whole peanut-specific IgE concentration of 0.63 kUA/L. As with Ara 
h 2-specific IgE testing, the results were affected by the inclusion of two subgroups of children; 
those who had known peanut allergy (47.8 kUA/L) and those with whole peanut test values 
above previously published positive predictive values (18 kUA/L). Children with challenge-
proven peanut allergy or tolerance had comparable median whole peanut-specific IgE levels of 
1.0 kUA/L and 1.2 kUA/L respectively confirming it to be an unhelpful test in the management 
of egg-allergic, peanut-naïve children sitting within the immunological grey area. Previously 
published studies concur that it has become unreasonable to preserve the measurement of 
whole-peanut specific IgE concentrations as an accurate test to discriminate allergy from 
tolerance (Martinet et al., 2016, Klemans, 2013, Wainstein et al., 2007, Aalberse et al., 2013). 
Unfortunately, the peanut skin prick test was similarly found to be a poor discriminator 
between allergic and tolerant children despite being helpful in the identification of peanut-
sensitised children at risk of peanut allergy. 
 
Skin prick testing remains the primary first line assessment tool for the review of egg-allergic 
children at risk of egg allergy. Despite its poor ability to predict peanut allergy in this 
population of children the negative predictive value using the cut-off value of <3mm was 
excellent at 100%. The association of a negative peanut skin prick test with tolerance concurs 
with earlier studies (POST, 2004). This test is therefore useful in eliminating a diagnosis of 
peanut allergy in egg allergic children, even if they have a positive whole peanut-specific IgE 
concentration. There was a significant difference between the two groups of peanut allergic 
and peanut tolerant children with allergic children having a mean wheal diameter of 10mm 
and tolerant children having a mean wheal diameter of 4mm although the results were 
influenced by the inclusion of the subgroups of children with peanut skin prick test or whole 
peanut-specific IgE concentrations above the 95% positive predictive values and children with 
known peanut allergy. The inclusion of the study subgroups is further examined in Section 6.4 
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below. Mean skin prick wheal diameters for these subgroups were 11mm and 7mm 
respectively. Subgroups of children with challenge-proven peanut allergy and peanut tolerant 
children both had mean peanut wheal diameters of 4mm. A positive peanut skin prick test was 
unable to discern between allergy and tolerance, being present in all 67 (100%) allergic 
children tested and 25 (83%) tolerant children. Children with a negative skin prick test to 
peanut below the manufacturer’s cut-off value should introduce peanut cautiously at home 
rather than being subject to an oral provocation challenge whilst those with a positive peanut 
skin prick test therefore require further investigation. Likelihood ratios were constructed to 
assist with the prediction of oral provocation challenge outcome, which is of particular value 
for children within this immunological grey area. 
 
Likelihood ratios for peanut skin prick testing and the measurement of whole-peanut and Ara 
h 2-specific IgE concentrations confirmed the pre-test probability of an egg-allergic child 
attending the tertiary paediatric allergy clinic at Bristol Royal Hospital for Children having 
peanut allergy to be 69%. A child in this group will have a higher relative risk for peanut allergy 
than a child without egg-allergy attending the clinic. Post-test probability was higher for all 
three tests. Ara h 2-specific IgE testing performed had the highest post-test probability of 97%, 
whilst whole peanut-specific IgE testing gave a post-test probability of 75% and skin prick 
testing gave a post-test probability of 74%. Ara h 2-specific IgE testing also gave the best post-
test probability for the analysis of subgroups. Even for challenged children where pre-test 
probability was lowest at 21%, the post-test probability rose to 60%. The post-test probability 
for peanut skin prick testing and whole peanut-specific IgE concentrations were far less useful 
at 23% and 25% respectively. This confirms that for children within the immunological grey 
area who require an oral provocation challenge, Ara h-2 is the only test that is of any benefit in 
predicting possible outcome. However, its clinical utility does have limitations. For example, a 
post-test probability of 60% is too low for the clinician to be able to make a diagnosis on the 
basis of the Ara h 2-specific IgE concentration alone, although it does provide them with 
information regarding the chance of each child reacting on oral provocation challenge which 
they can relay to the child’s parents or guardians when taking consent for the procedure.  
 
There may be some clinical utility for Ara h-2 testing for the small number of children within 
the positive predictive value subgroup who have a negative Ara h 2-specific IgE concentration 
as this may indicate tolerance. This study identified a single peanut-tolerant child with a very 
highly positive whole peanut-specific IgE concentration of 51.6kUA/L and a negative Ara h 2-
specific IgE concentration. The clinician who referred this infant chose to do so as he had a 
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small skin test response of 3mm and a negative Ara h 2-specific IgE, in the presence of a high 
total IgE level of 4556 kUA/L. The child had a clinical history of legume allergy and the clinician 
felt that his peanut-sensitisation might have been primarily related to cross-reactivity. 
Sensitisation to subunits of the 11S globulins present in legumes has been recognised in 
peanut-allergic patients (Nicolaou and Custovic, 2011).There was also a peanut-tolerant child 
with a high positive whole peanut-specific IgE concentration of 10.9 kUA/L and a negative Ara 
h 2-specific IgE concentration. Other studies have also identified this phenomena (Martinet et 
al., 2016). There were five further children from the positive predictive value subgroup who 
had a negative Ara h 2-specific IgE concentration who did not undergo an oral provocation 
challenge because their chance of tolerance was so low. Two of these children were excluded 
due to their whole peanut-specific IgE concentrations being 81.2 and 19.6 kUA/L whilst three 
others had been excluded on the basis of having skin prick tests of 8mm or above. These three 
children had whole peanut-specific IgE concentrations of 1.22, 6.7 and 14.3 kUA/L. In the light 
of the current study, it would now seem reasonable to re-evaluate these children with a view 
to offering them an oral provocation challenge providing they were aware of the possible low 
chance of them proving tolerant. In contrast, it is important to remember that four children 
with challenge proven peanut allergy had negative Ara h 2-specific IgE concentrations and low 
whole peanut-specific IgE concentrations. Some families may feel that the benefit of 
potentially removing the diagnosis of peanut allergy outweighs this risk. This re-evaluation 
could include specific IgE testing to other peanut components. 
 
An alternative explanation for peanut-allergic children having a positive whole peanut-specific 
IgE concentration and a negative Ara h 2- specific IgE concentration may be that they are 
sensitised to a component other than Ara h 2 (Atkinson, 1992). Other studies have proposed 
further specific IgE testing to additional peanut components, especially for children with a 
history suggestive of birch pollen allergy (Martinet et al., 2016). Ara h 8 is a Bet v 1 homologue 
and has been shown to be the major allergen in children with combined birch pollen and 
peanut allergy. These children appear to be of a different phenotype with their reaction to 
peanut tending to be mild (Asarnoj et al., 2010b, Mittag et al., 2004). Ara h 9 is important for 
Mediterranean patients and in a study of Spanish patients was reported to be the 
immunodominant allergen in 60% of patients, with only 42% recognising Ara h 2 (Vereda et al., 
2011). Its applicability to UK school children is as yet unknown. The cost of multiple peanut-
component testing for all patients undergoing clinical review would however be a very 
expensive way of identifying peanut allergy in such a small sample of patients and should be 
reserved for discordant children. The health economic implications of new tests must always 
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be considered. The cost of testing for multiple peanut components and reviewing children at 
multiple outpatient appointments is likely to be little cheaper than an oral provocation 
challenge. 
 
6.3 The biological mechanisms supporting Ara h 2-specific IgE concentration 
testing 
Analysis of the study results has identified the measurement of Ara h 2-specific IgE 
concentrations to be the best test for the prediction of peanut allergy in peanut-sensitised, 
peanut-naïve children with a history of egg allergy. The component Ara h 2 is a robust 
structure of five α-helices arranged in a superhelix, connected by several loops and stabilised 
by four disulfide bridges. It is not easily denatured, which explains why it is an 
immunodominant allergen. In the US, more than 95% of individuals with peanut allergy have 
demonstrated positive Ara h 2-specific IgE concentrations indicating possible clinical utility 
(Palmer et al., 2005, Scurlock and Burks, 2004, Koppelman, 2004, Zhou et al., 2013). In 
comparison, whole peanut-specific IgE and skin prick testing are based on more crude extracts 
which leads to the recognition of specific IgE antibodies to any peanut component resulting in 
a positive test results.  Some of these peanut components have a comparatively innocent 
clinical profile and react with other homologous proteins such as pollens. Studies have 
identified that individuals who only have detectable specific IgE to other components such as 
Ara h 8 or Ara h 9 are frequently asymptomatic, or prone to very mild symptoms. The reason 
why whole peanut-specific IgE tests and skin prick tests perform less well is that they are non-
selective and detect the presence of specific IgE to all components. Whole peanut skin prick 
tests and specific IgE assays contain several IgE antibody-binding determinants. This includes 
those which are not specifically associated with peanut allergy such as Bet v 1 homologues and 
other pollen cross-reactive determinants (Codreanu et al., 2011). Cross-reactive carbohydrate 
determinants (CCDs) have been implicated as being responsible for peanut-sensitisation in 
peanut tolerant, grass-sensitised patients (Guilloux et al., 2009). This results in many tolerant 
individuals testing positive. This study has demonstrated that a proportion of peanut tolerant 
children have positive Ara h 2-specific IgE and reasons for this are not entirely clear.  It may be 
that the testing is still not sufficiently developed and that further future developments in 
component-resolved diagnostic testing will result in improved accuracy. For example, ten 
epitopes of Ara h 2 have been mapped and it may be that some of these are associated with 
peanut allergy whilst others may be more commonly associated with asymptomatic peanut-
sensitisation (Barre, 2005). 
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It has been proposed that children who exhibit binding to multiple peanut epitopes are more 
sensitive (Flinterman et al., 2008). The presence of binding to multiple peanut epitopes has 
also been associated with an increased severity in allergic reactions (Shreffler et al., 2004, 
Astier et al., 2006). In contrast, a study of UK schoolchildren identified that 39 peanut tolerant 
children demonstrated positive specific IgE concentrations to all peanut components (Nicolaou 
et al., 2011). One small study of 15 peanut allergic and 16 tolerant patients examined eight 
immunodominant sequential epitopes on the seed storage proteins Ara h 1,2 and 3. Most of 
the allergic individuals demonstrated specific IgE binding to three immunodominant epitopes 
on Ara h 2 whilst these were recognised by less than 10% of the tolerant individuals, regardless 
of their whole peanut-specific IgE concentrations (Astier et al., 2006). Ten of the 16 tolerant 
individuals had resolved peanut allergy suggesting that if resources allowed, then further 
future research into epitope mapping may be valuable in the prediction of peanut tolerance 
among children with confirmed peanut allergy. Examination of the clinical utility of Ara h 2-
specific IgE concentrations in the diagnosis of peanut allergy in egg-allergic, peanut-sensitised 
children has raised a number of potential implications for current practice. 
 
6.4 Study applicability 
It is important that the findings of any study are considered in the light of the study population 
to which they apply. The sample of children in this study is representative of the local 
population; largely white British with approximately 16% of families deriving from an ethnic 
minority group. The ethnic minority children in this study were primarily of Polish, Somalian 
and Indian sub-continent heritage. The age of children in this sample is also representative of 
the spread of children attending the clinic. Egg allergy may take several years to resolve, 
evidenced by the large number of children in this study population demonstrating persistent 
egg allergy. The allergy clinic does review a large number of infants presenting with egg allergy 
and this population is slightly under-represented within this study population with only 14% of 
subjects being infants under two years of age. The age range of study children participating 
does reflect the surprisingly large number of children and adolescents who have actively 
avoided peanut. For some, especially the older teenagers, avoidance was on the basis of 
previous skin prick testing in early childhood, which had demonstrated peanut sensitisation 
subsequently interpreted as allergy without further investigation. In the light of the LEAP study 
research, it is now known that such unnecessary peanut avoidance will have resulted in the 
development of peanut allergy in some children (Du Toit, 2013). The problem of peanut 
avoidance among siblings of allergic children has been previously recognised as a problem 
(Lavine et al., 2015). Peanut avoidance was also often recommended by the referring GP or 
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due to parental anxiety. The LEAP study has highlighted the importance of early introduction 
of peanut among these children yet NHS paediatric allergy services are constantly under 
pressure and under resourced (RCP, 2003). Improved diagnostic testing is urgently required as 
a means of addressing the needs of the local population for the prevention of peanut allergy in 
future children. The need to evaluate the cut-off values for varying study populations, age 
groups and geographical reasons is widely accepted (van Erp et al., 2016). The primary analysis 
of the present study was for two groups of peanut allergic and tolerant children. These two 
groups comprise the entire clinic population. It would have been simpler to have only included 
children with challenge-proven allergy or tolerance in this study but this would not have been 
representative of clinical practice.  
 
There is an urgent need to expedite the diagnostic process among high-risk children to reduce 
the burden of allergy for future generations. The clinic population comprises several different 
subgroups of egg-allergic children potentially at risk of peanut allergy. The present study 
included the subgroups of children with known peanut allergy and those with test values 
above the 95% positive predictive value to ensure that the study population comprised all the 
cohorts of egg-allergic peanut-sensitised children the clinician is likely to encounter. However, 
the results presented confirm that differences do exist between subgroups and whilst it is 
important that these are recognised when managing each individual child, this inclusion of 
subgroups does complicate the analysis of data.   
 
The results for the subgroup of children with known peanut allergy were the most surprising.  
It had been anticipated that results would be comparable with those obtained from peanut-
sensitised egg-allergic children who had never consumed peanut. Data comparison between 
subgroups identified both whole-peanut and Ara h 2-specific IgE concentrations to be 
significantly higher in children who had experienced a reaction in the community. These two 
groups of children are therefore not directly comparable and their inclusion has resulted in an 
unexpected limitation upon this study. However, children with known peanut allergy were a 
very small group of children. 
 
The inclusion of three children with resolved peanut allergy could also be criticised. These 
children had been recruited into the study initially as part of the subgroup of children with 
known peanut allergy. Their very low whole peanut-specific IgE concentrations and skin prick 
test wheal diameters prompted the need for further investigation which resulted in the 
creation of this further subgroup. 
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The subgroup of children with whole peanut test results above previously published positive 
predictive values were not challenged. This could be criticised and would score poorly using 
the QUADAS-2 tool utilised above, but is in line with the majority of studies critiqued above in 
the Literature Review. As this is a study of usual care, this is also in line with current national 
practice. Furthermore, the large number of these children demonstrates the large proportion 
of egg-allergic children evaluated in a tertiary allergy clinic who will fall into this group. The 
majority of these children will not be challenged. This study proposes that there should be 
exceptions to this especially for children who have a negative Ara h 2- specific IgE 
concentration as reported in earlier studies (Ackerbauer et al., 2015). Lieberman et al 
examined 31 individuals with a whole peanut-specific IgE concentration of ≥15 kUA/L or above. 
All 28 with elevated Ara h 2-specific IgE concentrations failed an oral provocation challenge, 
whilst 3 with negative Ara h 2- specific IgE concentrations completed an oral provocation 
challenge without reaction despite having positive whole peanut-specific IgE concentrations of 
2.1, 36.59 and 46.89 kUA/L (Lieberman, 2015). Children with discordant whole peanut- and 
Ara h 2-specific IgE concentrations warrant further evaluation, and may benefit from a more 
detailed assessment of their peanut-component profile but this remains an area in need of 
further research. 
 
6.5 Implications of study findings and relevance to clinical practice 
The current study has confirmed that there is no longer a role for the routine use of whole-
peanut specific IgE concentrations in the diagnosis of peanut allergy in this population and that 
this should be replaced by the introduction of the routine measurement of Ara h 2-specific IgE 
concentrations instead. When used in isolation, Ara h 2-specific IgE concentrations were 
unable to replace the need for an oral peanut provocation challenge for the majority of egg-
allergic, peanut-naïve children who had peanut-sensitisation test values below the widely 
accepted 95% positive predictive value. The measurement of Ara h 2-specific IgE 
concentrations however was a useful complementary tool for clinicians. There may be a role 
for testing for multiple peanut components but this should be used judiciously as it incurs 
additional costs and further research into the clinical utility of this approach is needed.  
 
The measurement of Ara h 2-specific IgE concentrations as an additional tool for the diagnosis 
of peanut allergy within the Bristol Royal Hospital for Children paediatric allergy clinic has been 
advantageous. There are several children with high whole peanut-specific IgE or skin prick 
tests, albeit below the previously published positive predictive values, who few clinicians 
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would previously have been confident to challenge. A negative Ara h 2-specific IgE 
concentration within this group of children has led to a general change in behaviour, with an 
increase in the number of oral provocation challenges being offered. A reluctance to challenge 
children may inflict a peanut allergy diagnosis on a significant number of tolerant children. 
Clinicians working in smaller centres frequently perform fewer challenges than those working 
in tertiary centres, with many children being excluded from challenge unnecessarily. The 
growth of nurse-led allergy clinics may also in some centres be associated with a lack of 
confidence in challenging certain children due to a greater reliance upon diagnostic algorithms 
and guidelines rather than clinical acumen. 
 
An improved approach to the diagnosis and management of these children would be to 
employ the models discussed earlier to reduce the number of oral provocation challenges 
necessary. The development of two stepwise approach models described above (Models 2 and 
4) optimised the use of available tests. This is very useful in the tertiary paediatric allergy clinic 
where specific guidelines for the use of Ara h 2-specific IgE are not currently available and 
where children are reviewed by clinicians of all levels of experience, including specialist 
trainees and clinical nurse specialists. Clinicians may behave differently, partly dependent 
upon their level of experience. Both models require all egg-allergic, peanut-naïve children to 
undergo skin prick testing to identify peanut-sensitised children. The high negative predictive 
value for peanut skin prick testing highlights this test to be of great value. However, its value 
among a peanut-naïve study population primarily lies in the elimination of peanut allergy 
rather than in making a definitive diagnosis. The results of this study prompt the 
recommendation for the use of peanut skin prick testing as the initial screening test for use in 
clinic when reviewing egg-allergic, peanut-naïve infants and children. Children with a negative 
skin prick test to peanut below the manufacturer’s cut-off value can cautiously introduce 
peanut at home. If skin prick testing cannot be performed for some reason, as is the case when 
a child has taken antihistamines for example, then an alternative approach will be needed.  
 
Model 2, the two-step diagnostic algorithm which uses skin prick testing to peanut as the first 
step, is recommended for the management of egg-allergic, peanut-naïve children attending 
clinic who are identified as having a skin prick test wheal diameter of 6mm or above. These 
children then require venepuncture for Ara h 2-specific IgE testing.  If a child’s Ara h 2-specific 
IgE concentration is above the 0.39KAU/L cut-off value, the child can be given the diagnosis of 
peanut allergy with the knowledge that a small number of children may be misclassified. 
Future follow up of peanut allergic children every two years may eventually led to the 
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identification of tolerant children who have fallen into this group. Children who have an Ara h 
2-specific IgE concentration below the 0.39kUA/L cut-off are more likely to be peanut tolerant 
than allergic but will still require an oral provocation challenge, to prevent those children 
misclassified as tolerant experiencing a potentially severe allergic reaction in the community. 
 
Model 4 can be implemented for the management of children with a positive skin prick test 
which is less than 6mm. Children with an Ara h 2-specific IgE concentration of ≤0.39 kUA/L 
would be classified as peanut tolerant and those with a concentration above this level would 
require an oral provocation challenge. This model is anticipated to reduce the number of 
children who will require an oral provocation challenge although it would place a small 
number of children at risk. This risk could be reduced by the use of supervised feed clinics, 
where children attend an outpatient appointment where they ingest a standard portion of 
peanut under minimal supervision in the safety of a hospital environment. The use of the 
model in routine clinical practice could be simplified by the introduction of an app or 
computerised algorithm.  Now that NHS hospitals are moving towards paperless systems, 
iPads are being routinely introduced into many clinics which could easily facilitate this 
introduction. 
 
A negative Ara h 2-specific IgE concentration is not always associated with tolerance and 
children with discordant results will require further investigation. The reviewing clinician 
should consider additional testing to other components should be considered when Ara h 2 is 
negative in peanut-naïve children with birch pollen sensitivity. There may be a role for prick 
testing to birch as a useful first line test in the evaluation of children with positive whole-
peanut testing and negative Ara h 2-specific IgE as this may possibly reduce the number of 
blood tests to which the child is subjected, whilst also reducing costs. 
 
6.6 Study considerations 
The contemplation of a change in practice based on the findings of a research study will always 
have implications. These considerations include factors such as logistical or health economic 
considerations. One consideration in this study is the cost of additional component testing. 
The cost of Ara h 2-specific IgE concentration testing in addition to routine costing is 
considerable when applied to a large tertiary allergy clinic. The findings of the present study 
recommend replacing whole-peanut specific IgE testing with Ara h 2-specific IgE 
concentrations. The use of further component testing is recommended only on a case-by-case 
basis. This study restricted component-testing to Ara h 2 largely due to cost but also following 
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review of the literature which does not pose a very strong argument for multiple peanut 
component testing in all children. This was a study of routine clinical care and such 
indiscriminate testing is unlikely to ever be an NHS recommendation. Additionally, cross-
reactivity rates have been demonstrated to be low among very young children. As this study 
had initially planned to include a larger number of infants, evaluation of Ara h 9 was 
anticipated to be of limited interest (Dang et al., 2012). Bristol has a very low Mediterranean 
population, suggesting that Ara h 9 is unlikely to be an immunodominant allergen (Asarnoj et 
al., 2012b, Mittag et al., 2004). It is unlikely therefore that this decision had any detrimental 
effect upon the study outcome. 
 
A second minor consideration that may have restricted the ability of the study to make 
recommendations specifically for the management of infants under the age of two years was 
the small number of infants included. However, the age of included children does reflect the 
referral process within the Southwest region. The waiting time following receipt of a GP 
referral for a new patient appointment exceeds the 18 week pathway and any child referred 
on for an oral provocation challenge is likely to experience a further six month wait prior to the 
procedure. For this reason, the opportunity to challenge children under the age of two is 
limited.  
 
A further consideration is the varying quality of skin prick test extracts and specific IgE assays.  
The present study used high quality extracts but it should be recognised that the 
recommended stepwise models may perform differently with different skin test reagents of in 
vitro specific IgE testing systems. Further validation of the model may be required in other 
study centres. 
 
6.7 Study strengths and limitations 
There were some limitations to the current study, most of which relate to this being a study of 
routine clinical care, which is a consideration for clinical practice and the delivery of any 
recommendations. There was a time delay of several weeks between venepuncture and the 
oral provocation challenge. Some previous studies were able to take blood immediately prior 
to oral provocation challenge but if a second blood sample had been taken in the present 
study, this process would not replicate standard care, and therefore the findings would be less 
applicable to current practice. However, it is unlikely that there would be a dramatic difference 
in specific IgE concentrations between their clinical appointment and their oral provocation 
challenge. 
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The most important limitation to this study was the decision not to challenge children with 
whole peanut-specific IgE concentrations or skin prick test wheal diameters above previously 
published 95% positive predictive values, which was an ethical restriction. The exclusion of this 
cohort of children is not unusual among study populations with these children frequently 
being labelled as peanut allergic for safety purposes (Kim, 2016). The number of children in 
this subgroup who may have been misclassified as allergic rather than tolerant will be small. 
Within the HealthNuts study all peanut-sensitised children were challenged regardless of their 
whole peanut-specific IgE or skin prick test wheal measurements, and if children with test 
results above the positive predictive value had been excluded then the misclassification rate 
among children would have been 3% (Dang et al., 2012). The current study examined optimal 
ways of utilising available testing within clinical practice, working within commonly 
encountered restrictions. It would not be logistically possible, or safe, within routine clinical 
practice to challenge all peanut-naïve children falling within this positive predictive value 
subgroup. The study has identified optimal ways of managing this subgroup of children as 
previously discussed. 
 
A further limitation was that all provocation challenges were open challenges, as opposed to 
double-blind placebo-controlled food challenges. This was again reflective of routine clinical 
practice but the robust scoring system ensured that the oral provocation challenges were 
performed in an objective manner. 
 
One strength of this study is that it was a prospective study, which compares favourably with 
several other retrospective studies described in chapter 2. It is also the first study to 
specifically evaluate the diagnostic utility of Ara h 2-specific IgE concentrations in a clinic 
population of egg-allergic, peanut-sensitised children who have never knowingly ingested 
peanut. This is of prime importance given the recent publication of the LEAP trial, which 
examined the effectiveness of the randomised consumption of peanut in preventing allergy 
among high-risk egg allergic children, and in children with eczema (Du Toit, 2015). Allergy 
services are consequently under pressure to facilitate the early introduction of peanut to high-
risk infants but unfortunately have inadequate resources for the assessment of these children 
necessary to enable the safe introduction of peanut. Therefore tests able to better 
discriminate between peanut allergy and tolerance would be of considerable value. 
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6.8 Implications for future research 
This study has highlighted several areas for the focus of future research. Further research to 
identify other factors associated with peanut allergy which would complement use of the 
diagnostic model are required to elucidate the peanut allergy status of peanut-sensitised, 
peanut-naïve children with a history of egg allergy. This should include investigation of factors 
such as persistent egg allergy, age and pollen-sensitisation profiles. A valuable and interesting 
focus for future research includes the examination of the possible potential role of skin testing 
to pollens in the identification of peanut tolerant children. 
 
Evaluation of the small number of children with whole peanut-specific IgE or skin prick test 
values above the positive predictive value also requires clarification. Previously published 
studies do not concur on the clinical utility of multiple components or epitope mapping in the 
management of peanut-sensitised, peanut-naïve children. Further research will establish 
whether these children may benefit from further clarification of their sensitisation profile via 
the use of other peanut components or epitope mapping. Epitope mapping may also be of 
additional benefit for the identification of children who may have resolved peanut allergy. 
Further examination of the clinical utility of Ara h 2 epitope mapping for the prediction of 
peanut allergy resolution would have both patient and health economic benefits. 
 
A further minor focus for future research would be to assess the efficacy and user-
acceptability of the introduction of electronic diagnostic algorithms in the management of 
peanut-sensitised, peanut-naïve children. This could be examined in terms of cost-savings and 
compared with the existing management of this group of children to assess whether 
introduction of the model is associated with cost savings and a more streamlined and effective 
service. Finally, research into the applicability of the model to other high-risk populations of 
peanut-sensitised, peanut-naïve children is important. Other populations identified as being at 
high-risk of peanut-allergy include children with eczema and other populations where 
knowledge of a child’s peanut allergy status are also important include siblings of peanut 
allergic children, and children with tree nut allergy who are peanut-sensitised and peanut-
naïve. 
 
The inclusion of the several subgroups of children within the current study has highlighted that 
results can vary considerably between these groups.  It has been valuable to be able to 
examine these subgroups and identify where some of these differences lie. For clarity, and 
given the very small sample size of children within the known peanut allergy and resolved 
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peanut allergy subgroups, these two subgroups will be excluded from the journal paper to be 
submitted for publication. As the Allergy Department at Bristol Royal Hospital for Children has 
continued to record Ara h 2-specific IgE concentrations and peanut oral provocation challenge 
outcomes, this additional data from clinical practice will be added to the analysis prior to 




The results of this study clearly demonstrate the greater ability of sensitisation to Ara h 2 in 
distinguishing between peanut allergy and asymptomatic peanut sensitisation in egg-allergic, 
peanut-naïve children compared with diagnosis being based on skin prick testing or whole 
peanut-specific IgE concentrations. Analysis of subgroups identified a decrease in its clinical 
utility although it remained the best test. Unfortunately it performed least well for those 
children falling in the immunological grey area whose diagnosis was confirmed by a peanut 
oral provocation challenge. This is the group of children in whom an improved diagnostic test 
is most needed. The completion of this study has led to several recommendations. 
 
Children with a negative skin prick test to peanut below the manufacturer’s cut-off value are 
unlikely to have peanut allergy and do not require a peanut oral provocation challenge. 
Optimal cut-off values have been identified for the management and diagnosis of peanut 
allergy in high-risk children. This study suggests that whole peanut-specific IgE concentrations 
should not be used in isolation, as concentrations below the 15kUA/L have limited clinical 
utility and should be replaced by the measurement of Ara h 2-specific IgE concentrations. 
There was little clinical utility for the use of whole peanut-specific IgE concentrations except as 
a potential screening tool for peanut-sensitisation. Children with a whole peanut-specific IgE 
above 15kUA/L should be excluded from oral provocation challenge unless their individual 
sensitisation profile prompts further investigation. Whole peanut-specific IgE concentrations 
need not be measured for this purpose as the 95% positive predictive value of 8mm for skin 
testing can be used for this purpose. Optimal cut-off values were 6mm for skin prick test wheal 
diameters and 0.39kUA/L for the measurement of Ara h 2-specific IgE concentrations. These 
have greatest clinical utility when used as part of a two-step approach model which measures 
skin prick test wheal diameters to peanut followed by Ara h 2-specific IgE concentrations.  
 
When used in isolation, although the predictive ability of Ara h 2-specific IgE concentrations is 
superior to those of existing tests for whole peanut, their use was unable to replace the need 
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for an oral peanut provocation challenge for the majority of egg-allergic, peanut-naïve children 
who had peanut-sensitisation test values below the widely accepted 95% positive predictive 
value. Paediatric allergy has not yet reached the stage where laboratory-based testing can 
replace the gold standard of the peanut oral provocation challenge. 
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Appendix 8 
Fagan’s Nomogram for post-test probability of having peanut allergy for egg-allergic 
children with a positive Ara h 2-specific IgE concentration attending the tertiary 
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